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ABSTRACT 
 Carbohydrates surround nearly every cell in the human body. 
Glycosaminoglycans like chondroitin sulfate and heparan sulfate on the cell 
surface regulate protein ligand engagement and receptor activation to control a 
variety of biological processes including development, angiogenesis, and neuronal 
growth. These polysaccharides exert activity through protein binding to their 
diverse chemical structures. Therefore, the development of methods to tailor 
glycosaminoglycan populations at the cell surface with defined structures could 
provide novel approaches to control biological activity. Herein, two new methods 
to engineer the cell surface glycocalyx with known glycosaminoglycans are 
reported. Together, these methods provide complementary short- and long-term 
approaches to change carbohydrate structures at the cell surface to guide neuronal 
growth and stem cell differentiation. It is also critical to identify unknown 
protein-carbohydrate interactions that underlie biological phenomena. Novel 
GAG interactions with the orphan receptor Tie1 and angiopoietin ligands Ang1 
and Ang4 are reported herein. These interactions provide the first evidence for a 
physiological ligand for Tie1 since its discovery over 25 years ago. Moreover, 
interactions between Ang1 and Ang4 and heparan sulfate are shown to potentiate 
Tie2 survival signaling, providing novel insights into an important but poorly 
understood signaling axis. 
 Within the cell, thousands of proteins are modified by O-GlcNAc 
glycosylation, a process that is uniquely catalyzed by a single transferase and 
hydrolase pair unlike many other post-translational modifications. O-
GlcNAcylation functions in many biological contexts including transcription, 
translation, proteostasis, and metabolism. Key to understanding its effects on 
these physiological phenomena is the discovery of O-GlcNAc modification sites. 
However, due to a number of technical challenges, O-GlcNAc proteomics has not 
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progressed nearly as quickly as phosphoproteomics. Thus, developing new 
methods to enrich O-GlcNAcylated substrates and map modification sites is 
critical to unravel the myriad functions of O-GlcNAc. Herein, a labeling approach 
using a chemically cleavable tag is reported as an improved method to capture and 
release O-GlcNAcylated substrates. Unlike other methods, the cleavable Dde tag 
used herein is quantitatively removed under mild, neutral conditions and leaves a 
minimal residual tag on the O-GlcNAcylated peptide to be analyzed. Moreover, 
the Dde linker outcompetes a UV-cleavable tag that has been previously utilized 
in the field, identifying 414 unique O-GlcNAcylated peptides. Together, these 
results highlight the potential usefulness of the new approach developed herein to 
illuminate novel roles of O-GlcNAcylation in diverse systems. 
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C h a p t e r  1  
Glycosaminoglycans as Active Signaling Components of the 
Extracellular Matrix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter are published as: 
 
Griffin ME, Hsieh-Wilson LC. “Glycan engineering for cell and developmental 
biology.” Cell Chem. Biol. 2016, 23: 108-121. doi: 10.1016/j.chembiol.2015. 12.007. 
Review article. 
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1.1 Glycosaminoglycan Structures and Biosynthesis 
 Carbohydrates are generally thought of as a fuel source for life. However, 
these molecules also function in many other roles necessary for survival including 
development, angiogenesis, and neuronal growth.1-5 In particular, carbohydrates 
at the cell surface can strongly regulate signal transduction and cellular activity. 
This feat is achieved in large part through their structural diversity, which allows 
them to selectively bind to a variety of different proteins and in turn modulate 
their functions. Unsurprisingly, the dysregulation of cell-surface carbohydrate 
production and presentation can contribute to a variety of diseases including 
inflammation and cancer progression.6, 7 Therefore, discovering relationships 
between the chemical structures of carbohydrates, the proteins to which they 
bind, and the resulting biological functions is critical both for the basic 
understanding of many physiological processes and for the prevention and 
treatment of various pathologies.  
 Cell-surface carbohydrates exist in a variety of forms and are classified based 
on their overall size, membrane anchor, monosaccharide composition, glycosidic 
connections, and further modifications of the monosaccharide residues.8 Of 
particular interest is the class of carbohydrates known as glycosaminoglycans 
(GAGs), which exist as linear polysaccharides of generally 20 to 200 repeating 
disaccharide units.8 GAGs and their attached proteins, known collectively as 
proteoglycans, are almost ubiquitously present at the cell surface either anchored 
in the cell membrane or secreted into the extracellular matrix; however, the 
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Figure 1.1 Structures of GAG family members. GAGs are made of repeating disaccharide units. 
Three of the four families can be sulfated at different hydroxyl groups along the polysaccharide. 
chemical composition of GAG structures varies significantly between cell types. 
GAGs can be subdivided into four main classes based on their monosaccharide 
components: (1) chondroitin sulfate and dermatan sulfate, (2) heparin and 
heparan sulfate, (3) keratan sulfate, and (4) hyaluronan (Figure 1-1). Chondroitin 
sulfate and dermatan sulfate (CS/DS) contain a repeating disaccharide unit of a 
hexuronic acid (GlcA for CS and both GlcA and IdoA for DS) and GalNAc. 
Heparin and heparan sulfate (hep/HS) are made of a mixture of GlcA and IdoA 
(~10% GlcA for heparin and 10-50% GlcA for HS) along with GlcNAc, which can 
be deacetylated as GlcN. Keratan sulfate (KS) exists as repeats of Gal and GlcNAc. 
These three GAG structures are synthesized in the Golgi apparatus on their 
proteoglycan cores and can also be differentially sulfated on their hydroxyl 
groups. The fourth class of GAGs, hyaluronan or hyaluronic acid (HA), is unique 
in that it is not attached to a protein structure and is generally much larger than 
O
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the other three classes, existing upwards of 5 MDa or more in mass and 20 µm in 
length.9 Furthermore, the repeating unit of HA (GlcA and GlcNAc) is assembled 
at the cell membrane by hyaluronic acid synthases and is completely unsulfated. 
For the purpose of brevity, only CS/DS and hep/HS will be discussed further. 
 The repeating patterns of CS/DS and hep/HS can be classified further by their 
sulfation patterns. In mammals, CS and DS can be sulfated on the GlcA/IdoA-C2, 
GalNAc-C4, and GalNAc-C6 hydroxyl positions. Hep and HS can be modified at 
the GlcA/IdoA-C2, GlcN-C3, and GlcN-C6 hydroxyl positions as well as the free 
amine on GlcN. These modifications are catalyzed by carbohydrate 
sulfotransferases that reside in the Golgi apparatus.10 Sulfate groups can be 
removed by sulfatases; however, this generally occurs in lysosomes after GAG 
internalization during degradation.11 Only two enzymes, HS 6-O-endosulfatases 
Sulf1 and Sulf2, are known to modify GAG structures once they are secreted to 
the cell surface.12 
 CS/DS and hep/HS biosynthesis follow similar pathways.13, 14 First, a common 
tetrasaccharide (Xyl-Gal-Gal-GlcA) is appended to Ser residues of various 
proteins. Usually, this occurs at Ser-Gly/Ala-X-Gly sequences;15 however, this 
motif is not universally found at all modification sites. Next, the first N-
acetylhexosamine residue is attached to the core tetrasaccharide. This step 
commits the growing strand to either CS/DS (GalNAc) or hep/HS (GlcNAc). The 
identity of the attached GAG is dependent on a number of factors including the 
protein core.16 Although certain proteins like versican and glypicans are modified 
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only by CS or HS, respectively, others like syndecans can contain both structures 
simultaneously, whereas some proteins like neuropilin-1 have different structures 
attached to the same Ser residue on different copies of the protein.17, 18 The chains 
are then elongated by a number of polymerizing enzymes. For CS, GlcA can be 
epimerized to IdoA at this point to produce regions of DS. For hep/HS, GalNAc is 
first de-N-acetylated and N-sulfated, after which GlcA residues can be epimerized 
to IdoA. Finally, sulfotransferases modify hydroxyl groups along the length of the 
carbohydrate backbone to produce the mature sulfated polysaccharide. 
Importantly, these modification reactions do not proceed to completion, 
increasing heterogeneity of the final structure. Moreover, other than substrate 
preferences exhibited by the modifying enzymes, it is relatively unclear how the 
cell orchestrates structural heterogeneity of the produced GAG polysaccharides. 
It is hypothesized that regions of high and low sulfation density exist along the 
oligosaccharide, but little structural information is directly available due to the 
difficulties in GAG sequencing.19-21 Nevertheless, it is through these different 
structures that GAGs exert their biological activity by binding to proteins. Thus, 
to fully understand the biological activity of GAGs, it is critical (1) to discover the 
interactions between proteins and specific GAG structures and (2) to design 
methods to change GAG structures at the cell surface to alter and perhaps control 
biological function. 
 
 
  
6 
1.2 GAG Binding to the Receptor Tyrosine Kinase Superfamily  
 To control intracellular activity, GAGs must interact with transmembrane 
proteins on the cell surface to transfer external information across the cell 
membrane. One of the largest groups of these proteins is the receptor tyrosine 
kinase (RTK) superfamily.22, 23 Made up of 58 receptors organized into 20 
subfamilies, RTKs are characterized by the presence of an intracellular tyrosine 
kinase domain that is activated by receptor dimerization, causing cross-
phosphorylation of tyrosine residues on opposite receptors and leading to 
downstream activation of signaling pathways.23 Their extracellular domains are 
much more structurally diverse, allowing RTKs to function in a variety of 
fundamental biological processes including cell survival and motility.23-26 
Moreover, their dysregulation has been linked to a variety of disease states 
including cancer, diabetes, and atherosclerosis.27-29 
 RTKs generally function through binding to extracellular ligands. 
Interestingly, many of the RTK subfamilies have been linked to interactions with 
GAGs – either through binding to soluble protein ligands or to the receptor 
itself.30-41 One of the most famous examples of the involvement of GAGs is the 
ternary complex formed by fibroblast growth factor 1 (FGF1), FGF receptor 1 
(FGFR1), and hep/HS.30 As illustrated by crystallographic studies, hep/HS binds 
to the receptor-ligand complex using a binding site that spans both proteins in a 
2:2:2 stoichiometric ratio, cooperating to stabilize the active receptor dimer. 
Carbohydrate microarray studies have also illustrated that FGFR1 binding to 
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hep/HS is facilitated by FGF2 binding,36 providing mechanistic evidence for 
ternary complex assembly. Other examples of GAG binding to ligands and 
receptors include the vascular endothelial growth factor 1 (VEGF1) and VEGF 
receptor 1 (VEGFR1) system.32, 42 Surface plasmon resonance (SPR) analyses 
have shown that VEGFR1 but not VEGFR2 can directly interact with hep/HS. As 
seen before with FGF2/FGFR1, VEGF1 binding to hep/HS facilitates the 
formation of a ternary complex containing VEGFR2. More recently, CS-E has 
been demonstrated to bind to members of the erythropoietin-producing human 
hepatocellular (Eph) family of receptors.40, 41 CS-E binding to EphA4 and EphB3 
can facilitate receptor activation without the canonical ephrin (Efn) ligands, 
highlighting a novel mechanism of action for RTK signal transduction mediated 
by GAG binding.  
 Together, these results illustrate only a small portion of the knowledge gained 
from the discovery of GAG-RTK interactions and their biological consequences. 
However, our understanding of the connections between GAG binding and RTK 
signaling is far from complete. Given the sheer size of the RTK superfamily and 
the diverse biological settings where they function, it is quite possible that many 
new GAG-RTK interactions with significant biological ramifications remain still 
undiscovered. 
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1.3 Altering Cell-Surface GAG Populations 
 A variety of approaches have been developed to alter GAG structures at the 
cell surface and observe the resulting biological phenotype. The majority of these 
methods are reductive, meaning that they remove GAG structures through 
biosynthetic inhibition or degradation, and occur through genetic manipulation. 
These approaches include gene deletion or knockout, gene knockdown by RNAi, 
and gene overexpression. Genetic methods offer excellent spatial and temporal 
control, enabling the precise manipulation of specific genes in a cell-specific and 
inducible manner. However, because of the linear synthesis of the GAG backbone 
and the substrate specificity of individual sulfotransferases, the genetic disruption 
of a single enzyme may lead to dramatic changes in GAG populations and are 
generally unsuitable to probe in importance of individual sulfation epitopes. For 
example, N-deacetylation and N-sulfation of GlcNAc in HS biosynthesis is critical 
for further sulfation reactions. Therefore, knockout of the responsible enzyme N-
deacetylase and N-sulfotransferase 1 (Ndst1) leads not only to decreases in N-
sulfation but also O-sulfation at all other positions.2, 43 Similarly, the production of 
the CS-E epitope by carbohydrate sulfotransferase 15 (Chst15) requires the 
activity of Chst11 to first add a sulfate group to the GalNAc-C4 hydroxyl position 
and produce the CS-A epitope. Deletion of Chst11 leads to the loss of both the CS-
A and CS-E motifs.44 Moreover, knocking out GAG enzymes can lead to 
developmental defects or embryonic lethality, which can hinder the identification 
of functions in adult organisms.45 Nonetheless, important discoveries have been 
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made regarding the necessity of GAGs for proper development using genetic 
approaches. For instance, the importance of HS in bone maturation has been 
demonstrated by the production of a mouse model deficient in HS biosynthesis 
due to a hypomorphic mutation in the HS polymerase Ext1.46 These mice 
exhibited improper endochondral ossification during development, and this 
phenotype was attributed to the importance of HS binding with the growth factor 
Indian hedgehog.  
 An alternative reductive approach is the use of GAG degrading enzymes to 
selectively remove carbohydrates at the cell surface. As with genetic approaches, 
direct delivery or transgenic expression of the enzyme can be finely controlled to 
provide spatiotemporal selectivity. However, these enzymes lack fine substrate 
specificity and will at least partially degrade all CS or HS GAGs depending on the 
enzyme used. Furthermore, the longevity of this approach depends greatly on the 
stability of the enzyme, and long-term experiments may require multiple 
deliveries of the enzyme to avoid complications from newly synthesized GAGs. 
However, GAG degrading enzymes are invaluable tools to quickly and effectively 
remove nearly all GAGs of a specific subpopulation. One promising application of 
this method has been the delivery of chondroitinase ABC (ChABC) derived from 
the bacterium Proteus vulgaris to sites of spinal cord injury.47-49 Reactive 
astrocytes produce large quantities of CS after injury to inhibit axonal 
regeneration,50 and direct injection or viral delivery of ChABC has been 
associated with neuronal regrowth and functional recovery.47, 48 
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 Recently, complementary additive approaches have been developed to 
overcome the obstacle of structural selectivity found in reductive methods. In 
these methods, known collectively as de novo glycan display, carbohydrate or 
glycomimetic structures are directly inserted into plasma membranes using 
approaches such as lipid insertion, liposomal fusion, or protein conjugation.51-56 
These techniques provide excellent control over glycan structure, allowing 
known epitopes to be displayed for functional analysis. However, exogenous 
sugars are typically displayed alongside the native glycan population, which could 
obscure the biological effects of the newly added carbohydrates. To address this 
complication, de novo glycan display methods can be used in combination with 
reductive approaches to minimize the contributions of interfering endogenous 
carbohydrates. The versatility of the technique also allows for the display of a 
wide range of carbohydrate-based structures, including glycomimetics such as 
synthetic glycopolymers, glycans appended to simplified proteins, or even the 
glycan component of glycoproteins alone. As a relatively new field, de novo glycan 
display has only been applied to a limited number of biological contexts. For 
example, anchoring of lactosyl or cellobiosyl-containing glycopolymers in the cell 
membrane by passive lipid insertion was used to examine galectin-mediated 
crosslinking and aggregation.52 However, prior to the work outlined in Chapter 2, 
the ability to elicit biological activity as a function of glycan structures at the cell 
surface was unknown. Our work53, 54, along with other, simultaneous publications 
in the field55, 56, demonstrated that the display of defined carbohydrate structures 
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at the cell surface could be used to drive multiple biological processes including 
immunoevasion, neuronal outgrowth, and stem cell differentiation. Together, 
these results highlight the utility of de novo glycan display as a novel tool to 
directly connect carbohydrate structure and biological function unlike other 
existing methods.  
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C h a p t e r  2  
Methods for Short- and Long-Term Glycan Engineering at the Cell 
Surface to Control Biological Outcomes 
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2.1 Abstract 
 Cell-surface GAGs are mediators of a variety of critical signaling events and 
can dictate the biological activity of cell populations through their interactions 
with cell-surface receptors and soluble ligands. Many approaches to connect 
structural determinants of the cellular glycocalyx with biological function employ 
reductive approaches by reducing or eliminating glycan structures from the 
extracellular matrix. However, a forward approach in which specific glycans are 
anchored onto plasma membranes would allow more control over the exact 
carbohydrate structures being displayed at the cell surface. Moreover, this tactic 
would provide direct evidence for biological activity as a result of a carbohydrate 
structure. Here, two methods are presented to modify cell surfaces with defined 
carbohydrate structures. The first method employs the functionalization of CS 
polysaccharides with an aminooxy group and conjugation to ketone-displaying 
liposomes to directly fuse with the cell membrane. The second approach 
describes the transgenic expression of a transmembrane HaloTag construct, 
which can covalently bond with chlorohexyl-functionalized HS polysaccharides. 
These two complementary methods provide both short- and long-term display of 
known carbohydrates, which allow for the direct control of cellular fate in both 
neuronal growth and stem cell differentiation. 
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2.2 Liposomal Delivery of CS GAGs to Control Neuronal Growth 
2.2.1 Approach and Synthesis 
 Although some strategies for engineering cell-surface glycans have been 
reported,1-8 the remodeling of cell membranes with complex polysaccharides such 
as GAGs has not been demonstrated. Moreover, the application of these 
methodologies prior to our work has been largely limited to imaging2-5 or studying 
cell-surface phenomena, such as receptor clustering.6 Here we developed a 
method to display specific sulfated GAG structures on cell surfaces using a 
liposomal fusion strategy. Tailoring membranes with the CS-E sulfation epitope 
activated growth factor-mediated signaling pathways and enabled the fine-tuned 
modulation of neuronal growth. These findings demonstrate that chemically 
controlling the presentation of exogenous glycans on cell surfaces can induce 
sustained effects on cellular signaling and function. Our studies also highlight the 
potential for glycan engineering to modulate complex cellular events, and they 
provide a powerful, new tool for remodeling cell membranes with a wide variety 
of important biomolecules. 
 We chose to utilize liposomes as glycan carriers due to their biocompatibility, 
ease of preparation, low cytotoxicity, and tunable biophysical properties.9 Elegant 
studies have used glycan-presenting vesicles for intracellular antigen delivery10, 11 
or sugar-encapsulated vesicles with folate receptors for cell-specific metabolic 
labeling.4 However, only two liposomal methods have been developed to our  
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Figure 2-1. Schematic of liposomal delivery method for glycan engineering. Liposomes 
containing a ketone functional handle are produced and then functionalized with GAGs. Liposomes 
are then added to cells, where they fuse with the cell membrane to display carbohydrates on the cell 
surface. 
knowledge for the cell-surface display of exogenous molecules, namely 
fluorophores.12, 13 We expanded on these methods in an effort to incorporate 
large, sulfated GAGs into cell membranes (Figure 2-1). To promote membrane 
fusion and surface presentation of the glycans rather than intracellular uptake, we 
used cationic 1,2-dioleoyl-3-trimethylammoniumpropane chloride (DOTAP) and 
neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) as our 
primary lipids. Phosphatidylethanolamine lipids are an abundant, natural 
component of the neuronal cell membrane, and DOPE-based liposomes 
containing a lipid-functionalized fluorophore have been used to label a variety of 
cell types, including primary neurons.12 We also incorporated 2-dodecanone into 
the liposomes to add a ketone handle for appending the glycans via oxime 
chemistry. CS polysaccharides containing a peptide fragment with an N-terminal 
amine were readily derivatized with an aminooxy group by coupling them to  
Liposome
Formation
Functionalization of
Liposomes with GAGs Membrane Fusion
with Cells
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Figure 2-2. Synthesis of aminooxy-functionalized CS GAGs (2-6, 2-7, and 2-8).(a) N-
hydroxyphthalimide (1.2 eq), NaHCO3 (1.2 eq), DMF, 60 °C, 2 h, 88%; (b) TFA (3 eq), DCM, 1 h, 
99%; (c) EDC (1.1 eq), sulfo-NHS (1.1 eq), 100 mM MES pH 6.0, 300 mM NaCl, RT, 30 min, then 
polysaccharide-NH2, 50 mM NaHCO3, RT, 12, 60%. (d) hydrazine monohydrate (3 eq), ddH2O, RT, 
3 h, 92%. 
phthaloyl-protected aminooxyacetic acid followed by cleavage of the phthaloyl 
group with hydrazine monohydrate (Figure 2-2). The polysaccharides were then 
incubated with dodecanone-containing liposomes at 25 °C for 3 h to produce 
GAG-displaying vesicles. The synthetic ease and versatility of this approach 
represent advantages compared to existing methods, which require the radical-
mediated synthesis of polymers end-functionalized with lipids.5-8 With our 
approach, the lipid reagents are commercially available, and many biomolecules 
can be derivatized with aminooxy groups, including various glycans, peptides, 
lipids, nucleic acids, and proteins,14-16 thus providing a general strategy for 
displaying a diverse range of bioactive molecules.  
2.2.2 Validation 
Preliminary optimization of liposomal membrane fusion was performed on rat 
pheochromocytoma (PC12) cells using liposomes functionalized with a  
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Figure 2-3. Optimization of lipid composition of liposomes for membrane fusion. Liposomes 
were produced with different w/w ratios of DOPE and DOTAP and 10% w/w dodecanone. AF488-
hyd was incubated with the liposomes (ddH2O, RT, 3h) to spontaneously react with the presented 
ketone moiety. PC12 cells were then incubated with the fluorescent liposomes (37 °C, 30 min) and 
imaged to visualize fusion efficiency. 
hydrazide-conjugated fluorophore (AF488-hyd). We found that a 2:1 w/w ratio 
of DOPE:DOTAP was optimal for membrane fusion, as visualized by fluorescence 
microscopy (Figure 2-3). To approximate the relative levels of fluorophore 
incorporation at the cell surface, we incubated liposomes containing varying 
concentrations of AF488-hyd with PC12 cells on ice for 30 min. Cells labeled with 
liposomes containing 10 mol % AF488-hyd displayed similar fluorescence signal 
profiles by fluorescence-assisted cell sorting (FACS) analysis as cells labeled with 
an anti-CS-E monoclonal antibody17 that detected endogenous CS-E levels (Figure 
2-4). These results suggest that this liposomal strategy can incorporate exogenous 
molecules into cell membranes at levels roughly similar to those of endogenous 
CS polysaccharides. We next examined whether this approach could be used to  
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Figure 2-4. Quantifying cell surface labeling by liposomal delivery. PC12 cells were 
functionalized with liposomes containing different amounts of 2-dodecanone (w/w) that had been 
reacted with AF-488 and analyzed by flow cytometry. As an approximation, these data were 
compared to PC12 cells labeled with a CS-E monoclonal antibody.  
 
 
 
 
 
\ 
 
 
 
 
 
Figure 2-5. Biophysical characterization of conjugated liposomes. (A) Schematic of different 
liposomes used for characterization. (B) Liposomes were negatively stained with uranyl acetate and 
imaged using TEM (scale bar = 50 nm). (c) DLS was used to measure average liposome 
hydrodynamic diameters, which showed increases after functionalization. Zeta potential analysis 
showed a negative shift in potential after functionalization with sulfated GAGs. (d) Energy dispersion 
spectroscopy showed the incorporation of sulfur after functionalization with sulfated GAGs.  
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display large GAG polysaccharides on cell surfaces. Liposomes containing 2:1 
w/w DOPE:DOTAP and 10% w/w dodecanone were functionalized with CS-E-
enriched polysaccharides (∼70 kDa). To characterize their biophysical properties, 
we used transmission electron microscopy (TEM), dynamic light scattering 
(DLS), and zeta potential measurements. The liposomes exhibited parameters 
predicted to favor membrane fusion, including spherical morphologies, average 
diameters ranging between 132.6 and 159.6 nm, and good stabilities (zeta 
potentials of ±46−69 mV; Figure 2-5b). The change from positive to negative 
electrokinetic potential (69 to −46 mV; Figure 2-5c) confirmed successful 
conjugation of the sulfated polysaccharides. Furthermore, energy dispersive 
spectroscopy (EDS) verified the presence of sulfur on CS-functionalized 
liposomes after CS conjugation (Figure 2-5d). To test for membrane fusion, PC12 
cells were treated with chondroitinase to remove endogenous CS, incubated with 
CS-E-modified liposomes, and immunostained with an anti-CS-E antibody. 
Importantly, strong immunostaining for CS-E was observed on the surfaces of 
cells treated with CS-E-functionalized liposomes compared to chondroitinase-
treated cells without liposome addition, indicating efficient incorporation of the 
polysaccharides (Figure 2-6).  
2.2.3 Controlling Intracellular Signaling  
 Having validated the method, we investigated whether the approach could be 
used to control cellular signaling pathways. Previous studies from our laboratory  
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Figure 2-6. Validation of cell functionalization with CS-E via liposomal delivery. PC12 cells 
were left untreated, treated with chondroitinase ABC (ChABC), or treated with ChABC and then CS-
E displaying liposomes (IIIE) and then immunostained with a CS-E monoclonal antibody. 
have demonstrated that CS-E polysaccharides can recruit nerve growth factor 
(NGF) to the cell surface and promote the assembly of NGF-tropomyosin 
receptor kinase (Trk) complexes.18 Complex formation, in turn, activates protein 
kinase B (Akt) and phosphatidylinositol 3-kinase (PI3K) signaling pathways and 
thereby enhances neurite outgrowth.19 Thus, we reasoned that cell-surface 
presentation of exogenous CS-E polysaccharides might recruit NGF to the 
membrane and assist in the formation of activated signaling complexes to induce 
these biological responses. Embryonic day 18 (E18) rat cortical neurons were 
cultured in vitro for 7 days and then treated with liposomes displaying CS-E- or 
CS-C-enriched polysaccharides (IIIE or IIIC, 30 min, 37 °C). Neurons were 
stimulated with the neurotrophin NGF for 0, 10, 30, or 60 min, and Akt activation 
was monitored using a phospho-Ser473 Akt antibody. Remarkably, neurons 
remodeled with CS-E polysaccharides showed approximately a 3-fold increase in 
Akt activation relative to untreated neurons at each time point (Figure 2-7), 
consistent with increased recruitment of NGF to the cell surface and robust  
+ ChABC + ChABC
+ IIIE
- ChABC
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Figure 2-7. Potentiation of Akt signaling via cell surface glycan engineering. Embryonic 
cortical neurons were left untreated or functionalized with CS-C- (IIIC) or CS-E- (IIIE) displaying 
liposomes. Cells were then stimulated with NGF, and Akt activation was monitored by (A) Western 
blotting with (B) quantification. * P < 0.05. 
activation of Trk receptors. In contrast, neurons remodeled with CS-C 
polysaccharides showed phospho-Akt levels similar to those of untreated 
neurons. These results support the importance of the CS-E motif in NGF-
stimulated Trk activation.18 Moreover, they show that liposomal-mediated 
presentation of specific, sulfated CS polysaccharides on cell surfaces can activate 
important neuronal signaling pathways.  
2.2.4 Controlling Neuronal Growth 
 We next examined whether the exogenous CS-E-mediated activation of Trk 
pathways could direct neuronal growth. Rat E18 hippocampal neurons were 
cultured in vitro for 2 days and subsequently treated for 30 min with liposomes 
prefunctionalized with CS-A-, CS-C-, or CS-E-enriched polysaccharides. Neurons 
were then incubated in media lacking liposomes for an additional 24 h and 
immunostained with an anti-α-tubulin antibody to image the processes using  
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Figure 2-8. Surface lifetime of lipid-anchored molecules. PC12 cells were functionalized with 
(A) AF488- (II) or (B) fluorescent CS-E- (IIIE) functionalized liposomes and monitored by 
microscopy. The membrane lifetime of both molecules lasts only a few hours, with the signal from 
the small molecule dye being slightly longer lived. Scale bar = 50 μm for (A) and 30 μm for (B). 
confocal fluorescence microscopy. Initial studies revealed no appreciable 
difference in neurite outgrowth between neurons displaying the different 
sulfation motifs. We postulated that the membrane lifetime of the exogenous CS 
GAGs might be too short to elicit functional responses such as neurite outgrowth, 
which requires de novo protein and lipid biosynthesis. Therefore, we assayed the 
membrane lifetime of the exogenous lipids by treating PC12 cells with liposomes 
bearing fluorophore-conjugated CS-E polysaccharides and monitoring the 
fluorescence signal over 24 h (Figure 2-8). A decrease in signal was observed 
within 6 h, and loss of the signal progressed over the course of 10 h. After 16 h, 
weak fluorescence was detected around the cell periphery, suggesting that the CS-
conjugated lipids had been internalized or had diffused into the medium. To 
circumvent this problem, we repeated the outgrowth assays with multiple 
additions of liposomes every 8 h over a 24-h period. Under these conditions, we  
10 h 16 h 24 h0 h 3 h 6 h
10 h 16 h 24 h0 h 3 h 6 hA
B
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Figure 2-9. Controlling neurite outgrowth via cell surface glycan engineering. Embryonic 
hippocampal neurons were left untreated or treated with CS-A- (IIIA), CS-C- (IIIC), or CS-E- (IIIE) 
functionalized liposomes once every 8 hours for 24 h. Samples were (A) visualized by 
immunofluorescence and (B) quantified. For all samples, liposomes were produced with 10% w/w 2-
dodecanone except for the panel of IIIE liposomes. Neurite outgrowth could be finely tuned by the 
amount of CS-E added onto the surface. Treatment with liposomes that had been incubated with 
CS-E without the aminooxy group showed no difference in outgrowth compared to control samples. 
Scale bar = 50 μm. * P < 0.05. 
found that cell-surface presentation of CS-E polysaccharides significantly 
enhanced neurite outgrowth by 36.3 ± 3.3% relative to untreated neurons (Figure 
2-9). As expected, neurons displaying CS-A or CS-C polysaccharides showed 
minimal neurite outgrowth when compared to untreated neurons (10.8 ± 4.8% 
and 1.3 ± 1.8%, respectively). As a further control, dodecanone-containing 
liposomes were reacted with CS-E polysaccharides lacking the aminooxy 
functionality and then incubated with the cells. No difference in neurite 
outgrowth was observed relative to untreated neurons. Remarkably, the extent of 
neurite outgrowth could be finely tuned by controlling the concentration of CS-E 
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polysaccharides at the cell surface. Liposomes containing 0% to 10% dodecanone 
were conjugated with aminooxy-functionalized CS-E and then incubated with E18 
rat hippocampal neurons as above. Notably, we observed a dose-dependent 
increase in neurite outgrowth from 4.0% to 36.3% as the dodecanone 
concentration was increased from 2.5% to 10% (Figure 2-9). Together, these 
studies demonstrate that this approach for engineering glycans on cell surfaces 
can be used to finely modulate both the signaling and functional responses of 
neurons. 
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2.3 HaloTag Anchoring of HS GAGs to Control Stem Cell Differentiation 
2.3.1 Approach and Synthesis 
 Heparan sulfate (HS) glycosaminoglycans (GAGs) have recently been 
identified as important regulators of stem cell differentiation.20-24 HS GAGs exert 
this control by selectively interacting with proteins involved in the differentiation 
process, such as fibroblast growth factors (FGFs), bone morphogenic proteins 
(BMPs), and wingless-type MMTV integration site family members (Wnts).22, 25 
Furthermore, specific sulfation patterns of HS have been implicated in the 
progression of ESCs from self-renewal to a differentiated state. For example, 
undersulfated HS is found on pluripotent cells,23 whereas highly sulfated HS is 
associated with differentiated cells and has been proposed to promote 
interactions between soluble FGF and BMP factors and their receptors.22 
However, the precise sulfated epitopes and mechanisms involved in the 
generation of specific cell lineages remain unclear. We postulated that the 
presentation of particular HS GAG structures on ESC surfaces might enable the 
selective activation of signaling pathways and thereby induce desirable cell fates. 
Such an approach would also provide novel insights into the structure-function 
relationships of HS GAGs and their roles in stem cell biology.  
 Elegant studies have recently shown that the short-term display of synthetic 
HS glycopolymers can promote stem cell specification to form intermediate 
neural rosettes.26 However, directing the generation of fully differentiated,  
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Figure 2-10. Schematic of HTP glycan engineering approach. HS GAGs modified with the CL 
linker are added directly to cells expressing the transmembrane HTP construct, which covalently 
bonds to the CL linker. 
mature cell types will likely require the development of new methods to enable 
the long-term, stable presentation of defined HS GAGs. Although our liposomal 
method as well as the passive lipid insertion technique can elicit short-term 
cellular responses,8, 27 the lipid tail anchor limits the membrane lifetime of the 
exogenous glycans to several hours. To address these shortcomings, we 
developed a method to tailor cell surfaces with specific HS derivatives using 
membrane-bound HaloTag proteins (HTPs) as anchors (Figure 2-10). Molecules 
covalently attached to HTPs displayed prolonged cell-surface lifetimes of more 
than one week, circumventing the temporal limitation of lipid anchors. Moreover, 
mouse ESCs remodeled with heparin/trisulfated HS underwent accelerated exit 
from selfrenewal and commitment to a neural lineage through early activation of 
extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK) signaling pathways. These results highlight the potential to elucidate the 
functional roles of HS GAGs and direct cell differentiation by remodeling the 
glycocalyx of stem cells. 
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Figure 2-11. Synthesis of 2-13 and F-CL. (a) Boc2O (2 eq), MeOH, 0 °C, 2 h, 91%; b) 60% NaH 
(1.5 eq), DMF, 0 °C, 1 h, then 1-chloro-6-iodohexane (1.2 eq), 24 h, 37%; c) TFA (6 eq), DCM, 4 h, 
then 2-12 (1 eq), DCM, 24 h, 67%; d) 5-(((2-(carbohydrazino)methyl) thio)acetyl)-aminofluorescein 
(F) (0.5 eq), MeOH, 16 h, 75%. 
 HTP is a modified alkane dehalogenase that forms a covalent adduct with 
chloroalkane substrates.28 Strategies based on HTP have been adapted for diverse 
applications, ranging from cancer diagnostics to chemical proteomics.29-31 
However, most reported applications have used HTP methods to append 
molecules that serve as detection or capture agents. We chose to exploit the HTP 
platform to modulate biological processes in living cells. We first investigated the 
membrane lifetime of molecules conjugated to HTPs. N-tert-Butyloxycarbonyl 
(Boc)-protected 1-(2-(2-amino-ethoxy)ethoxy)-6-chlorohexane 2-1131 was 
deprotected with trifluoroacetic acid and reacted with N-hydroxysuccinimidyl 
levulinate 2-12 to obtain chloroalkane linker (CL) 2-13 (Figure 2-11). 
Condensation of 2-13 with a fluorescein-hydrazide derivative gave CL-conjugated 
fluorescein (F-CL).  
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2.3.2 Validation 
 To test the approach, hemagglutinin (HA)-tagged HTP was stably expressed in 
Chinese hamster ovary (CHO) cell membranes by fusing it to the platelet-derived 
growth factor receptor (PDGFR) transmembrane domain. Cells were then 
incubated with F-CL for one hour at 37 °C, and individual wells were fixed and 
imaged every twelve hours for eight days. Remarkably, we observed a strong 
fluorescence signal that persisted for at least eight days after only a single F-CL 
treatment (Figure 2-12). In contrast, no fluorescence signal was observed when 
cells were treated with the fluorescein-hydrazide derivative alone or with cells 
lacking HTP. These results indicate that the display of HTP conjugates is specific 
and long-lived despite membrane turnover, highlighting the potential of this 
approach to exert long-lasting effects on cellular function. We next examined 
whether this method could be used to present HS GAGs on cell surfaces. 
Although the glucosamine sugars in heparin/HS are mostly N-acetylated or N-
sulfated, the free amine is also present in low abundance (1–3%), which provides 
a convenient functional handle for attaching the chloroalkane linker in a single 
step. We biotinylated HS (B-HS) and conjugated it to 1 by reductive amination 
chemistry (B-HS-CL; Figure 2-13). CHO cells stably expressing HTP were 
incubated with B-HS or B-HS-CL at 37 °C for six hours. Cells were lysed and 
subjected to blotting analysis using an anti-HA antibody and streptavidin 
IRDye800. Importantly, biotinylated HS was detected only from HTP-expressing  
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Figure 2-12. Surface lifetime of HTP-anchored molecules. CHO cells expressing HTP were 
treated with (A) F-CL or (B) F and monitored by microscopy for over one week. Surface labeling 
was observed at 8 days with no nonspecific labeling from unlabeled fluorescein (F). Scale bar = 50 
μm. 
 
 
 
 
 
Figure 2-13. Synthesis of B-HS and B-HS-CL. (a) BrCN (excess), 0.2 M NaOH pH 11, RT, 10 
min, then BiotinPEG4NH4 (excess), 0.2 M sodium borate pH 8, RT, 12 h; (b) 2-13 (excess), 
NaBH3CN (excess), MeOH, ddH2O, RT, 16 h. 
cells treated with B-HS-CL, but not B-HS, which lacks the chloroalkane moiety 
(Figure 2-14). Immunocytochemical analysis of cells further confirmed the 
presence of biotinylated HS on HTP-expressing cells incubated with B-HS-CL, but 
not B-HS. Together, these studies demonstrate the selective display of HS GAGs 
on cell surfaces using HTP anchors. 
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Figure 2-14. Glycan engineering with HS GAGs. CHO cells expressing HTP or not were 
incubated with B-HS-CL or B-HS. Incorporation of HS onto the cell surface was validated by (A) 
immunofluorescence or (B) Western blotting. Scale bar = 50 μm. 
2.3.3 Deconvoluting the Role of HS GAG Sulfation Epitopes in FGF Activation 
 With a method for the long-lived presentation of GAGs in hand, we examined 
the ability of our non-natural presentation of HS GAGs to stimulate stem cell 
signaling pathways. HS GAGs regulate FGF-FGF receptor (FGFR) signaling events 
involved in stem cell differentiation by assisting in the assembly of active growth 
factor/receptor complexes.32, 33 Activation of FGF2-FGFR1, in turn, initiates 
several intracellular signaling pathways, including the ERK/MAPK cascade.34 A 
distinct period of increased ERK1/2 phosphorylation through FGF signaling 
triggers ESCs to exit self-renewal and the transition to a neural cell fate.35, 36 To 
display particular sulfated HS structures on ESCs and stimulate the FGF2-FGFR1 
pathway, we conjugated 2-13 to various heparin/HS polysaccharides. The 
commercially available polysaccharides (12–13 kDa) were derived from a single  
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Figure 2-15. Chemical structures of HS GAGs.  
natural source and chemically desulfated to produce heparin/HS with defined 
sulfation motifs. Specifically, CL-functionalized heparin/trisulfated HS (HS-CL), 
fully desulfated heparin/HS (de-HS-CL), O-desulfated heparin/HS (deO-HS-CL), 
6-O-desulfated heparin/HS (6-deO-HS-CL), and 2-O-desulfated heparin/HS (2-
deO-HS-CL) were readily generated in one step under standard reductive 
amination conditions (Figure 2-15). A homogeneous population of pluripotent 
mouse ESCs were obtained commercially and transiently transfected with the 
HTP construct. The ESCs were treated with heparinase II to remove endogenous 
HS GAGs and incubated overnight in serum-depleted medium containing the 
various HS-CL derivatives. Cells were then stimulated with FGF2 and assayed for 
ERK1/2 activation by immunoblotting with antibodies against phosphorylated 
(pThr202/pTyr204) and total ERK1/2. To our delight, ESCs engineered to display 
heparin/trisulfated HS exhibited a 1.5-fold increase in ERK1/2 phosphorylation 
compared to untreated cells (Figure 2-16a). HS-CL had no effect on ESCs lacking 
HTP, confirming that ERK1/2 activation required the HTP anchors (Figure 2-
16b). Moreover, ERK1/2 activation was dependent on the sulfation pattern, as  
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Figure 2-16. ERK1/2 activation by cell surface engineering. (A) mESCs were transfected with 
the HTP construct, functionalized with different HS-CL structures and then stimulated with FGF2. 
ERK1/2 phosphorylation was measured by Western blotting and quantified. (B) The same 
experiment was conducted with untransfected mESCs. * P < 0.05. 
cells engineered with other selectively desulfated heparin/HS variants showed no 
significant increase in phospho-ERK1/2 levels. 
 Structural and biochemical studies have led to conflicting reports on the 
pivotal determinants of HS-FGF2-FGFR1 complexation and ERK1/2 activation.33, 
37, 38 For example, crystallographic studies suggested that 6-O-sulfation is critical 
for both ligand and receptor binding,33 whereas certain biochemical studies 
indicated that downstream ERK1/2 activation elicited by the complex is not 
significantly attenuated by loss of the 6-O-sulfate group.38 Interestingly, the same 
crystallographic studies showed that the other sulfate groups are also important 
for interactions with FGF2, suggesting that all three of the sulfate groups may be 
required for formation of the ternary HS-FGF2-FGFR1 complex.33 To clarify the 
role of sulfation, we used GAG microarrays18 to probe the ternary interaction  
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Figure 2-17. Ternary complex formation between FGF2 and FGFR1 with HS. Microarrays were 
incubated with FGFR1-Fc with and without FGF2. Bound FGFR1-Fc was visualized by an anti-
human Fc antibody. 
more closely. Microarrays printed with various concentrations of the HS 
derivatives were incubated with an FGFR1-Fc fusion protein in the presence or 
absence of FGF2. Binding of FGFR1-Fc was visualized using an anti-Fc antibody 
conjugated to AlexaFluor 647. We found that FGFR1 bound preferentially to 
heparin/trisulfated HS only in the presence of FGF2, suggesting the formation of 
a ternary complex (Figure 2-17). Consistent with our ERK1/2 activation studies, 
binding of FGFR1 was significantly attenuated by either 2-O- or 6-O-desulfation of 
HS. Taken together, our studies suggest that both 2-O- and 6-O-sulfation of HS are 
critical for FGF2-FGFR1-mediated ERK1/2 activation in ESCs. Thus, an HTP-
based approach can be used to hijack endogenous signaling pathways and 
deconvolute the sulfation requirements of complex GAG-mediated processes.  
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2.3.4 Accelerating Stem Cell Differentiation 
 Finally, we investigated whether the HTP-dependent presentation of specific 
heparin/HS epitopes could promote stem cell differentiation into mature cell 
types. Dopaminergic neurons from fetal sources have shown long-term cell 
survival and preliminary clinical benefits when implanted into patients with 
Parkinson’s disease.39, 40 As such, the development and refinement of in vitro 
systems to generate neuronal cell populations could have widespread biomedical 
implications for the treatment of neurological diseases. The differentiation of 
ESCs into dopaminergic neurons is promoted by FGF8b.41 Interestingly, our 
microarray studies indicated that FGF8b and its receptor FGFR3c are capable of 
forming ternary complexes with heparin/trisulfated HS, whereas complex 
assembly was attenuated with 2-O-desulfated or 6-O-desulfated heparin/HS and 
was not observed with fully O-desulfated heparin/HS (Figure 2-18). Pluripotent 
mouse ESCs transiently expressing HTP were treated with heparinase II and then 
grown in neural induction medium supplemented with FGF2 and HS-CL. For 
comparison, ESCs were treated identically, but in the absence of HS-CL 
(untreated) or replacing HS-CL with de-HS-CL. After two days, the FGF2-
containing medium was substituted with a neural induction medium containing 
FGF8b. We monitored the differentiation process at specific time points by 
profiling the gene expression levels of specific markers using real-time 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses  
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Figure 2-18. Ternary complex formation between FGF8b and FGFR3c with HS. Microarrays 
were incubated with FGFR3c-Fc with and without FGF8b. Bound FGFR3c-Fc was visualized by an 
anti-human Fc antibody. 
(Figure 2-19). The transcription factors NANOG and SOX1 are well-established 
markers for pluripotency and self-renewal exit/neural lineage commitment, 
respectively, whereas TUJ1 is widely used as a specific marker for mature, fully 
differentiated neurons.42 In parallel, the presence of NANOG, SOX1, and TUJ1 in 
cells was imaged by immunocytochemistry (Figure 2-20). We found that mRNA 
NANOG levels declined most rapidly in ESCs treated with HS-CL, which is 
consistent with an accelerated loss of pluripotency. In contrast, the levels 
remained high until day nine in untreated cells and cells treated with de-HS-CL. 
The decrease in NANOG levels at day nine for untreated and de-HS-CL treated 
cells is most likely due to de novo HS biosynthesis following the single heparinase 
treatment. Consistent with an accelerated loss of pluripotency, the decline in 
NANOG levels in HS-CL-treated cells was accompanied by a corresponding  
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Figure 2-19. Accelerated stem cell differentiation with glycan engineering (qRT-PCR). 
mESCs expressing HTP were incubated with nothing, HS-CL, or de-HS-CL and cultured in 
differentiation medium as described. Differentation was monitored by qRT-PCR of NANOG, SOX1, 
and TUJ1. * P < 0.05, ** P < 0.01. 
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Figure 2-20. Accelerated stem cell differentiation with glycan engineering 
(immunofluorescence). mESCs from the experiment described in Figure 2-18 were stained for 
NANOG (green), SOX1 (red), or TUJ1 (red) and DAPI (blue). Scale bar = 50 μm. 
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Figure 2-21. Mature neuronal processes on differentiated mESCs.  mESCs from the 
experiment described in Figure 2-18 were allowed to grow to 9 or 12 days and were stained for 
TUJ1 (red) and DAPI (blue). Scale bar = 50 μm. 
increase in the neuroectoderm-specific marker SOX1. At day six, SOX1 levels 
were significantly higher in HS-CL-treated cells than in untreated or de-HS-CL-
treated cells, suggesting that HS-CL-treated cells had undergone accelerated exit 
from self-renewal and commitment to an intermediate, neuroectoderm state. 
Importantly, cells remodeled with HS-CL also showed significantly higher levels 
of TUJ1 than untreated or de-HS-CL-treated cells at all time points, which is 
indicative of faster progression to a mature, differentiated neuronal phenotype. 
As expected, the cells also developed more elaborate neurite processes than the 
untreated cells and de-HS-CL treated cells (Figure 2-21). Interestingly, cells 
Day 12
untreated de-HS-CLHS-CL
Day 9
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remodeled with de-HS-CL showed significantly lower amounts of SOX1 at day 
nine and TUJ1 at days three and six compared to untreated cells, which is 
consistent with studies suggesting that undersulfated HS may help to maintain 
pluripotency and restrict differentiation.23 Together, our results illustrate the 
power of using long-term cell-surface displays of HS GAGs to activate specific 
signaling events and drive the differentiation of stem cells into mature neuronal 
populations. 
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2.4 Materials and Methods for Liposomal Experiments 
2.4.1 Chemicals, Biochemical Reagents, Cell Lines, and Animals  
All chemicals and reagents were of analytical grade, obtained from Sigma Aldrich, 
and used without further purification unless specified. Chondroitin sulfate (CS)-
A, -C, and -E polysaccharides and chondroitinase ABC (ChABC) were purchased 
from Seikagaku Corporation. 1,2-Dioleoyl-sn-glycero-3-phosphoethanolaime 
(DOPE) and 1,2-dioleoyl-3-trimethylammoniumpropane chloride (DOTAP), 
were purchased from Avanti Polar Lipids, Inc. All secondary antibodies 
(AlexaFluor (AF) 680 goat anti-rabbit, AF680 goat anti-mouse, and AF488 goat 
anti-mouse), AF488 hydrazide sodium salt (AF488-hydrazide), and cell culture 
media and reagents were obtained from Life Technologies Corporation. Adherent 
pheochromocytoma cells (PC12 cells; CRL-1721.1), horse serum (HS), and F-12K 
media (30-2004) were obtained from American Type Culture Collection. 
Accutase (AM105) was received from Innovative Cell Technologies, Inc. Nerve 
growth factor (NGF) was obtained from R&D Systems, Inc. Primary antibodies 
against phospho-Akt (Ser473) (4060) and total Akt (4691) were purchased from 
Cell Signaling Technology, Inc. Sprague-Dawley rats were obtained from Charles 
River Laboratories, Inc. 
2.4.2 Synthetic Methods 
tert-Butyl 2-((1,3-dioxoisoindolin-2-yl)oxy)acetate (2-1). To a solution of N-
hydroxyphthalimide (3.03 g, 18.6 mmol, 1.20 eq) in DMF (30 mL) was added 
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NaHCO3 (1.56 g, 18.6 mmol, 1.20 eq). The mixture was stirred at 60 °C for 1 h, 
after which tert-butyl 2-bromoacetate (2.77 mL, 15.5 mmol) was added. The 
reaction mixture was stirred for 16 h at 60 °C. The mixture was then diluted with 
DCM (30 mL), extracted with 1 M NaHCO3 until the aqueous layer became 
colorless, washed with ddH2O (2 x 25 mL) and brine (1 x 25 mL), dried over 
MgSO4, and concentrated to afford a yellow solid 2-1. The product was purified by 
silica flash chromatography (Hex:EtOAc, 85:15) to afford a white solid 2-1 (3.76 
g, 88%). 1H NMR (500 MHz, CDCl3): δ 1.48 (s, 9H, CH3), 4.71 (s, 2H, CH2), 7.75-
7.76 (m, 2H, J = 5 Hz, Ar-H), 7.84-7.85 (m, 2H, J = 5 Hz, Ar-H).  
2-((1,3-Dioxoisoindolin-2-yl)oxy)acetic acid (2-2). Compound 2-2 was synthesized 
as previously described.43 Briefly, TFA (2 mL) was slowly added to a solution of 4 
(0.51 g, 1.8 mmol) in DCM (6.0 mL). The mixture was stirred at RT for 2 h under 
Ar. The reaction was then concentrated and azeotroped with DCM (3 x 5 mL) to 
afford a white solid 5 (0.40 g, 99%). 1H NMR (500 MHz, CDCl3): δ 4.88 (s, 2H, 
CH2), 7.85-7.87 (m, 2H, J = 10 Hz, Ar-H), 7.93-7.94 (m, 2H, J = 10 Hz, Ar-H). 
2-((1,3-Dioxoisoindolin-2-yl)oxy)-conjugated CS polysaccharides (2-3, 2-4, 2-5). To 
a buffered solution containing 0.1 M MES and 0.5 M NaCl (pH 6.0), 2-2 (5.0 mg, 
0.023 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC; 4.2 mg, 0.027 mmol, 1.2 eq), sulfo-N-hydroxysuccinimide (sulfo-NHS; 7.5 
mg, 0.035 mmol, 1.5 eq) were added, and the mixture was stirred at RT for 30 
min. Concurrently, CS-E, CS-A, or CS-C (4.0 mg, ~70 µmol, ~0.5 eq) was stirred in 
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0.05 M NaHCO3 for 30 min. The polysaccharide amine solution was then added to 
the small molecule acid mixture and allowed to react for 12 h at RT under Ar. The 
mixture was then purified via dialysis against ddH2O for 48 h (6 x 8 h) using a 
molecular weight membrane of 35,000 Da, followed by gel filtration 
chromatography (G-25). Fractions containing the polysaccharide were 
lyophilized to afford white solids. For 2-3 CS-E: 1H NMR (500 MHz, CDCl3): δ 
2.04 (s, 3H, CH3), 3.28-3.49 (m, 2H, CH), 3.51-4.35 (m, 9H, CH, CH2OSO3-), 
4.42-4.67 (m, 1H, CH), 7.48 (m, 2H, Ar-H), 7.58 (m, 2H, Ar-H). 64% yield. For 2-
4 CS-A: 1H NMR (500 MHz, CDCl3): δ 2.03 (s, 3H, CH3), 3.40 (br s, 1H, CH), 3.64 
(br s, 1H, CH), 3.72-3.95 (m, 6H, CH), 4.03 (br s, 2H, CH), 4.51-4.63 (m, 2H, 
CH), 7.62 (m, 1H, Ar-H), 7.77 (m, 1H, Ar-H). 60% yield. For 2-5 CS-C: 1H NMR 
(500 MHz, CDCl3): δ 2.02 (s, 3H, CH3), 3.39 (br s, 1H, CH), 3.64 (br s, 1H, CH), 
3.72-4.06 (m, 6H, CH, CH2OSO3-), 4.12-4.27 (m, 3H, CH), 4.57 (br s, 1H, CH), 
7.62 (m, 2H, Ar-H), 7.75 (m, 2H, Ar-H). 78% yield. 
Aminooxy-conjugated CS polysaccharides (2-6, 2-7, 2-8). Hydrazine monohydrate 
(1 µL, 0.031 mmol, 4.3 eq) was added dropwise to a solution of 2-3, 2-4, or 2-5 
(4.0 mg, ~70 µmol) in ddH2O (4 mL), and the mixture was stirred for 3 h at RT 
under Ar. The solution was then purified via dialysis against ddH2O for 48 h (6 x 8 
h) using a molecular weight membrane of 35,000 Da, followed by gel filtration 
chromatography (G-25). Fractions containing the polysaccharide were 
lyophilized to afford white solids. For 2-6 CS-E: 1H NMR (600 MHz, CDCl3): δ 
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2.04 (s, 3H, CH3), 3.38 (br s, 1H, CH), 3.56-3.85 (m, 5H, CH), 3.86-4.33 (m, 4H, 
CH, CH2OSO3-), 4.42-4.67 (m, 2H, CH). For 2-7 CS-A: 1H NMR (500 MHz, 
CDCl3): δ 2.04 (s, 3H, CH3), 3.39 (br s, 1H, CH), 3.61 (br s, 1H, CH), 3.69-3.87 
(m, 6H, CH), 4.08 (br s, 2H, CH), 4.46-4.64 (m, 2H, CH). For 2-8 CS-C: 1H NMR 
(500 MHz, CDCl3) δ 2.03 (s, 3H, CH3), 3.38 (br s, 1H, CH), 3.61 (br s, 1H, CH), 
3.69-4.06 (m, 5H, CH, CH2OSO3-), 4.15-4.27 (m, 3H, CH), 4.46-4.65 (m, 2H, CH). 
Fluorophore-conjugated aminooxy-CS-E (2-9). The protocol for conjugating 
aminooxy-CS-E with fluoresceinamine was adapted from Glabe et al.44 To a 
stirring solution of 2-6 (1.00 mg, 14.29 µmol) in ddH2O (1 mL) was added 
cyanogen bromide (1.00 mg, 0.00094 mmol, excess) in ddH2O (0.3 mL). The pH 
of the reaction was adjusted to 11.0 using 0.2 M NaOH, which was stirred for 10 
min at RT. The mixture was then desalted on a disposable PD-10 Sephadex 
column (17-0851-01, GE Healthcare Biosciences) using 0.2 M sodium borate 
buffer (pH 8.0). The CS-E fractions were pooled (3 mL) and immediately stirred 
with fluoresceinamine (1.00 mg, 0.0029 mmol, excess) in the dark overnight (12 
h). The mixture was concentrated and purified on a G-25 Sephadex column in the 
dark. The CS-E fractions were again pooled, flash frozen, and lyophilized to afford 
an orange solid 2-9.  
2.4.3 Liposomal Formation and Characterization 
Liposome formation. A solution of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE, 120 µL, 10 mg/mL in CHCl3), dodecanone (12 µL, 10 mg/mL in CHCl3), 
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and 1,2-dioleoyl-3-trimethylammoniumpropane chloride salt (DOTAP, 60 µL, 10 
mg/mL in CHCl3) was thoroughly mixed and then dried with a stream of argon 
followed by high vacuum for 12 h. The dried lipids were reconstituted in ddH2O 
(2 mg/mL total lipids) and hydrated for 30 min. The mixture was then sonicated 
for 2 min and extruded (11 passes through the membrane) to form large 
unilaminar vesicles using a mini-extruder (Avanti Polar Lipids, Inc.) according to 
the manufacturer’s instructions. 
Liposome conjugation. AF488-hydrazide-presenting liposomes: Liposomes (100 
µL, 2.24 mM dodecanone) were incubated with AF488-hydrazide (12.8 µL, 1.75 
mM, 10:1 ketone/hydrazide) for 3 h at RT in the dark overnight at a 
stoichiometric ratio to label approximately 10% of the available ketones. This 
ratio was chosen after method optimization to conserve carbohydrate material 
but maintain a significant amount of cell labeling. CS-aminooxy-tethered 
liposomes: Liposomes (100 µL, 2.24 mM dodecanone) were reacted with CS-
A/C/E-aminooxy-polysaccharides 2-6, 2-7, or 2-8 (~20 µL, 33.3/31.7/25.6 µM) 
for 3 h at RT in the dark overnight. Mixed liposomes: Liposomes (100 µL, 2.24 
mM dodecanone) were reacted with CS-A/C/E-aminooxy polysaccharides 2-6, 2-
7, or 2-8 (~20 µL, 33.3/31.7/25.6 µM) for 4 h at RT in the dark, followed by 
AF488-hydrazide at a stoichiometric ratio to label approximately 10% of the 
available ketones. 
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Dynamic light scattering (DLS). Ketone-presenting (I) and AF488-hydrazide- (II), 
CS-A-ONH2- (IIIA), CS-E-ONH2- (IIIE), and mixed AF488/CS-A-ONH2- (IV) 
conjugated liposomes were generated as described above and diluted (1:20) with 
1.5 mM KCl. The size distributions of these liposomal samples were then 
determined using a DynaPro NanoStar (Wyatt Technologies) DLS instrument. 
The data are represented as the mean liposomal hydrodynamic diameter ± S.E.M. 
with eight to ten measurements conducted per experiment (n = 3). 
Zeta potential analyses. Ketone-presenting (I) and AF488-hydrazide- (II), CS-A-
ONH2- (IIIA), and CS-E-ONH2- (IIIE), mixed AF488/CS-A-ONH2- (IV) 
conjugated liposomes were generated as described above, diluted (1:20) with 1.5 
mM KCl, and subjected to zeta potential analyses using a ZetaPALS (Brookhaven 
Instruments Corp.) analyzer. The data are represented as the mean zeta potential 
± S.E.M. with three to ten measurements conducted per experiment (n = 3). 
Transmission electron microscopy (TEM) and energy dispersion spectroscopy (EDS). 
Dodecanone-containing liposomes were prepared and conjugated with AF488-
hydrazide and CSA-aminooxy polysaccharide 2-7 as described above. A drop of 
each liposome sample was placed on a TEM copper/carbon grid for 30 s, which 
was then blotted using filter paper. A drop of 2% uranyl acetate was then added to 
each sample for 5 min followed by blotting with filter paper. The grid was then 
rinsed with ddH2O and dried. TEM and elemental analyses of each liposome 
sample were performed using an FEI Tecnai F30UT (300 kV) equipped with a 
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high angle annular dark field detector, an Oxford energy dispersion X-ray 
detector, and an AMT CCD camera. 
2.4.4 Biological Procedures 
Cell culture. PC12 cells were cultured on collagen-coated (10 µg/mL) tissue 
culture plates in F-12K media supplemented with 6.5% HS, 6.5% FBS, and 1x 
penicillin/streptomycin (P/S) at 37 °C with 5% CO2. Hippocampal and cortical 
neurons were cultured in Neurobasal media supplemented with B27, 20 mM 
GlutaMAX, and 1x P/S at 37 °C with 10% CO2. 
Cell-surface remodeling. AF488-hydrazide-bearing liposomes were diluted 1:100 
with the appropriate cell culture medium and incubated with PC12 cells or 
hippocampal neurons for 30-45 min. The medium was removed, and the cells 
were washed three times with 0.5 mL of sterile 1x phosphate buffered saline 
(PBS). Fresh medium (0.5 mL) was then added, and the cells were imaged live 
under a Zeiss LSM 5 Pascal inverted confocal microscope (Carl Zeiss 
Microscopy). For labeling differentiated PC12 cells with CS-E, PC12 cells were 
cultured on collagen-coated tissue culture plates and stimulated with NGF (100 
µM; 256-GF, R&D Systems) to induce differentiation. After 4 d of NGF treatment, 
the cells were treated with 1 U/mL ChABC (1:1 activation buffer (0.4 M Tris/HCl 
pH 8.0, 0.4 M NaOAc, 0.1% BSA)/complete medium) for 2 h (37 °C, 5% CO2). 
The cells were then washed with PBS (4 x 0.5 mL), and medium that was 
supplemented with CS-E-functionalized liposomes (diluted 1:100) was added for 
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30-45 min. After fusion, the cells were fixed with 4% paraformaldehyde (PFA) in 
PBS for 20 min, stained with a monoclonal mouse anti-CS-E antibody (1:250 in 1% 
BSA/0.1% Triton X-100/PBS; 4 °C, 12 h), followed by an AF488-conjugated goat 
anti-mouse antibody (1:1000 in 1% BSA/0.1% Triton X-100/PBS; RT, 1 h), and 
imaged using a Zeiss LSM-5 Pascal inverted confocal microscope. 
Immunochemistry. For imaging, cells were fixed with 4% PFA in PBS (15 min), 
rinsed with PBS twice, permeated, and blocked with a solution containing 1% BSA 
and 0.1% Triton X-100 (20 min), incubated with a monoclonal mouse anti-CS-E 
antibody (1:250; 4 °C, 12 h), washed with PBS (2 x 5 min), incubated with an 
anti-mouse AF488 antibody (1:1000; RT, 1 h), washed with PBS (2 x 5 min), and 
imaged under a Zeiss LSM 5 Pascal inverted confocal microscope. 
Flow cytometry. Dodecanone-containing liposomes were prepared as mentioned 
above with the exception that the ratio of dodecanone to DOPE was varied (0, 5, 
10, 15, and 20% w/w). PC12 cells were cultured until ~80% confluent and then 
detached from the tissue culture plate using TrypLE. The cells were twice washed 
with cold PBS (500 µL) and spun down (1,400 x g, 2.5 min). For AF488-hydrazide 
labeling, the cells with resuspended and incubated on ice in a buffered solution 
(45 mM BSA, 10 mM HEPES, and DNase I (0.5 U/mL) in HBSS at pH 7.4) 
containing 0, 5, 10, 20% w/w ketone-hydrazide conjugated liposomes for 30 min 
(diluted 1:100). The dye concentration was adjusted per condition according to 
the ketone concentration in the liposomes at a stoichiometric ratio to label 
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approximately 10% of the available ketones. After labeling, the cells were again 
twice washed with cold PBS (500 µL) and spun down (1,400 x g, 2.5 min). After 
resuspension in the buffer listed above, the cells were filtered through a 40 µm-
filtered FACS tube, and subjected to flow cytometric analyses using a FACS-
Calibur flow cytometer (BD Biosciences). For CS-E labeling, PC12 cells were 
incubated with a monoclonal mouse anti-CS-E antibody (1:250) for 1 h followed 
by two wash cycles, incubated with an AF488-conjugated goat anti-mouse 
antibody (1:1000) for 1 h on ice, washed again twice, and subjected to flow 
cytometric analyses. The labeled samples were referenced to untreated cells. As 
controls, PC12 cells were separately incubated with liposomes without the ketone 
and hydrazide-AF488 or the AF488-conjugated goat anti-mouse antibody. Each 
sample was run in duplicate, and each sample set was performed twice. 
Cell internalization assay. Liposomes were reacted with 9 as mentioned above for 3 
h at RT in the dark. The liposome stock solution was diluted 1:100 with HBSS (45 
mM BSA, 10 mM HEPES, pH 7.4) and added (400 µL) to PC12 cells for 30 min on 
ice in the dark. After labeling, the cells were diluted with PBS (500 µL), washed (3 
x 500 µL wash/centrifuge cycles), and added to RPMI medium without phenol 
red. The cells were imaged live at 0, 3, 6, 10, 16, and 24 h after labeling under a 
Zeiss 700 LSM confocal microscope. 
Neurite outgrowth assays. Hippocampal neurons from E18 Sprague-Dawley rats 
were dissected as previously described45 and plated at 2,000 cells/well on poly-
  
55 
lysine-coated 96-well plates (BD Biosciences) in 50 µL of complete DMEM (10% 
FBS, 1% P/S) for 30 min, followed by 150 µL of complete Neurobasal (B27, 20 
mM GlutaMAX, 1% P/S). After 48 h, CS-A, -C, and -E-conjugated liposomes (10% 
w/w dodecanone; 2.5-10% ketone for CS-E dose-dependent studies) were diluted 
1:100 in 200 µL of complete Neurobasal and added. The medium was replaced 
after 30 min to remove the remaining liposomes and unreacted CS. Due to 
endocytosis of CS after approximately 6-10 h, cells were treated with 
polysaccharide-displaying liposomes again at 8 and 16 h, followed by medium 
replacement 30 min after addition. At each time point, the cells were fixed with 
4% PFA (20 min), washed with PBS (2 x 5 min), permeabilized with 1% BSA and 
0.1% Triton X-100 in PBS (15 min), washed with PBS (2 x 5 min), incubated with 
a mouse α-tubulin antibody (Sigma-Aldrich; 1:1000) at 4 °C for 12 h, washed with 
PBS (2 x 5 min), incubated with a AF488-conjugated goat anti-mouse antibody 
(1:1000) at RT for 1 h, washed with PBS (2 x 5 min), and imaged under a Zeiss 
LSM 5 Pascal inverted confocal microscope as previously described.17 Each well 
was reconstructed in Adobe Illustrator after capturing a 9 x 9 grid of 2034-pixel 
images. Four to five wells were blindly subjected to MetaMorph (Molecular 
Devices) neurite outgrowth software analyses to calculate the mean outgrowth 
per neuron. As controls, untreated neurons, neurons subjected to ketone 
liposomes without polysaccharide, and neurons treated with ketone liposomes 
(+CS-E without an aminooxy group) were assayed for outgrowth. The data are 
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represented as the mean outgrowth percentage (± S.E.M.) with n = 7 (200 cells 
measured per assay). 
Stimulation assays. Cortical neurons from E18 Sprague-Dawley rats were dissected 
as previously described46 and plated at 5 x 106 cells per poly-ornithine-coated 
(Sigma Aldrich) 10-cm plate in complete DMEM (10% FBS, 1% P/S) for 30 min, 
followed by complete Neurobasal (B27, 20 mM GlutaMAX, 1% P/S). After 7 d, 
CS-C- and CS-E-conjugated ketone liposomes (10% w/w dodecanone) were 
added to the complete Neurobasal for 30 min. The medium was then replaced 
with fresh complete Neurobasal that contained 50 ng/mL NGF (256-GF; R&D 
Systems), and the neurons were stimulated for 0, 10, 30, and 60 min. At each time 
point, the medium was evacuated, the cells were scraped and collected in cold 
PBS (1 mL), centrifuged (4 °C, 3,000 x g, 2.5 min), and homogenized in lysis 
buffer (50 mM Tris/HCl pH 7.4, 250 mM mannitol, 50 mM NaF, 1 mM EDTA, 1 
mM EGTA, 1 mM DTT, 1 mM Na2VO4, 1% Triton X-100, and 1x complete 
protease inhibitors (Roche) by 10 passages through a 26-gauge 3/8” needle on ice. 
The lysates were then cleared (4 °C, 16,000 x g, 15 min), and the total protein 
concentration was determined for each sample using a BCA assay kit (Thermo 
Scientific Pierce). Western blot analyses were performed as previously 
described,17 blotting separately with a rabbit anti-phospho-Ser473 Akt antibody 
and a rabbit anti-Akt antibody at 1:1000 in 5% BSA. Akt activation was calculated 
by determining the ratio of phospho-Akt to total Akt for each time point and 
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condition normalized to α-tubulin staining. Relative Akt activation was reported 
with respect to the untreated values (+NGF, no liposomes). 
 
2.5 Materials and Methods for HaloTag Experiments 
2.5.1 Synthetic Methods   
N-Boc-2-(2-hydroxyethoxy)ethylamine (2-10). Compounds 2-10 and 2-11 were 
synthesized as previously described.31 A solution of di-tert-butyl dicarbonate 
(Boc2O) (2.18 g, 10.0 mmol, 1 eq) in anhydrous methanol (2 mL) was added 
dropwise to a stirring solution of 2-(2-aminoethoxy)ethanol (1.05 g, 9.99 mmol) 
in anhydrous methanol (20 mL) at 0 °C. The mixture was stirred for 30 min at 0 
°C and then warmed to RT. After 2 h, the solution was diluted with DCM (30 
mL), washed with ddH2O (3 x 25 mL) and brine (1 x 25 mL), dried over MgSO4, 
filtered, and concentrated to afford a colorless oil 2-10 (1.85 g, 91%). 1H NMR 
(500 MHz, CDCl3): δ 1.42 (s, 9H, CH3), 3.30 (t, J = 5.1 Hz, 2H, CH2N), 3.49-3.58 
(m, 4H, CH2OCH2), and 3.68-3.75 (m, 2H, CH2OH). MS (ESI) calcd. for 
C4H11NO2+ [M + H+] 206.14, found 206.10.  
N-Boc-1-(2-(2-aminoethoxy)ethoxy)-6-chlorohexane (2-11). A solution of 2-10 
(0.34 g, 1.7 mmol) in DMF (2 mL) was added dropwise to a stirring solution of 
60% NaH (0.095 g, 2.4 mmol, 1.4 eq) in DMF (30 mL) at 0 °C. The mixture was 
stirred for 1 h at 0 °C, after which 1-chloro-6-iodohexane (0.30 mL, 2.0 mmol, 1.2 
eq) was added. Stirring was continued for 24 h at RT, and then the reaction was 
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quenched with 1 M HCl and extracted with DCM, ddH2O (6 x 25 mL) and brine 
(1 x 25 mL), dried over MgSO4, filtered, and concentrated to afford a yellow oil. 
Purification by silica gel flash chromatography using 3:1 Hex/EtOAc gave 2-11 as 
a colorless oil (0.20 g, 37%). 1H NMR (500 MHz, CDCl3): δ 1.33-1.40 (m, 2H, 
CH2), 1.43 (s, 9H, CH3), 1.44-1.48 (m, 2H, CH2), 1.55-1.64 (m, 2H, CH2), 1.73-
1.80 (m, 2H, CH2), 3.30 (t, J = 5.2 Hz, 2H, CH2N), 3.45 (t, J = 6.7 Hz, 2H, CH2Cl), 
3.49-3.57 (m, 6H, CH2O), and 3.57-3.61 (m, 2H, CH2O). MS (ESI) calcd. for 
C14H29ClNO5+ [M + H+] 324.20, found 324.21.  
2,5-Dioxopyrrolidin-1-yl 4-oxopentanoate (2-12). N-Hydroxysuccinimide (NHS; 
0.55 g, 4.8 mmol, 1.1 eq) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) hydrochloride (0.91 g, 4.8 mmol, 1.1 eq) were added to a stirring solution 
of levulinic acid (0.50 g, 4.3 mmol) in anhydrous DCM at 0 °C. The mixture was 
warmed to RT and stirred for 2 h, at which time the reaction was diluted with 
DCM, extracted with ddH2O (3 x 25 mL) and brine (1 x mL), dried over MgSO4, 
filtered, and concentrated to afford a white fluffy solid 2-12 (0.69 g, 75%). 1H 
NMR (500 MHz, CDCl3): δ 2.21 (s, 3H, CH3), 2.83 (s, 4H, CH2CH2-succinimide), 
and 2.86-2.92 (m, 4H, CH2CH2-levulinate). MS (ESI) calcd. for C9H11NO5+ [M + 
H+] 214.08, found 214.10.  
N-(2-(2-(6-Chlorohexyloxy)ethoxy)ethyl)-4-oxopentanamide (2-13). Trifluoroacetic 
acid (TFA) (0.14 mL, 1.8 mmol, 6 eq) was added dropwise to a stirring solution of 
2-11 (0.10 g, 0.31 mmol) in anhydrous DCM (5 mL). The mixture was stirred at 
  
59 
RT for 4 h, then azeotroped with toluene, and concentrated to afford the free 
amine as a yellow oil, which was used without further purification. This 
intermediate (0.025 g, 0.074 mmol) was stirred with N,N-diisopropylethylamine 
(DIPEA; 0.076 mL, 0.436 mmol, 6 eq) in anhydrous DCM (3 mL) for 20 min at 
RT, to which 2-12 (0.016 g, 0.075 mmol, 1 eq) was added and stirred overnight. 
After 24 h, the reaction was diluted with DCM (20 mL) and extracted with ddH2O 
(3 x 25 mL) and brine (1 x 25 mL), dried over MgSO4, filtered, and concentrated 
to afford a yellow oil. Purification by silica gel flash chromatography using 97:3 
DCM/MeOH gave 2-13 as a colorless oil (0.016 g, 67%). 1H NMR (500 MHz, 
CDCl3): δ 1.33-1.41 (m, 2H, CH2), 1.42-1.49 (m, 2H, CH2), 1.56-1.65 (m, 2H, 
CH2), 1.73-1.81 (m, 2H, CH2), 2.18 (s, 3H, CH3), 2.43 (t, J = 6.6 Hz, 2H, 
CH2C(O)), 2.79 (t, J = 6.6 Hz, 2H, CH2C(O)), 3.41-3.49 (m, 4H, CH2Cl and 
CH2N), 3.51-3.56 (m, 4H, CH2O), 3.56-3.63 (m, 4H, CH2O), 6.15 (bs, 1H, NH). 
MS (ESI) calcd. for C15H28ClNO4+ [M + H+] 322.18, found 322.20. 
Fluorescein-chloroalkane linker conjugate (F-CL). To a solution of 2-13 (2.6 mg, 8.1 
µmol) in 0.5 mL anhydrous MeOH was added 5-(((2-
(carbohydrazino)methyl)thio)acetyl)aminofluorescein (F) in ddH2O (4.0 mg, 8.1 
µmol, 1 eq; C-356, Life Technologies). The mixture was stirred for 12 h at RT in 
the dark, concentrated, and purified by silica gel flash chromatography in the dark 
using a 97:3 DCM/MeOH mixture to afford the desired compound as an orange 
solid (4.8 mg, 75%). 1H NMR (500 MHz, D2O): δ 1.26-1.33 (m, 2H, CH2), 1.33-
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1.39 (m, 2H, CH2), 1.40 (s, 3H, CH3), 1.44-1.52 (m, 2H, CH2), 1.63-1.70 (m, 2H, 
CH2), 3.32-3.55 (m, 20H, CH2), 6.42-6.48 (m, 2H, Ar-H) 6.49-6.60 (m, 4H, Ar-H), 
7.07 (dd, J = 8.3, 2.9 Hz, 1H, Ar-H), 7.73-7.81 (m, 1H, Ar-H), and 8.21-8.30 (m, 
1H, Ar-H). MS (ESI) calcd. for C39H43ClN4O10S-2Na+ [M-2 + Na+] 817.23, found 
817.25. 
Biotinylated heparan sulfate (B-HS). To a stirring solution of EZ-Link NHS-PEG4-
biotin (0.10 g, 0.17 mmol; 21363, Thermo Scientific) in dry DCM (5 mL) was 
added a solution of ethylenediamine (0.022 mL, 0.33 mmol, 2 eq) and 
triethylamine (TEA; 0.15 mL, 1.1 mmol, 6 eq) in dry DCM (1 mL). The mixture 
immediately turned cloudy upon addition and was then stirred for 1.5 h at RT. 
The precipitate was filtered, and the reaction was concentrated to afford the 
conjugated amine as a white solid (0.068 g, 76%), which was used without further 
purification. De-6-O-sulfated HS (7.0 mg, 0.58 µmol) was dissolved in ddH2O (1 
mL), followed by the addition of cyanogen bromide in ddH2O (5.0 mg, 47 µmol, 
excess). The pH was adjusted to 11.0 using 0.2 M NaOH and stirred for 10 min. 
The mixture was then desalted on a PD-10 Sephadex column using 0.2 M sodium 
borate (pH 8.0). The HS fractions were pooled (3 mL) and immediately stirred 
with the biotin-conjugated amine (5.0 mg, 9.4 µmol, excess) overnight (12 h). The 
mixture was then flash frozen, lyophilized, redissolved in ddH2O (0.5 mL), and 
purified using a G-25 Sephadex column. The desired fractions were pooled, flash 
frozen, and lyophilized to afford B-HS as a white solid (99% recovery). 1H NMR 
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(600 MHz, D2O): δ 3.29 (bs, 1H), 3.72-3.91 (m, 5H), 4.04-4.13 (m, 1H), 4.18-4.32 
(m, 1H), 4.33-4.44 (m, 1H), 4.84 (bs, 1H), 5.26 (bs, 1H, IdoA C-1), 5.42 (bs, 1H, 
GlcN C-1); substoichiometric: 1.30 (bs, 2H, CH2-biotinPEG4), 1.43 (bs, 2H, CH2-
biotinPEG4), 1.50-1.52 (m, 2H, CH2-biotinPEG4), 2.05 (bs, 3H, NHAc), 2.29 (t, 
2H, CH2-biotinPEG4), 2.52-2.60 (m, 2H, CH2-biotinPEG4), 2.78-2.82 (m, 2H, 
C(O)CH2-biotinPEG4) 2.99-3.03 (m, 1H, CH-biotinPEG4), 3.32-3.54 (m, 22H, 
CH2O- and CH2N-biotinPEG4). Biotin(PEG)4 incorporation was estimated to be 
0.9 molecules per polysaccharide. 
Biotinylated heparan sulfate with chloroalkane linker (B-HS-CL). A solution of 2-13 
(4.0 mg, 12 µmol, excess) and NaBH3CN (2.0 mg, 32 µmol, excess) in 1:1 
MeOH:ddH2O (400 µL) was added to B-HS (2.0 mg, 0.17 µmol) in ddH2O (500 
µL). MeOH (approximately 300 µL) was added until the reaction turned from 
cloudy to colorless, and the mixture was stirred for 12 h at RT, concentrated, and 
purified by gel filtration chromatography using G-25 Sephadex resin. The pooled 
fractions containing the polysaccharide were lyophilized to yield a white powder 
(99% recovery). 1H NMR (600 MHz, D2O): δ 3.24 (bs, 1H), 3.62-3.89 (m, 5H), 
4.04-4.14 (m, 1H), 4.17-4.32 (m, 1H), 4.33-4.44 (m, 1H), 5.24-5.45 (m, 2H, IdoA 
C-1, GlcN C-1); substoichiometric: 1.07 (d, J = 6.3 Hz, 3H, CH3-CL), 1.50-1.54 (m, 
2H), 2.01 (s, 3H, NHAc), 2.18-2.23 (m, 6H), 2.34-2.45 (m, 2H), 2.75 (s, 2H), 2.99-
3.10 (m, 2H). CL incorporation was estimated to be 1.8 CL molecules per 
polysaccharide.  
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General procedure for chloroalkane heparin/heparan sulfate derivatives. In a typical 
procedure, 2-13 (4.0 mg, 12 µmol, excess) was dissolved in MeOH and ddH2O 
(1:1, 400 µL) with NaBH3CN (2.0 mg, 32 µmol, excess) and added to HS, de-HS, 
deO-HS, 6-deO-HS, or 2-deO-HS (2.0 mg, 0.17 µmol) in ddH2O (500 µL). MeOH 
(approximately 300 µL) was added until the reaction turned from cloudy to 
colorless, and the mixture was stirred for 12 h at RT, concentrated, and purified 
by gel filtration chromatography using G-25 Sephadex resin. The pooled fractions 
containing the polysaccharides were lyophilized to yield white powders (99% 
recovery of polysaccharide in all cases). CL incorporation was estimated to be 
between 0.4 to 4 molecules per polysaccharide. HS-CL: 1H NMR (600 MHz, D2O): 
δ 3.29 (bs, 1H), 3.78-3.91 (m, 2H), 4.06 (bs, 1H), 4.12 (bs, 1H), 4.20-4.31 (m, 
2H), 4.33-4.44 (m, 2H), 4.91 (bs, 1H), 5.27-5.46 (m, 2H, IdoA C-1, GlcN C-1); 
substoichiometric: 1.19 (dd, J = 6.3, 0.9 Hz, 3H, CH3-CL), 1.67-1.77 (m, 2H), 2.06 
(bs, NHAc), 2.20-2.31 (m, 6H), 2.38-2.45 (m, 2H), 2.73 (s, 2H), 2.77-2.86 (m, 
2H). de-HS-CL: 1H NMR (600 MHz, D2O): δ 3.77-3.94 (m, 4H), 3.96-4.12 (m, 
2H), 4.19-4.38 (m, 2H), 4.92 (bs, 1H), 5.08-5.23 (m, 2H, IdoA C-1), 5.40 (bs, 1H, 
GlcN C-1); substoichiometric: 1.19 (d, J = 6.2 Hz, 3H, CH3-CL), 1.68-1.77 (m, 
2H), 2.02 (bs, 3H, NHAc), 2.41 (t, J = 6.8 Hz, 2H), 2.66 (s, 2H), 2.79 (t, J = 6.8 Hz, 
2H). deO-HS-CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 3.62-3.77 (m, 4H), 
3.78-3.93 (m, 3H), 4.06 (bs, 1H), 4.12 (bs, 1H), 4.95 (bs, 1H, IdoA C-1), 5.38 (bs, 
1H, GlcN C-1); substoichiometric: 1.19 (d, J = 6.3 Hz, 3H, CH3-CL), 1.70-1.75 (m, 
2H), 2.04 (bs, 3H, NHAc), 2.21-2.26 (m, 6H), 2.40-2.43 (m, 2H), 2.66 (s, 2H), 
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2.78 (t, J = 6.9 Hz, 2H). 6-deO-HS-CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 
3.64-3.95 (m, 5H), 4.05 (bs, 1H), 4.26 (bs, 1H), 4.36 (bs, 1H), 4.93 (bs, 1H), 5.28-
5.41 (m, 2H, IdoA C-1, GlcN C-1); substoichiometric: 1.19 (dd, J = 6.3, 1.7 Hz, 3H, 
CH3-CL), 1.69-1.76 (m, 2H), 2.06 (bs, 3H, NHAc), 2.18-2.30 (m, 6H), 2.41 (td, J = 
6.9, 1.7 Hz, 3H), 2.66 (d, J = 1.7 Hz, 2H), 2.79 (td, J = 6.9, 1.5 Hz, 2H). 2-deO-HS-
CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 3.60-3.93 (m, 5H), 3.94-4.29 (m, 
3H), 4.35 (bs, 1H), 5.30-5.45 (m, 2H, GlcN C-1, IdoA C-1); substoichiometric: 
1.19 (d, J = 6.3 Hz, 3H, CH3-CL), 1.69-1.77 (m, 2H), 2.05 (bs, 3H, NHAc), 2.21-
2.34 (m, 6H), 2.44 (t, J = 6.8 Hz, 2H), 2.72-2.83 (m, 4H). 
2.5.2 Biological Procedures  
Transmembrane HaloTag protein DNA construct. The sequence encoding the 
HaloTag protein (HTP) was PCR amplified from the pFC14K HT7 CMV Flexi 
Vector (Promega) to introduce a 5’ SacII restriction site and a 3’ SalI restriction 
site using the following primers: 
 HTP-upstream:   TTATCCGCGGTGGATCCGAAATCGGTACTGGCTTT 
 HTP-downstream: ACTAGTCGACACCGGAAATCTCCAGAGTAGACAG  
The PCR product was digested with SalI and SacII according to standard 
procedures and gel purified. The pDisplay vector (pD; Life Technologies) was 
linearized with SalI and SacII according to standard procedures and purified using 
a QIAquick PCR purification kit (Qiagen). The insert was ligated into the 
linearized vector using T4 DNA ligase. The HTP gene was inserted between the 
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sequence encoding the N-terminal murine Ig κ-chain leader and the C-terminal 
PDGFR transmembrane domain to generate the final HTP construct. The plasmid 
was confirmed by Sanger sequencing (Laragen Inc.). 
Cell culture. All cell cultures were maintained at 37 °C and 5% CO2 unless 
otherwise indicated. CHO cells were cultured on tissue culture plates in F12 
medium supplemented with 10% FBS and 1% P/S and were passaged after 
reaching ~80% confluency. mESCs were cultured strictly according to ATCC 
protocols to maintain a homogeneous population of pluripotent cells. Confluent 
MEFs were treated with mitomycin C (10 µg/mL in DMEM with 10 % FBS and 1% 
P/S) for 3 h at 37 °C to provide a feeder cell layer for mESCs. mESCs were 
cultured directly on the MEF feeder layer in DMEM (ATCC) with 10% non-heat-
inactivated FBS and 0.1 mM β-mercaptoethanol (defined henceforth as complete 
DMEM). To passage or isolate mESCs for transfection, collagenase IV (10 µg/mL) 
in DPBS (with CaCl2 and MgCl2) was equilibrated to 37 °C and 5% CO2 and added 
to mESCs (3 mL) and allowed to detach the cells for 3-5 min at 37 °C. The cells 
were gently agitated to remove the large colonies, leaving the majority of 
remaining MEFs attached to the plate. The released mESCs were then added to 6 
mL of pre-warmed complete DMEM and centrifuged (1,200 rpm for 2.5 min). The 
collagenase IV-containing medium was aspirated, and the cells were resuspended 
in 10 mL of fresh pre-warmed complete DMEM. At this time, the cells were either 
transferred to new tissue culture plates on top of a confluent layer of mitomycin 
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C-treated MEFs for further culture or to plates pre-coated with 0.2% gelatin for 
transfection. mESCs were passaged every 3 to 5 days, depending on their colony 
sizes and proximity to one another, and the medium was replaced every 2 days. 
HTP transfections. CHO cells were plated and transfected with the HTP plasmid 
using Lipofectamine LTX (Life Technologies) according to the manufacturer’s 
protocol. For transfecting mESCs, the protocol for Xfect mESC Transfection 
Reagent was followed. Briefly, mESCs were plated on 0.2% gelatin-coated 6-well 
plates at 1 x 106 cells/well in complete DMEM. After 5 h, the HTP plasmid-lipid 
transfection complexes were generated and added according to the 
manufacturer’s instructions. The mESCs were then incubated for 3 h with the 
transfection complexes at 37 °C and 5% CO2, and the medium was replaced with 
2 mL of pre-warmed complete DMEM. 
Generation of an HTP-expressing stable cell line. CHO cells lacking 
galactosyltransferase I (pgsB-618, ATCC) that had been transfected with HTP 
were selected using complete F12 medium supplemented with 700 µL of G418 
solution (0.8 mg/mL). The medium was replaced every 2 d for 3 weeks. After 3 
weeks, the cells were incubated with fresh F12 medium containing 5 µM F-CL for 
1 h (37 °C, 5% CO2) and then sorted via fluorescence-activated cell sorting 
(FACS) using a FACS-Aria Flow Cytometer Cell Sorter (BD Biosciences) with an 
excitation wavelength of 488 nm. 
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HTP labeling for fluorescent imaging analyses. CHO cells were plated and cultured 
on poly-ornithine-coated (10 µg/mL) glass coverslips in complete F12 medium 
(10% FBS, 1% P/S) at 37 °C and 5% CO2. For labeling, the medium was replaced 
with fresh F12 medium that contained 5 µM F or F-CL for 1 h (37 °C, 5% CO2). 
The cells were then washed with PBS (2 x 1 mL), fixed with 4% 
paraformaldehyde in PBS (15 min at RT), rinsed with PBS (2 x 1 mL), 
permeabilized with a solution containing 1% BSA and 0.1% Triton X-100 (20 min 
at RT), incubated with a monoclonal mouse anti-Myc antibody (1:1000; 12 h at 4 
°C), washed with PBS (2 x 5 min), incubated with a goat anti-mouse AF568 
secondary antibody (1:1000; 1 h at RT), and washed with PBS (2 x 5 min). The 
coverslips were mounted with VECTASHIELD mounting medium containing 
DAPI (Vector Laboratories Inc.) and imaged using a Zeiss LSM 700 inverted 
confocal microscope.  
HTP labeling for Western blot analyses. CHO cells stably expressing HTP were 
cultured on 10-cm plates in complete F12 medium until approximately 85% 
confluent. The medium was then replaced with fresh F12 medium (4 mL) that 
contained 5 µg/mL B-HS or B-HS-CL, and the cells were incubated for 6 h at 37 
°C. After labeling, the medium was removed, and the cells were scraped and 
collected in cold PBS (1 mL), centrifuged (3,000 rpm for 2.5 min at 4 °C), and 
homogenized in 150 µL of lysis buffer (50 mM Tris/HCl pH 7.4, 250 mM 
mannitol, 50 mM NaF, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM Na2VO4, 1% 
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Triton X-100, and 1x cOmplete protease inhibitor cocktail (Roche) via 10 
passages through a 26g x 3/8” needle on ice. The lysates were then clarified by 
centrifugation (15,000 rpm for 15 min at 4 °C) and transferred to clean 
microcentrifuge tubes, after which the total protein concentration was 
determined for each sample using the Bradford assay (Bio-Rad Laboratories). 
Samples were boiled for 5 min with SDS-PAGE loading buffer and resolved by 
SDS-PAGE on 4-12% Bis-Tris gels (Life Technologies). Proteins were transferred 
to PVDF membranes and blocked with blocking buffer (5% milk in a solution of 
50 mM Tris pH 7.6, 150 mM NaCl, and 0.5% Tween-20 (TBST)) for 1 h at RT. 
Blots were incubated with IRDye800 streptavidin (1:1000; LI-COR Biosciences) 
and an anti-HA rabbit monoclonal antibody (1:1000) overnight at 4 °C in 
blocking buffer, rinsed twice with TBST, and incubated again with an AF680-
conjugated goat anti-rabbit IgG antibody (1:10000) for 1 h at RT. Membranes 
washed three times with TBST for 5 min at RT and were then imaged and 
quantified using an Odyssey scanner (LI-COR Biosciences).  
HTP-conjugate lifetime assay. CHO cells were plated onto 15-mm coverslips, 
cultured, and labeled with 5 µM F or F-CL in F12 medium for 1 h (37 °C, 5% 
CO2). Cells were rinsed once with prewarmed PBS and subsequently cultured 
with fresh F12 medium (37 °C, 5% CO2). At each time point (between 0.5 and 8 
d), the coverslips were removed from culture, submerged in PBS for 2 min, fixed 
with 4% paraformaldehyde in PBS for 15 min, and then washed in PBS for 5 min. 
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The coverslips were blotted dry, mounted onto glass microscope slides using 
VECTASHIELD mounting medium containing DAPI, and imaged using a Zeiss 
LSM 700 inverted confocal microscope. 
Microarray analyses. Glycosaminoglycan microarrays were generated as 
previously described.18 Slides were blocked with 10% FBS in PBS for 1 h at RT. 
Stock solutions of FGF2, FGF8b, FGFR1-Fc (2 µM), and FGFR3c-Fc were 
prepared in sterile 1x PBS containing 1% BSA. Blocked slides were washed once 
with PBS and slowly rocked with 150 µL of 1% BSA/PBS containing 1 µM receptor 
with or without 1 µM ligand (i.e., 1 µM FGFR1-Fc ± 1 µM FGF2; 1 µM FGFR3-Fc ± 
1 µM FGF8b) for 2 h at RT. Slides were washed three times with PBS and 
incubated with an AF647-conjugated goat anti-human Fc antibody (1:5000) in 1% 
BSA/PBS for 1 h at RT in the dark with gentle rocking. Slides were then washed 
three times with PBS and twice with ddH2O and blown dry under a stream of 
filtered air. Arrays were scanned using a G2565BA DNA Microarray Scanner 
(Agilent), and fluorescence was quantified using GenePix 5.0 software (Molecular 
Devices) with normalization against local background. The data represent the 
average of 10 spots per concentration of polysaccharide. 
ERK activation assays. Pluripotent mESCs were transfected with the HTP plasmid 
as described above. After 48 h, the cells were detached with collagenase IV (10 
µg/mL, 3 mL) in DPBS, pelleted, and resuspended in 2 mL of complete DMEM 
containing 1 U/mL heparinase II (HepII, Sigma-Aldrich) for 2 h at 37 °C with 
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gentle mixing every 15 min. HepII was quenched with 6 mL of complete DMEM, 
and the cells were pelleted and resuspended in complete DMEM. mESCs were 
then plated on six-well plates coated with 0.2% gelatin and incubated with HS-CL, 
de-HS-CL, deO-HS-CL, 6-deO-HS-CL, or 2-deO-HS-CL (5 µg/mL) overnight. 
Cells were serum-starved the following day with DMEM containing 0.5% FBS for 
8 h and then stimulated for 15 m with DMEM containing 0.5% FBS and 10 ng/mL 
of FGF2. Cells were then quickly washed with 1 mL of ice-cold PBS, scraped, and 
pelleted. The pellet was lysed and homogenized as described above. Samples were 
boiled for 5 min with SDS-PAGE loading buffer, resolved by SDS-PAGE on 4-12% 
Bis-Tris gels, transferred to PVDF membrane, and blocked for 1 h at RT with 
Odyssey Blocking Buffer (LI-COR Biosciences). Membranes were immunoblotted 
with a rabbit anti-phospho-ERK monoclonal antibody (1:2000) overnight at 4 °C 
and then a mouse anti-ERK monoclonal antibody (1:2000) for 1 h at RT. Blots 
were then incubated with an AF680-conjugated goat anti-mouse IgG antibody 
(1:10000) and IRDye800-conjugated goat anti-rabbit IgG antibody (1:10000) for 1 
h at RT. Membranes were washed three times with TBST for 5 min and then 
imaged and quantified using an Odyssey scanner (LI-COR Biosciences). Ratios of 
phospho-ERK to total ERK were calculated for each condition and normalized to 
an untreated control. Statistical analysis was performed using a one-way ANOVA 
with post-hoc analysis by Dunnett’s test against the untreated control. Data 
represent the mean ± S.E.M. for three independent experiments (n = 3). 
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Neuronal differentiation assays. Pluripotent mESCs were transfected with the HTP 
plasmid and HepII treated as described above. The reaction was quenched with 6 
mL of complete DMEM, pelleted, and resuspended in 1 mL of neural induction 
medium (1 part DMEM:F12 (1:1) 1% N-2 supplement, 1% P/S and 1 part 
Neurobasal, 1% GlutaMAX, 1% B-27, 1% P/S). HepII-treated cells were then 
added to 0.2% gelatin-coated plates in 2 mL of neural induction medium 
containing FGF2 (10 ng/mL) and HS-CL derivatives (untreated, HS-CL, or de-
HS-CL; 5 µg/mL). The medium was replaced after 48 h with fresh neural 
induction medium containing FGF8b (10 ng/mL). At 3, 6, and 9 days after HepII 
treatment, the cells were subjected to RNA isolation for qRT-PCR and 
immunocytochemistry analyses. 
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR).  
mESCs were cultured and subjected to neuronal differentiation as described 
above. At different time points (Day 3, 6, and 9), RNA was extracted from 
untreated cells and cells treated with HS-CL or de-HS-CL using the RNeasy Mini 
Kit (Qiagen) per the manufacturer’s instructions. RNA concentrations were 
obtained with a NanoDrop 2000 UV-Vis spectrophotometer (Thermo Scientific), 
and then the RNA samples were converted to cDNA using the iScript Advanced 
cDNA Synthesis Kit (Bio-Rad). qRT-PCR was performed using an Applied 
Biosciences 7300 Real-Time PCR System with primers for GAPDH, SDHA, 
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NANOG, SOX1, and TUJ1. Primers for amplification of genes of interest are listed 
below. 
 GAPDH-F: AACAGAAACTCCCACTCTTC 
 GAPDH-R: CCTGTTGCTGTAGCCGTATT (111 bp amplicon) 
  
 SDHA-F:  GCTGGAGAAGAATCGGTTATGA 
 SDHA-R:  GCATCGACTTCTGCATGTTTAG (97 bp) 
 
 NANOG-F: TTTGGAAGCCACTAGGGAAAG 
 NANOG-R: CCAGATGTTGCGTAAGTCTCATA (115 bp) 
 
 SOX1-F:  ACACACACACACACACTCTC  
 SOX1-R:  CCTCAAGATCTGGTCAGGAATG (101 bp) 
 
 TUJ1-F:  CCATTCTGGTGGACTTGGAA 
 TUJ1-R:  GCACCACTCTGACCAAAGATA (103 bp) 
The following conditions were used for each 20-µL qRT-PCR reaction: 5 µL of 
cDNA (10 ng/µL), 1 µL of primer mixture (10 µM forward and 10 µM reverse), 10 
µL of 2x SYBR master mix, and 4 µL of ddH2O. The cycle threshold (Ct) values for 
NANOG, SOX1, and TUJ1 were first normalized against the geometric mean of 
GAPDH and SDHA at each condition and time point. Each data point was then 
normalized to the untreated value at day 3 to report relative changes. Statistical 
analysis was performed for each gene at each time point using a one-way ANOVA 
with post-hoc analysis by Dunnett’s test against the untreated control. Data 
represent the mean ± S.E.M. from two samples run in triplicate (n = 2).    
Immunocytochemistry. Untreated mESCs and mESCs treated with HS-CL or de-HS-
CL were subjected to neuronal differentiation as described above. At 3, 6, and 9 
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days after HepII treatment, mESCs were fixed with 4% paraformaldehyde in PBS 
(15 min), rinsed with PBS (2 x 1 mL), permeabilized with a solution containing 
1% BSA and 0.1% Triton X-100 (20 min), and incubated with a rabbit anti-
NANOG monoclonal antibody (1:1000), a goat anti-SOX1 polyclonal antibody 
(1:250), or a rabbit anti-TUJ1 monoclonal antibody (1:1000) for 3 h at RT. Cells 
were washed with PBS (2 x 1 mL) and then incubated with an AF488-conjugated 
goat anti-rabbit antibody (1:5000), AF568-conjugated donkey anti-goat antibody 
(1:5000), or AF568-conjugated goat anti-mouse antibody (1:5000), respectively, 
for 1 h at RT. Cells were imaged using a Zeiss LSM 700 inverted confocal 
microscope.  
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C h a p t e r  3  
Discovery of Orphan Receptor Tie1 and Angiopoietin Ligands 
Ang1 and Ang4 as Novel GAG-Binding Partners  
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3.1 Abstract 
 The Tie/Ang signaling axis is necessary for proper vascular development and 
remodeling. However, the mechanisms that modulate signaling through this 
receptor tyrosine kinase pathway are relatively unclear. In particular, the role of 
the orphan receptor Tie1 is highly disputed. Although this protein is required for 
survival, Tie1 has been found both to inhibit and yet be necessary for Tie2 
signaling. While differing expression levels have been put forth as an explanation 
for its context-specific activity, the lack of known endogenous ligands for Tie1 has 
severely hampered understanding its molecular mode of action. Here we describe 
the discovery of orphan receptor Tie1 and angiopoietin ligands Ang1 and Ang4 as 
novel GAG binding partners. We localize the binding site of GAGs to the N-
terminal region of Tie1, which may provide structural insights into the 
importance of this interaction regarding the formation of Tie1-Tie2 
heterodimerization. Furthermore, we use our mutagenesis studies to guide the 
generation of a mouse model that specifically ablates GAG-Tie1 binding in vivo for 
further characterization of the functional outcomes of GAG-Tie1 binding. We also 
show that GAGs can form a trimeric complex with Ang1/4 and Tie2 using our 
microarray technology. Finally, we use our HaloTag glycan engineering platform 
to modify the cell surface of endothelial cells and demonstrate that HS GAGs can 
potentiate Tie2 signaling in a sulfation-specific manner, providing the first 
evidence of the involvement of HS GAGs in Tie/Ang signaling and delineating 
further the integral role of HS GAGs in angiogenesis. 
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3.1 Tie/Ang Signaling in Developing, Mature, and Remodeling Vasculature 
 Discovered in 1992, the Tie family of proteins is part of the RTK superfamily 
and consists of two members: Tie1 and Tie2 (Figure 3-1).1-4 Along with the 
related angiopoietin (Ang or Angpt) ligands Ang1, Ang2, and Ang4,5-7 the 
Tie/Ang signaling pathway is critical for the proper formation and maintenance of 
the vascular system.8-10 Initial studies of Tie1 and Tie2 found that constitutive 
knockout of either receptor led to severe subcutaneous edema and tissue swelling, 
causing embryonic lethality for Tie2-deficient mice between embryonic days 10.5 
and 12.5 (E10.5 - E12.5) and for Tie1-deficient mice starting at E13.5.11-13 Tie1-
deficient embryos that did not die in utero died upon birth due to respiratory 
failure likely caused by fluid accumulation in the lungs. Closer examination of the 
embryos showed stunted blood vessel networks, providing a possible mechanism 
for the edemic phenotype. Later studies linked the loss of Tie1 with impaired 
lymphogenesis via improper valve and collecting vessel development.14-16 
Moreover, Tie1 has been linked to numerous pathologies including tumor 
angiogenesis and atherosclerosis,17, 18 and Tie/Ang proteins have been targeted as 
both anti-angiogenic and anti-sepsis therapeutics,19, 20 illustrating the widespread 
importance of Tie/Ang signaling. 
 The Tie/Ang signaling axis shares some mechanistic similarities with other 
RTKs. For example, Tie2 is activated by dimerization or multimerization through 
binding to Ang1 or Ang4, leading to cross-phosphorylation of its intracellular 
domains and downstream signaling through the PI3K/Akt survival pathway.9  
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Figure 3-1. Domain structures of receptor tyrosine kinases Tie1 and Tie2. 
However, Tie2 signaling is different from many other RTKs in that the protein is 
constantly activated in mature vessels. Ang1 is secreted by pericytes that 
surround vascular endothelial cells, activating Tie2 to promote cell survival 
(Figure 3-2). During angiogenesis, pericytes dissociate from the endothelial cells, 
which then produce Ang2 for autocrine antagonism of Tie2 survival signaling. If 
new blood vessels form with intact pericyte layers, pro-survival Tie2 signaling 
through Ang1 resumes. If unsuccessful, endothelial cells undergo apoptosis due to 
the lack of survival signaling.9 The effect of Ang4, which appears to be human-
specific and functionally distinct from its mouse ortholog Ang3,7, 21 remains 
relatively unknown compared to Ang1 and Ang2. 
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Figure 3-2. General mechanism of Tie/Ang signaling. In quiescent vasculature, Ang1 is secreted 
by pericytes to activate Tie2 on endothelial cells (EC). Upon receiving pro-angiogenic cues like 
VEGF, pericytes dissociate from ECs, which then secrete Ang2 to antagonize Ang1/Tie2 signaling.  
 Unlike Tie2, Tie1 is considered an orphan receptor.9, 22, 23 Without a 
physiological ligand, its importance in vascular development and remodeling has 
proven much more difficult to unravel. Tie1 is generally though of as an 
antagonist of Tie2 signaling through the formation of Tie1/Tie2 heterodimers.24 
Experiments using shRNA-mediated knockdown of Tie1 demonstrated that Tie2 
activation by Ang1 is elevated after depletion of Tie1.25 However, a recent in vivo 
study showed that endothelial deletion of Tie1 in adult mice paradoxically leads 
to decreased Tie2 activation and downstream signaling,26 suggesting instead that 
the Tie1/Tie2 interaction is necessary to promote Ang1-mediated vascular 
responses. In a separate report, Tie1 was suggested to both sustain and inhibit 
Tie2 function in different physical locations of newly forming blood vessels 
through changes in Tie1 expression levels.22 However, a separate way to account 
for these differences in activity could be the presence of an undiscovered ligand 
for Tie1. GAGs are prevalent on the cell surface of most cells including the 
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endothelium and have previously been shown to bind both to RTKs and their 
respective ligands,27-36 making them an ideal candidate for binding to not only 
Tie1 but also Ang ligands. Moreover, given the prevalence of GAG-RTK 
interactions in other systems involved in angiogenesis including VEGF/VEGFR,29, 
37 it is not difficult to envision the involvement of GAGs in the Tie/Ang signaling 
axis. 
 
3.2 GAGs Are Physiological Ligands for Orphan Receptor Tie1 
3.2.1 ELISA, Carbohydrate Microarray, and Surface Plasmon Resonance 
 We first examined whether Tie1 and Tie2 were receptors for GAGs using our 
carbohydrate enzyme-linked immunosorbent assay (ELISA) method.38 Here, 
commercially available Tie1- and Tie2-Fc conjugates were immobilized onto 
Protein A/G coated plates. Biotinylated CS-E and trisulfated hep/HS (HS) were 
then incubated with the immobilized proteins for 3 h at RT, and bound GAGs 
were visualized using horseradish peroxidase (HRP)-conjugated streptavidin. 
Excitingly, we found that both CS-E and HS bound strongly to Tie1, both with 
nanomolar binding affinity (Figure 3-3; CS-E: 19.9 ± 5.8 nM, HS: 6.16 ± 0.37 nM). 
These data represent the first evidence of a physiological ligand for the Tie1 
receptor since its discovery 25 years ago.2 Furthermore, we found that Tie2 did 
not exhibit any measurable binding to either GAG structure, illustrating the 
specificity of the Tie1-GAG interaction. 
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Figure 3-3. Carbohydrate enzyme-linked immunosorbent assay for Tie1-GAG binding. 
Immobilized Tie1-Fc or Tie2-Fc were probed with biotinylated CS-E or biotinylated HS.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Carbohydrate microarrays to examine sulfation specificity of Tie1-GAG binding. 
Tie1-Fc was incubated with printed (A) CS and (B) HS microarray. Bound Tie1-Fc is visualized with 
an anti-human Fc antibody. 
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Figure 3-5. Carbohydrate surface plasmon resonance to examine kinetics of Tie1-GAG 
binding. Biotinylated (A) CS-E or (B) HS were immobilized onto a CM5 sensor chip, and Tie1-Fc 
was flowed over at different concentrations. Kinetic parameters were obtained by fitting to a one-to-
one Langmuir binding model. 
 We next assessed the sulfation specificity of the Tie1-GAG interactions using 
carbohydrate microarrays.33 Tie1- and Tie2-Fc conjugates were incubated on glass 
slides with different CS and HS epitopes electrostatically immobilized on the 
surface. Bound proteins were detected using a fluorescently tagged anti-human Fc 
antibody. As expected, Tie1 showed robust binding with the CS-E (Figure 3-4a) 
and HS (Figure 3-4b) epitopes with minimal binding to all other sulfation 
patterns. 
 Finally, we further quantified the Tie1-GAG interactions using surface 
plasmon resonance (SPR) analysis.38 In this experiment, SPR CM5 sensor chips 
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covalently modified with carboxymethylated dextran were functionalized with 
streptavidin to allow for immobilization of biotinylated CS-E or HS. Solutions of 
Tie1-Fc at different concentrations were then flowed over the modified chip 
followed by buffer only, and the response rate was measured over time. We were 
pleased to see that both CS-E (Figure 3-5a) and HS (Figure 3-5b) gave dissociation 
constants that were similar to those observed via ELISA (CS-E: 14.7 nM; HS: 3.16 
nM). Both carbohydrates also demonstrated similar binding kinetics with koff 
values around 10-4 s-1, suggesting a theoretical half-life for the complexes of 
roughly 18 min (CS-E) and 38 min (HS). These off rates are smaller than those 
reported for known hep/HS binding proteins VEGFR1 and neuropilin 1 (Nrp1),37 
implicating the physiological relevance of these binding events in vascular tissue. 
3.2.2 Identification of the Tie1-GAG Binding Site 
 Having shown that Tie1 binds to GAGs through numerous methods, we aimed 
to decipher the exact location of the Tie1-GAG binding site to help provide 
structural clues on the importance of these novel interactions. No known 
consensus primary sequence or secondary structure has been found as a 
predictive measure for GAG-protein binding. As expected, GAG binding in many 
cases requires numerous surface-exposed positively charged Arg and Lys 
residues, which can occur on any number of domain structures. Tie1 contains 
both immunoglobulin-like (Ig) domains, which interact with hep/HS in FGFR1,27 
and fibronectin type III (FNIII) domains, which bind to CS-E in EphA4 and -B3 
receptors.39, 40  
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Figure 3-6. Tie1 truncations to determine Tie1-GAG binding domain. (A) Full length (FL) and 
truncated (delCFN1) Tie1-Fc were expressed and purified. (B) Expressed Tie1-Fc constructs were 
used in carbohydrate ELISA as described earlier. Both constructs maintain binding to GAGs, 
suggesting that binding occurs in the N-terminal domains of Tie1. 
 As a first step, we produced Tie1-Fc conjugates that contained, the full-length 
ectodomain (Tie1-FL-Fc) or a C-terminal truncation that eliminated the three 
FNIII domains (Tie1-delCFN-Fc). The two constructs were expressed as secreted 
proteins and purified by immobilized metal affinity chromatography (IMAC) 
using a C-terminal 6xHis tag (Figure 3-6a). These constructs were then used in 
the ELISA format described above. We found that both constructs showed 
binding with CS-E and HS, suggesting that the Tie1-GAG binding site was 
contained within the N-terminal Ig1/2 or EGF1-3 domains (Figure 3-6b). We  
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Figure 3-7. Homology model of Tie1. (A) Ribbon structure of Tie1 homology model built by 
SWISS-MODEL using Tie2 crystal structure. (B) Surface electrostatic potential maps of Tie1 and 
Tie2. 
tried to express complementary N-terminal truncations of the protein, but none 
of these constructs expressed at high enough quantities to be used in the ELISA. 
This result is likely due to the predicted globular structure formed by the N-
terminal domains in the final folded protein. 
 Because we could not isolate the Tie1-GAG binding site further by truncation, 
we turned to computational docking of GAG structures with Tie1 to predict key 
residues for the interaction.33 This approach has been successfully used to define 
likely regions of GAG binding on a number of proteins, including the malarial 
protein VAR2CSA, tumor necrosis factor α (TNFα), and Ephs A4 and B3.33, 39, 40 
To conduct docking, we first produced a homology model of Tie1 based on the 
solved Tie2 crystal structure41 using the SWISS-MODEL program (Figure 3-7a).42  
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Figure 3-8. Docking of CS-E and HS hexasaccharides to Tie1. Top 10 and top 1 binding poses 
of (A) CS-E and (B) HS onto the Tie1 homology model. 
Tie2 shares the same domain structure as Tie1 along with 39% total amino acid 
identity. Upon inspection of the electrostatic potential maps of the Tie1 and Tie2 
structures (Figure 3-7b), the Tie1 model displays a large electropositive region 
encompassing parts of the Ig1 and three EGF domains. This electropositivity is 
severely attenuated in the Tie2 structure, providing evidence for the specificity of  
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Figure 3-9. Amino acids in putative GAG binding site of Tie1. Positively charged amino acids 
surrounding the top binding pose for (A) CS-E and (B) HS. 
GAG binding to Tie1. Interestingly, this region of Tie1 had previously been 
suggested to interact with a complementary electronegative face of Tie2.25  
 With a model for Tie1 in hand, we then docked hexasaccharide structures of 
CS-E and HS to the predicted structure and ranked poses based on the calculated 
binding energies. The top 10 poses of both CS-E and HS clustered in one portion 
of the large electropositive region centered on the Ig1 domain (Figure 3-8). Upon 
closer inspection, the top ranked pose of both docked GAG structures showed 
close association with six positively charged residues: Arg-38, Arg-52, Arg-79, 
Arg-82, Arg-91, and Arg-95 (Figure 3-9). Using genomic alignment, we found that 
four of these six residues (Arg-38, Arg-52, Arg-82, Arg-91) were highly conserved  
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Figure 3-10. Sequence alignment of N-terminal Tie1 gene. Predicted binding site amino acids 
are bolded with conserved amino acids highlighted. 
throughout all mammals (Figure 3-10), with Lys-95 showing moderate 
conservation as well. 
 We turned to the ELISA format to test the accuracy of our computational 
predictions. Wild-type Tie1-Fc (Tie1-WT) along with a mutant containing all six 
residues mutated to Ala (Tie1-6A) and a second mutant containing R38A and 
R82A (Tie1-2A) were cloned and expressed using the secretion system 
previously described. Importantly, both mutants expressed well, suggesting that 
the mutations did not affect protein folding as seen for the N-terminal 
truncations. We were pleased to see that binding of both biotinylated CS-E and 
HS was severely attenuated after mutation (Figure 3-11), confirming that these 
residues were critical for the Tie1-GAG interaction. We attempted the same 
experiment using single mutations, but neither showed complete loss of Tie1  
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Figure 3-11. Carbohydrate ELISA of Tie1 mutant constructs. FL, wild-type (WT), 6A, and 2A 
mutants were expressed, purified, and used in carbohydrate ELISA binding assays as previously 
described. Both mutant constructs completely lost binding to GAGs, corroborating the 
computational results.  
binding, suggesting that the double mutation was the minimal perturbation 
necessary to disrupt the Tie1-GAG interaction. 
3.2.3 Contextualization of Tie1-GAG Binding 
 Although up to this point we had tested Tie1 binding to GAGs using both CS-E 
and HS, we desired to establish which GAG structures would be the most relevant 
for in vivo binding. Tie1 is expressed universally on endothelial cells during late 
development,43 after which expression levels are strongly downregulated in the 
adult except in a small subset of remodeling endothelial cells.22 Tie1 expression is 
also stimulated during angiogenic processes such as wound healing and tumor 
formation and regions of nonlaminar flow like branch points of vessels.17, 18 
Therefore, examining the GAGs produced by endothelial cell lines would provide 
helpful information to decipher the relative importance of CS-E and HS in Tie1 
binding. 
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 Previously, methods to quantify the absolute amounts of different GAG 
sulfation patterns on the cell surface, termed glycosaminoglycanomics, have 
found that human umbilical vein endothelial cells (HUVECs) are dominated by 
HS.44 In fact, HUVECs, which are used as a model system for systemic endothelial 
cells, were found to contain the highest proportion of HS and the HS epitope out 
of all cell lines tested. HS was found at nearly a 10:1 w/w ratio compared to CS. 
Moreover, CS-E was not detected in HUVECs in this analysis, strongly suggesting 
that HS was the physiologically relevant GAG for Tie1 binding at least in systemic 
endothelial cells.  
 We confirmed these finding using a cell binding assay (Figure 3-12). HUVECs 
were grown to confluency, treated with or without a mixture of heparinase I and 
III and fixed. Cells were then incubated with Tie1-WT-Fc or Tie1-2A-Fc, and 
binding of the constructs was detected using a fluorescently tagged anti-human Fc 
antibody. Importantly, we saw that Tie1-WT binding was significantly decreased 
after treatment of the cells with heparinase I/III, with all remaining Tie1-WT 
staining colocalizing with residual HS signal as detected by an anti-HS antibody. 
Moreover, binding of Tie1-2A was not observed even with cell surface HS intact. 
Together, these results suggest that cell surface HS is necessary for Tie1 binding 
through the predicted Tie1-GAG binding interface and that loss of cell surface HS 
or the residues necessary for this interaction is sufficient to prevent Tie1 binding. 
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Figure 3-12. HS-dependent Tie1 binding to endothelial cells. Untreated or heparinase-treated 
EA.hy926 cells were probed with Tie1-WT and visualized with an anti-human Fc antibody (red). In 
parallel, cells were probed using an anti-HS antibody (green) and DAPI (blue). Robust binding was 
observed for untreated cells, which was lost upon heparinase treatment. Tie1-2A showed no 
binding to cells, suggesting that binding to HS is necessary to cell surface binding. 
3.2.4 Towards a Functional Role of Tie-GAG Binding 
 To further characterize the importance of the Tie1-HS binding interaction, we 
turned to cellular assays. Unfortunately, Tie1 presents a number of unique 
challenges to understand its functional role. For example, the most common 
method to examine the functional output of an RTK is through phosphorylation 
assays.45 Although Tie1 contains an intracellular tyrosine kinase domain, evidence 
of Tie1 homodimeric activation and cross-phosphorylation has not been observed 
as seen for other RTKs,46, 47 precluding a commonly used, facile readout for RTK 
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activity. Early reports using chimeric proteins containing the intracellular Tie1 
kinase domain fused to extracellular domain of either tropomyosin-related kinase 
A (TrkA) or colony stimulating factor 1 (c-fms) receptor provided conflicting 
results over whether “forced” homodimerization by stimulation with the 
canonical ligands of TrkA or c-fms could induce cross-phosphorylation,48, 49 
further obfuscating the relevance of Tie1 kinase activity. Conversely, Tie2 
activation by angiopoietin ligands can lead to Tie1 phosphorylation through 
heterodimerization;46, 47 however, this approach introduces additional HS-binding 
partners to the experiment (see Section 3.4), preventing the straightforward 
delineation of the role of HS binding on one protein within the larger system.  
 To circumvent these concerns, we focused on examining the transient 
association of Tie1 with other cell surface receptors. The Tie1/Tie2 heterodimer 
has been documented previously and is the basis of Tie2-induced phosphorylation 
of Tie1;46, 47 however, this interaction has been observed using standard co-
immunoprecipitation techniques. Instead, cross-linking of surface receptors has 
been used to preserve the interaction for co-immunoprecipitation.46, 50, 51 More 
recently, integrin α5β1 has also been implicated to associate with Tie1 and Tie2 at 
the cell surface,51 and its removal prevents Tie2 signaling.26 As proof of principle, 
we used the immortalized endothelial cell line EA.hy926 and treated the cells with 
the cell-impermeable cross-linking agent 3,3’-dithiobis(sulfosuccinimidyl 
propionate) (DTSSP). Cells were then lysed and immunoprecipitated for Tie1. 
Cells treated with DTSSP showed robust co-immunoprecipitation of Tie2 as well  
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Figure 3-13. Tie1 association with Tie2 and α5-integrin. EA.hy926 cells were treated with cross-
linker DTSSP, lysed, and immunoprecipitated for Tie1. Samples were analyzed by Western blotting. 
as integrin α5 (Figure 3-13). In the near future, we plan to expand this assay out 
with heparinase treatment and cell surface glycan engineering (see Section 3.4.3).  
 As an alternative approach to observe Tie1/Tie2 heterodimers, we have also 
employed proximity ligation assays (PLA).52 This assay is similar in format to 
standard immunocytochemistry (ICC) techniques where two proteins are probed 
for with separate primary antibodies. The method diverges from ICC in that the 
secondary antibodies are modified with single stranded DNA oligonucleotides 
rather than fluorescent dyes. Through subsequent annealing and ligation steps, a 
substrate is formed for rolling circle amplification, at which point fluorescently 
labeled nucleotides are incorporated into the growing DNA strand. These 
fluorescent oligonucleotides can then be detected by standard 
immunofluorescence imaging. Importantly, this procedure will produce punctate 
staining only at locations where both primary antibodies bound, providing a signal 
only where the two target proteins are in close proximity with one another. We 
optimized this assay for the Tie1/Tie2 heterocomplex using two antibodies  
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Figure 3-14. Direct observation of Tie1/Tie2 heterocomplexes by PLA. EA.hy926 cells were 
fixed, immunostained with (A) anti-Tie1 and anti-Tie2 antibodies or (B) anti-Tie1 antibody alone, 
stained with the PLA staining protocol, and visualized by microscopy. Tie1/Tie2 heterocomplexes 
are revealed as punctate red staining and can be normalized to cell count by DAPI (blue) nuclear 
staining. Scale bar = 20 μm. 
specific for the extracellular domains of each protein (Figure 3-14). Briefly, 
HUVECs or EA.hy926 cells were fixed, blocked, and probed with the appropriate 
Tie1 and Tie2 antibodies. Cells were then subjected to PLA procedures according 
to the manufacturer’s specifications. Cells were then co-stained with DAPI and 
visualized by confocal microscopy. We were pleased to observe the formation of 
punctate staining at the cell surface when both antibodies were used, whereas a 
control sample lacking one of the two primary antibodies showed minimal 
background. As before, we will apply both heparinase and glycan engineering 
techniques to this assay to further delineate the effect of HS on Tie1/Tie2 
heterodimerization. 
3.2.5 Generation of a Tie1-GAG-Binding Deficient Mouse Model 
 Further examination of the Tie1-GAG binding event requires the use of 
functional systems. Here again, the Tie/Ang signaling axis provides a number of 
BA
  
98 
unique challenges. Unlike many other functional outcomes of RTKs such as 
growth promotion or inhibition, the outcomes of the Tie/Ang pathway such as 
vessel development, maturation, and remodeling are not easily testable in vitro. 
The closest related in vitro assay, measuring apoptosis in response to serum and 
growth factor starvation, has been used infrequently with angiopoietin ligand 
stimulation;53 however, very few other reported in vitro assays exist that can 
directly examine the formation and maintenance of vascular tissue. Instead, many 
researchers have turned to in vivo models to test Tie/Ang function.  
 The lethality of constitutive Tie1 and Tie2 knockout models prevented further 
examination of Tie1/2 function in adult animals.11-13 This led to the development 
of floxed Tie1 animals crossed with mice expressing cre recombinase under 
endothelial-specific, tamoxifen-dependent promoters (such as the Cdh5-creERT2 
and Tal1/SCL-creERT lines) to provide adult mice with endothelial-specific Tie1 
knockout.17, 26 Although these mice have been invaluable for the study of Tie1 
function in vivo, they do not provide a straightforward way to ascertain the 
importance of the Tie1-GAG interaction specifically. Similarly, a number of 
different HS biosynthesis conditional knockout animals exist, with Ndst1 being 
commonly used since animals have much lower HS sulfation in the targeted 
tissue.54, 55 However, these models also suffer from questions of specificity for our 
purposes. HS binds to a number of angiogenic ligands and receptors; thus, 
understanding the ramifications of the Tie1-GAG interaction caused by a global 
decrease in overall HS sulfation (and thereby overall HS/protein binding) may be 
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also difficult to parse. Therefore, we turned our attention to a mouse model that 
could specifically disrupt the Tie1-GAG interaction using insights gained from 
mutational studies. 
 To achieve this selective mouse model, we chose to pursue a novel approach 
using gene editing with the clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 platform.56-58 Here, the Cas9 nuclease protein is directed 
to specific regions of the genome by a complementary single stranded RNA 
sequence known as a guide RNA (gRNA). Once localized to the sequence, Cas9 
induces a double strand break within the complementary genomic DNA (gDNA) 
sequence. In the absence of a repair template, endogenous machinery of the cell 
undergoes non-homologous end joining (NHEJ), thereby producing random 
insertions and deletions (indels). Alternatively, a repair template is added along 
with the gRNAs and Cas9. Here, homology-directed repair (HDR) machinery can 
compete with NHEJ to incorporate the repair template at the DSB site. This 
approach has been used successfully to incorporate a variety of site mutations, 
small reporter tags, and fluorescent protein fusions onto endogenously expressed 
proteins.59 Importantly, this approach provides a number of benefits compared to 
other methods like lentiviral delivery or transient expression in that the 
incorporation event is highly controlled and will not interrupt other genes at 
random, expression levels will be controlled by the endogenous promoter and 
subjected to native regulation, and endogenous proteins do not need to be 
silenced to replace with a mutated sequence. Furthermore, CRISPR/Cas9  
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Figure 3-15. Validation of guide RNAs in HEK-293T cells. HEK-293T cells were transfected with 
the pCAG-EG(Tie1)FP plasmid plus empty pX459 (no gRNA) or pX459 containing gRNA1 or 
gRNA5. gRNA targeting efficiency was measured by the formation of GFP+ cells. 
transgenic animal production does not require the extensive screening of stem 
cell clones like previous transgenic methods.60 Finally, we believe that this 
approach will be a powerful new tool for glycobiology, allowing a clear-cut 
method to understand the importance of a single GAG-receptor binding event 
without globally affecting other carbohydrate-protein interactions. 
 We decided to target the R38A and R82A mutations for genomic 
incorporation. The efficiency of mutation incorporation by HDR decreases 
rapidly more than 10-20 base pairs (bp) away from the DSB site.61 Because the 
codons for these residues are roughly 130 bp away from one another, we decided 
to use a dual gRNA approach that would cut near each of the targeted mutation 
sites. gRNAs were designed using the online CHOPCHOP computational tool for 
the sequences flanking each codon, and four to five gRNAs for each region were 
selected based on predicted cutting efficiency and minimal off-target homology. 
These gRNAs were cloned into pX459 gRNA/Cas9 vector to test their cutting 
efficiency. We chose to use a recently described activity assay for gRNA 
no gRNA gRNA1 (R82) gRNA5 (R38)
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screening in which the genomic region of interest is cloned within a broken GFP 
construct (pCAG-EGxxFP).62 If cut, the vector undergoes self-mediated HDR 
using homology regions of GFP flanking the inserted gDNA sequence to produce a 
functional GFP construct. The Tie1 genomic region of interest was amplified from 
murine gDNA and inserted into the pCAG-EGxxFP construct to produce pCAG-
EG(Tie1)FP. pX459 vectors containing each gRNA and pCAG-EG(Tie1)FP were 
co-transfected into human embryonic kidney (HEK) 293T cells, which were then 
visualized after 48 h (Figure 3-15). gRNAs that produced the highest percentage 
of GFP+ cells were chosen for in vivo experiments. 
 Next, the repair template was designed. Two types of repair templates have 
been used previously: single stranded oligonucleotides (ssODNs) or double 
stranded DNA (dsDNA).59 ssODNs generally are upwards of 200 nucleotides (nt) 
in length, with roughly 60 nt of homologous sequence on either side of the 
inserted sequence. Conversely, dsDNA templates are less effective for HDR and 
require hundreds of bp of homologous sequence for efficient incorporation. 
Because we aimed to incorporate mutations roughly 130 bp apart, we tried both 
approaches. Two ssODN constructs were produced containing one of the two 
mutations flanked by roughly 60 nt of homologous sequence. The dsDNA 
construct was designed to contain the same central 130-bp sequence flanked by 
roughly 550 bp of homologous sequence. Within the region surrounding the Arg-
38 and Arg-82 codons, a number of mutations were made. First, the two codons 
were mutated to Ala codons. Second, a silent mutation was incorporated into the  
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Figure 3-16. CRISPR/Cas9-mediated in vivo Tie1 mutations. (A) Schematic of CRISPR/Cas9 
strategy to introduce R38A and R82A mutations in vivo. Two gRNAs specific to regions around 
each codon of interest along with a dsDNA donor will be used to introduce the mutations. (B) 
Sequencing results from successful heterozygous mutations in B6SJL-F1/J blastocysts. 
protospacer motif (PAM) for each gRNA. Cas9 recognition of gDNA requires an 
NGG motif known as the PAM immediately at the 3’-end of the gRNA 
complementary sequence. Loss of the NGG seqeunce prevents Cas9 from cutting 
the sequence again after the mutation has been incorporated. Finally, silent 
mutations were added at each site to incorporate restriction enzyme cut sites to 
allow for facile genotyping. Both the ssODN and ssDNA constructs were 
commercially purchased along with the gRNA sequence and Cas9 protein. 
 To test efficiency in vivo, the two gRNA/Cas9 complexes were formed in vitro 
and pronuclearly injected into fertilized B6SJL-F1/J murine zygotes at 20 ng/µL 
each along with either the pair of ssODNs or dsDNA construct at 20 or 10 ng/µL, 
respectively, in 10 mM Tris pH 8.0, 1 mM EDTA. B6SJL-F1/J mice (the F1 
generation crossing of a C57BL/6 female and a SJL/J male) were chosen because 
WT: T T G C G T G C C A G G  
82: T T G G C G G C C A G A 
WT: A G A A A C G C T G G G  
38: A G A A G G C C C A A G 
A B
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of their relatively large litter sizes and hybrid vigor compared to inbred lines. 
Zygotes were allowed to develop to the blastocyst phase, at which point they 
were subjected to genotyping to test for incorporation of the desired mutations. 
Genotyping was achieved by harvesting gDNA from the blastocysts followed by 
PCR amplification of the desired sequence and Sanger sequencing (Figure 3-16). 
In both cases, the majority of the zygotes proceeded to the blastocyst stage 
(ssODN: 15/18; dsDNA: 15/21), suggesting that the injection solutions were 
nontoxic. Interestingly, sequencing results showed that the majority of the 
blastocysts resulting from ssODN injection showed random indels, with no 
sample showing proper incorporation. This was unexpected as ssODN repair 
templates had previously been described as highly efficient. We were happy to 
see that 4/15 blastocysts from dsDNA injection showed proper incorporation of 
the mutations at both of the sites (Figure 3-16b). We chose this method to 
proceed to large-scale injection and implantation. 
 For large-scale injection and implantation, roughly 80 fertilized zygotes were 
harvested from the oviducts of superovulated, mated B6SJL/J mice, injected with 
the gRNA/Cas9/dsDNA mixture described above, allowed to mature to the 
blastocyst stage, and then implanted at ~20 zygotes per surrogate mother. This 
was repeated three times, which resulted in seven litters containing 19 total pups. 
The litter sizes were small, but this is expected since loss of Tie1, which could be 
caused by indels from competing NHEJ processes, is embryonic lethal. 
Unfortunately, none of the animals possessed the desired genotype. The 
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experiment was repeated using a higher concentration of dsDNA (20 ng/µL) and 
incubation of the zygotes with the NHEJ inhibitor SCR7.63 Here, four litters 
containing a total of 15 pups were obtained. Excitingly, three pups were 
heterozygous for the desired mutations, with the other Tie1 allele containing 
small in-frame deletions. Two of the pups were produced from zygotes incubated 
with SCR7, whereas one was derived from untreated zygotes. The SCR7-treated 
pups contained 6- and 9-bp deletions, and the untreated pup contained a larger in-
frame deletion of 90 bp, providing anecdotal evidence of the efficacy of SCR7 in 
inhibiting at least large NHEJ events. The now adult mice are currently set up in 
breeding pairs with C57BL/6 mice to expand the colony for future homozygous 
crossing and phenotypic analysis. 
 
3.3 HS GAGs Bind to Angiopoietin Ligands and Potentiate Tie2 Signaling 
3.3.1 ELISA 
 In addition to the Tie receptors, we also examined whether the related 
angiopoietin ligands Ang1, -2, and -4 could also interact with HS. Previously, Ang1 
but not Ang2 has been shown to associate with the extracellular matrix (ECM) via 
its linker peptide region;64 however, the purified Ang1 constructs used therein did 
not bind to heparin or soluble Tie2-Fc. In a separate report, Ang3, the functionally 
distinct murine ortholog to human Ang4, was shown to be anchored to the 
extracellular matrix through HSPGs like perlecan,65 raising the possibility of Ang4 
association with HS. To test binding, we used a modified version of the  
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Figure 3-17. Carbohydrate ELISA using angiopoietin ligands. Ang-6xHis constructs 
immobilized on Cu plates were probed with biotinylated HS as previously described. Ang1 and 
Ang4 show nanomolar affinity to HS, whereas Ang2 does not bind. 
carbohydrate ELISA platform. Ang constructs containing a C-terminal 6xHis tag 
were immobilized onto copper functionalized plates and incubated with 
biotinylated HS. Here, Ang1 and Ang4 showed strong binding to HS, with 
dissociation constants of 2.23 ± 0.27 nM and 42.0 ± 43.0 nM, respectively, whereas 
Ang2 did not show binding to HS (Figure 3-17). The strong affinity of Ang1 for 
HS is in direct conflict with results described from previous experiments.64 
However, the constructs used in the previous paper were over-expressed in 
murine cancer cell lines LLC and TA3 and the simian kidney cell line Cos7, which 
may have produced misfolded forms of the protein. 
3.3.2 Ternary Complex Formation with Tie2 
 GAGs have been shown previously to both facilitate and impede the formation 
of a ligand-receptor interaction,33 thus exerting control over receptor activation 
and signaling. To rapidly delineate whether HS binding to Ang1 or Ang4 affects 
their binding to Tie2, we employed carbohydrate microarrays to directly observe  
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Figure 3-18. Ternary complex formation of Tie2-Ang-HS. HS carbohydrate microarrays were 
incubated with Tie2-Fc with or without (A) Ang1 or (B) Ang4. Immobilized Tie2-Fc was visualized 
using an anti-human Fc antibody. Binding of Tie2-Fc to the microarray in the presence of Ang1 or 
Ang4 suggests the formation of carbohydrate-protein-protein ternary complexes. 
the formation of ternary, carbohydrate-protein-protein interactions (Figure 3-18). 
Here, Tie2-Fc, which was previously shown not to bind HS, was incubated with 
the HS microarrays in the presence or absence of Ang1 or Ang4. Tie2 
immobilized onto the microarray through its interaction with HS-bound Ang1/4 
was visualized by a fluorescently tagged anti-human Fc antibody. As previously 
shown, signal from Tie2 alone was not observed on the HS microarray. 
Interestingly, Tie2 signal dramatically increased in the presence of either Ang1 or 
Ang4, suggesting that the Ang/HS interaction does not interfere with Ang/Tie2  
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binding and that the three biomolecules can exist as a single ternary complex. 
Moreover, the assembly of this ternary complex is sulfation pattern dependent, 
forming only with the HS motif. This mode of ternary complex formation has 
previously been demonstrated for both FGF2-FGFR1 and FGF8-FGFR366 and 
suggests that HS at the cell surface can potentiate Ang/Tie2 signaling by bringing 
Ang ligands into close proximity with the Tie2 receptor. 
3.3.3 Potentiation of Tie2 Signaling by Glycan Engineering 
 To examine whether cell surface HS could affect Ang/Tie2 signaling, we 
decided to utilize our HTP glycan engineering technique.66 Endothelial cells are 
generally very refractory to transient transfection;67 therefore, a lentiviral 
delivery approach was developed. Here, the HTP transmembrane construct was 
cloned into a pENTR4 vector and transferred to a pLenti-CMV-Blast destination 
vector using Gateway cloning.68 Lentiviruses (HTP-LV) were produced using 
third generation packaging plasmids in HEK-293T cells and concentrated by PEG 
precipitation.69 The endothelial EA.hy926 cell line was treated with different 
amounts of HTP-LV and subjected to selection with blasticidin after 48 h. Cells 
from the sample treated with the lowest amount of HTP-LV that survived three 
days after all untreated cells were killed were used as the EA.hy926-HTP cell line 
moving forward. To validate the expression of HTP on the cell surface, EA.hy926-
HTP and untransduced, parental cells were treated with cell-impermeable AF488-
CL and Hoescht 33324 dye for 15 min at 37 °C, washed, and live imaged (Figure  
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Figure 3-19. Production of an HTP-expressing endothelial cell line. EA.hy926 cells were 
treated with an HTP-expressing lentivirus and selected for incorporation. The resulting cells (+ HTP-
LV) and the parental cells (- HTP-LV) were treated with AF488-CL to visualize cell-surface HTP. 
Scale bar = 50 μm. 
3-19). As expected, cells treated with HTP-LV showed robust surface labeling by 
AF488-CL, whereas the parental cells showed no surface labeling.  
 With HTP-expressing endothelial cells in hand, we set to test the effect of cell-
surface HS on Ang/Tie2 signaling (Figure 3-20). To achieve this, EA.hy926-HTP 
cells were first treated with heparinase I/III to eliminate endogenous HS and then 
grown to confluency. Cells then treated with either 5 µg/mL HS-CL or desulfated 
(deS) HS-CL for 2 h at 37 °C in serum-starved medium (0.5% fetal bovine serum). 
Cells were washed and then incubated for another 4 h in serum-starved medium 
Hoescht AF488-CL merge
- HTP-LV
+ HTP-LV
+ HTP-LV
+ AF488-CL
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Figure 3-20. Potentiation of Tie2 signaling by glycan engineering. EA.hy926 cells expressing 
HTP were treated with de-HS-CL or HS-CL and stimulated with Ang1, Ang2, or Ang4. Tie2 
activation was quantified by measurement of Akt phosphorylation at Thr-308 using Western blotting. 
and then treated with 500 ng/mL Ang1, Ang2, or Ang4 for 30 min at 37 °C. Cells 
were then washed with PBS and immediately lysed. Phosphorylation of Akt at 
Thr308, which is dependent on 3-phosphoinositide dependent kinase 1 (PDK1), 
was then measured by Western blotting as a readout for downstream Tie2 
signaling. Impressively, we saw that for both Ang1 and Ang4, the presence of HS-
CL on the cell surface led to a significant increase in Akt phosphorylation 
compared to cells displaying with the non-binding de-HS-CL. No significant 
difference was observed at basal levels or with Ang2, suggesting that this effect is 
specific to increased Tie2 activation by Ang1 and Ang4 bound to HS. Together 
with the ternary complexation data, these results suggest that HS, which is highly 
50
50
untreated Ang1 Ang2 Ang4
P = 0.0023
P = 0.012
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upregulated at the cell surface of endothelial cells, can potentiate Tie2 activation 
by Ang1 and Ang4 through the formation of active ternary signaling complexes. 
3.4 Conclusions 
  The results presented herein provide the first evidence for the involvement of 
HS in the Ang/Tie signaling pathway. The binding of orphan receptor Tie1 to 
GAGs is the first report of a ligand for this protein since its discovery 25 years 
ago. Furthermore, the use of biochemical and chemical biology tools to identify 
amino acid residues necessary for the Tie1-GAG interaction has allowed the 
production of an animal model that is deficient in this interaction without 
removing the protein or the carbohydrate. This is the first report of an animal 
model using this approach, which will provide unparalleled, specific information 
of the importance of a protein-carbohydrate interaction in vivo. Moreover, the 
interaction between HS and Ang1 and Ang4 parallel the widely observed 
phenomenon of HS-ligand interactions. Using our glycan engineering method, we 
were able to provide direct evidence that HS on the cell surface potentiates 
signaling through HS-Ang1/4-Tie2 ternary complexes as demonstrated by our 
carbohydrate microarrays. These results as a whole provide crucial information 
regarding the regulation of the Tie/Ang signaling axis and may help further 
delineate the molecular mechanisms of a well-known but poorly understood RTK 
subfamily. 
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3.5 Methods and Materials 
3.5.1 General Methods 
Molecular biology. All reagents used for molecular biology were obtained from 
New England Biolabs unless otherwise noted. All primers were obtained from 
Integrated DNA Technologies. All miniprep, maxiprep, and gel extraction steps 
were conducted using Zymogen kits (Genesee Scientific). Cloning was generally 
achieved using the NEBuilder HiFi Cloning Master Mix (New England Biolabs). 
Human Tie1 cDNA was obtained from pDONR223-TIE1 plasmid (23946, 
Addgene) and cloned into a pCDNA3.1 vector (ThermoFisher Scientific) 
containing an N-terminal Ig κ-leader sequence and C-terminal human IgG1 Fc and 
6xHis tags. Truncations and site mutations were produced using the Q5 site-
directed mutagenesis kit (New England Biolabs). The transmembrane HTP 
construct was produced as previously described.66 To produce the lentiviral 
construct, he HTP sequence was first cloned into the pENTR4 vector (17424, 
Addgene) and then transferred into the pLenti-CMV-Blast vector (17451, 
Addgene) using the Gateway LR Clonase kit (ThermoFisher Scientific). Vectors 
used to test gRNA sequences include pCAG-EGxxFP (50716, Addgene) and 
pX459 (62988, Addgene).  
Cell culture. All reagents used for cell culture were obtained from ThermoFisher 
Scientific unless otherwise noted. The EA.hy926 cell line, HEK-293T cell line and 
HUVECs were obtained from the American Type Culture Collection. EA.hy926 
and HEK-293T cells were cultured in DMEM with 10% fetal bovine serum (FBS) 
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and 1x penicillin/streptomycin (P/S) (referred to now on as complete DMEM). 
HUVECs were cultured using endothelial cell basal medium (EBM-2, Lonza) with 
the EGM-2 Bulletkit additives (Lonza) (referred to now as EGM-2 medium) and 
were used for experiments between 0 and 5 passages. For serum starvation, 
EA.hy926 cells were cultured in DMEM with 0.5% FBS and 1x P/S. Cells were 
generally grown on plastic, tissue culture treated plates (Sarstedt) without any 
coating. For experiments, cells were plated onto plastic plates (for lysate 
harvesting) or glass-bottom plates (imaging) precoated with 5 µg/cm2 bovine 
fibronectin (Sigma Aldrich) and 10 µg/cm2 rat tail collagen type I (Sigma 
Aldrich). Plates were coated by incubation of plates with the above-mentioned 
proteins in sterile PBS for 1 h at 37 °C followed by two rinses with sterile PBS and 
were used immediately. 
Western blotting. Protein samples were first diluted with one-fourth volume of 4x 
sodium dodecyl sulfate-polyacrylamine gel electrophoresis (SDS-PAGE) loading 
buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS, 40% glycerol, 0.4% 
bromophenol blue) and heated to 95 °C for 10 min. Samples were then loaded 
onto NuPAGE 4-12% Bis-Tris protein gels (NP0355BOX, ThermoFisher 
Scientific) and resolved using 180 V at RT for 1 h with constant voltage. The 
molecular weight of protein targets was estimated using Precision Plus Protein 
Dual Color Standards (Bio-Rad). Gels were then transferred onto Immobilion-FL 
PVDF membrane (IPFL00010, EMD Millipore) using 250 mA at 4 °C for 1-1.5 h 
with constant amperage. Membranes were then blocked for 1 h at RT with either 
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5% BSA in TBST (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween) for 
phosphoprotein detection, 1:1 Li-COR blocking buffer/TBS for goat primary 
antibodies, or with 5% nonfat milk in TBST, depending on the antibody 
specifications. In general, primary antibodies were used at 1:1000 (1 µg/mL) in 
the same buffer as the blocking step with incubation at 4 °C overnight with gentle 
rocking. Blots were rinsed thrice with TBST prior to incubation with secondary 
antibodies. In general, highly cross-adsorbed secondary antibodies containing 
AlexaFluor 680 or AlexaFluor 790 (ThermoFisher Scientific) were used at 
1:10000 (0.2 µg/mL) in the same buffer as the blocking step with incubation at RT 
for 1 h with gentle rocking. Blots were then washed thrice for 5 min with TBST 
prior to imaging with the Li-COR Odyssey CLx. Quantification was performed 
using Image Studio Software (Li-COR). Blots were stripped using NewBlot PVDF 
Stripping Buffer (Li-COR) according to the manufacturer’s protocol. 
3.5.2 Protein Expression and Purification 
For each protein construct, five 15-cm plates of 90% confluent HEK-293T cells in 
20 mL complete DMEM were transfected with 20-30 µg plasmid using 
poly(ethyleneimine) (23966-2, Polysciences, Inc.). Briefly, DNA was diluted in 2 
mL pre-warmed, serum-free DMEM and PEI (1 mg/mL in sterile ddH2O) was 
added dropwise with vigorous shaking at a 3:1 w/w PEI/DNA ratio. DNA/PEI 
complexes were allowed to form for 20 min at RT and then added dropwise to 
each plate. After 24 h, the medium in each plate was replaced with DMEM 
containing 2% FBS and 1x P/S. Sometimes, proteins were found to be truncated 
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once secreted into the medium. To prevent this, the medium was supplemented 
with 0.5x cOmplete protease inhibitor cocktail without ETDA (PIC-, 
11697498001, Sigma Aldrich). At 3 d post-transfection, the medium was 
harvested and centrifuged to remove cell debris. A new 20-mL aliquot of DMEM, 
2% FBS, 1x P/S was added, which was harvested 2 d later, centrifuged, and 
combined with the first aliquot. The solution pH was adjusted to 8.0 using 2 M 
Tris, and medium was rotated end-over-end for 2 h at 4 °C with 500 µL Ni-NTA 
resin (Qiagen) prewashed twice with PBS. The resin was separated from the 
medium by centrifugation and loaded onto a disposable column (Bio-Rad). The 
resin was washed with 10 mL phosphate wash buffer (100 mM sodium phosphate 
pH 7.4, 300 mM NaCl, 10 mM imidazole), and protein was eluted with two 
aliquots of 1 mL elution buffer (50 mM sodium phosphate pH 7.4, 150 mM NaCl, 
250 mM imidazole). Elution samples were combined and buffer exchanged by 
centrifugation with PBS. Samples were stored at 4 °C for up to one week or flash-
frozen and stored at -20 °C. 
3.5.3 Protein-GAG Binding Assays. 
Carbohydrate enzyme-linked immunosorbent assay. Biotinylated CS-E and HS were 
prepared as previously described.38 Initial ELISAs were performed with 
commercially available Tie1- and Tie2-Fc conjugates (R&D Systems). Wells of 
Protein A/G 8-well strips (ThermoFisher Scientific) were rinsed twice with 200 
µL PBST (PBS + 0.02% Tween-20) and then incubated with 100 µL 10 µg/mL 
Tie1-Fc or Tie2-Fc in 1% bovine serum albumin (BSA, Fisher Scientific) in PBS for 
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1 h at RT with gentle rocking. Wells were rinsed thrice with PBST and next 
incubated with 200 µL 5% BSA in PBS for 1 h at RT. During this incubation step, a 
dilution series of biotinylated CS-E or HS was produced in PBS. Wells were again 
rinsed thrice with PBST, and 50 µL of each GAG-containing solution was added to 
the wells. Wells were incubated with GAG-containing solutions for 3 h at RT with 
gentle rocking. Wells were rinsed four times with PBST and then incubated with 
100 µL 1:15000 HRP-conjugated streptavidin (ThermoFisher Scientific) for 1 h at 
RT with gentle rocking. Wells were again rinsed four times with PBST and then 
incubated with 100 µL development solution (R&D Systems) for 15 min at RT in 
the dark. Reactions were quenched by the addition of 100 µL 2 N H2SO4, and 
absorbance was read at 450 nm. Assays were performed in duplicate for each 
concentration, and values were reported as the average ± SEM. Curves were fitted 
and KD values were calculated with Prism 7 (GraphPad) using the nonlinear curve 
fitting of standard binding with Hill slope function. For experiments using over-
expressed, purified proteins, protein concentrations were first normalized using 
the bicinchoninic acid (BCA) assay (ThermoFisher Scientific) and used the same 
as the purchased proteins mentioned above. 
GAG microarrays. GAG microarrays were generated and conducted as previously 
described.33 Briefly, slides were blocked with 10% FBS in PBS for 1 h at RT. Stock 
solutions of Tie1-Fc, Tie2-Fc, Ang1, and Ang4 (2 µM) were prepared in sterile 
PBS containing 1% BSA. Blocked slides were washed once with PBS and slowly 
rocked with 150 µL of 1% BSA/PBS containing 1 µM Tie1-Fc for 2 h at RT. For 
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ternary complex formation, 150 µL of 1% BSA/PBS containing 1 µM Tie2-Fc with 
or without 1 µM ligand (i.e., 1 µM Tie2-Fc ± 1 µM Ang1; 1 µM Tie2-Fc ± 1 µM 
Ang4) were used immediately without prior incubation. Slides were washed three 
times with PBS and incubated with an AF647-conjugated goat anti-human Fc 
antibody (1:5000) in 1% BSA/PBS for 1 h at RT in the dark with gentle rocking. 
Slides were then washed three times with PBS and twice with ddH2O and blown 
dry under a stream of filtered air. Arrays were scanned using a G2565BA DNA 
Microarray Scanner (Agilent), and fluorescence was quantified using GenePix 5.0 
software (Molecular Devices) with normalization against local background. The 
data represent the average of 10 spots per concentration of polysaccharide. 
Surface plasmon resonance. All experiments were conducted using a Biacore T200 
instrument (GE Healthcare). A CM5 sensor chip (GE Healthcare) was first 
functionalized with streptavidin using the manufacturer’s amine coupling 
protocol. Briefly, all flow cells of a CM5 sensor chip (GE Healthcare) were 
incubated with a 1:1 molar ratio of N-hydroxysuccinimide and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide for 3 min at a flow rate of 10 µL/min 
followed by 1 µM streptavidin in 0.01 NaOAc pH 5.0 until the response rate 
leveled off (saturating the flow cell surface). Remaining reactive groups were 
quenched by ethanolamine. Solutions of biotinylated CS-E or HS were then each 
flowed over one of the four flow cells (CS-E: flow cell 2; HS: flow cell 4) to 
provide a response value of roughly 25 RU. As a control, an antibody specific to 
CS-E was flowed over the CS-E containing flow cell and corresponding control 
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cell to ensure successful loading of biotinylated GAG. To test binding of Tie1-Fc 
to the biotinylated GAGs, a two-fold dilution series of Tie1-Fc (starting at 100 
nM) was produced and flowed over the flow cells for 300 s at a rate of 20 µL/min. 
Dissociation of Tie1-Fc was then monitored for 350 s using the same flow rate. 
Between each run, the surface was regenerated using 2.5 M MgCl2 at a flow rate of 
30 µL/min. Response values are reported after substraction of the control (-GAG) 
cell. The resulting curves were fit to the one-to-one Langmuir binding model 
equation using the Biacore SPR evaluation software.  
3.5.4 Computational Methods 
Structure modeling. The Tie1 homology model was constructed using the program 
SWISS-MODEL42 with human Tie2 ligand-binding domain (PDB ID 2GY5)41 as a 
template and the sequence of human Tie1 (UniProt ID P35590). The Tie1 
homology model was briefly minimized in vacuum using the DREIDING force 
field70 to reduce steric clashes built into the model. To produce the GAG ligand 
for docking, a dodecasaccharide structure was first generated for CS-E and HS, 
and the ligand side chains were relaxed by a brief minimization step. Ligands were 
then placed in a water box, and a molecular dynamics (MD) simulation was run 
for 5 ns. The structure closest to the average structure over the 5 ns MD run was 
selected as the conformation for docking. The dodecasaccharide was then 
truncated to a hexasaccharide by removing three monosaccharides from the 
reducing and non-reducing ends. 
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Docking and binding site determination. First, a coarse round of docking is 
performed. Here the ligand is docked to the entire protein surface. Prior to the 
docking run, the protein structure is “alanized” by replacing bulky, nonpolar 
residues (Val, Leu, Ile, Met, Phe, Try, and Trp) with Ala to allow for more 
complete sampling of the binding site. The protein is split into regions, and 
spheres are generated for docking. For each region, docked ligand poses are 
generated, scored, and clustered into families based on energy and root-mean-
square deviation. For each cluster, the lowest energy pose known as the family 
head is output, generally producing 120 poses for each docked region. These 
poses are then de-alanized and undergo side chain optimization using SCREAM71 
to produce a unique set of protein side chain conformations for each pose. The 
top docking regions are identified by ranking the average energy of the top five 
poses in each region. Top regions are then subjected to an additional round of 
docking. Here a minimization step is performed to improve protein-ligand 
interactions following side chain placement and optimization with SCREAM. 
These poses are clustered as before, and family heads are output. The scoring 
energy known as the snap binding energy used to rank poses is equal to the 
complex energy minus protein energy and ligand energy.  
3.5.5 Biological Assays 
Cell-surface crosslinking. EA.hy926 cells were plated onto precoated six-well plates 
and grown to confluency with complete DMEM. Cells were rinsed three times 
with ice-cold PBS and then incubated with 100 µL 1 mM DTSSP in PBS (freshly 
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prepared) for 30 min at RT with gentle rocking. Unreacted DTSSP was quenched 
by addition of 5 µL 1 M Tris pH 8.0 with incubation for 15 min at RT. The 
crosslinking solution was then removed, and cells were lysed by scraping with 
ice-cold 200 µL Triton lysis buffer (20 mM HEPES pH 7.9, 150 mM NaCl, 1% 
Triton X-100, 5% glycerol, 1x PIC-). Lysates were rotated end-over-end for 10 
min at 4 °C and then centrifuged for 10 min at 21,000 x g to remove all insoluble 
material. The lysates were transferred to new tubes and rotated end-over-end 
with 1 µg Gt anti-Tie1 (AF619, R&D Systems) overnight at 4 °C. The next day, 20 
µL magnetic Protein A/G beads (ThermoFisher Scientific) prewashed with HBS 
(50 mM HEPES pH 7.9, 150 mM NaCl) was added to each sample and rotated 
end-over-end for 1 h at 4 °C. Beads were then washed with 500 µL HBS, 0.1% 
Triton X-100 thrice for 5 min at 4 °C. After the final wash, all wash buffer was 
removed, and the beads were resuspended in 30 µL 1x SDS-PAGE loading buffer + 
20 mM DTT (freshly prepared) and heated to 95 °C for 10 min. Samples were 
processed for Western blotted as described above. Blots were probed with 1 
µg/mL Gt anti-Tie1 (AF619, R&D Systems), 1 µg/mL Gt anti-Tie2 (AF313, R&D 
Systems), and 1 µg/mL Gt anti-α5 integrin (AF1864, R&D Systems).  
Proximity ligation assays. EA.hy926 cells were plated onto precoated 96-well glass 
bottom plates and grown to confluency. Cells were then washed twice with PBS 
and then fixed with 4% paraformaldehyde in PBS for 20 min at RT. Cells were 
rinsed thrice with PBS and blocked with the DuoLink blocking buffer (Sigma 
Aldrich) for 1 h at RT. Cells were rinsed twice with PBS and incubated overnight 
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at 4 °C with 1:100 Ms anti-Tie1 (MAB619, R&D Systems) and 1:100 Rb anti-Tie2 
(H176, Santa Cruz Biotechnology) in 1% BSA/PBS. Cells were then carried 
through the Duolink labeling protocol scaled to 30 µL reactions per well according 
to the manufacturer’s protocol (DUO92101, Sigma Aldrich). Cells were visualized 
using an LSM 710 confocal microscope (Zeiss) with a 40x oil immersion objective 
and preset filter settings for Texas Red and DAPI. A Z-stack of images was 
collected for each field of view, and a single image was produced using maximal 
pixel intensity. 
Lentivirus production. Lentiviruses were produced by co-transfecting two to four 
10-cm plates of 90% confluent HEK-293T cells in complete DMEM with the HTP 
lentiviral plasmid and pLP1, pLP2, and VSV-G helper plasmids (ThermoFisher 
Scientific) at 4.3 µg, 6.2 µg, 3.1 µg, and 3.7 µg, respectively, using Lipofectamine 
3000 (ThermoFisher Scientific) according to the manufacturer’s protocol. 
Medium was harvested and replaced with complete DMEM at 24, 48, and 72 h, 
centrifuged to remove cell debris, and combined. Lentivirus particles were either 
directly flash frozen and stored at -80 °C or were concentrated by PEG-6000 
precipitation as previously described.69 Precipitated lentiviruses were 
resuspended in complete DMEM, flash frozen, and stored at -80 °C. 
Generation and validation of EA.hy926-HTP cell line. EA.hy926 cells were grown to 
80% confluency in a six-well plate with complete DMEM and then treated with 0-
20 µL of the concentrated HTP-LV stock along with 8 µg/mL polybrene (Sigma 
Aldrich). After 48 h, cells were split 1:3 into new six-well plates in complete 
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DMEM containing 5 µg/mL blasticidin (InvivoGen). Medium was changed every 
2 d. After roughly 1-1.5 weeks, all cells in the untreated well had died. Cells were 
treated for an additional 3 d with 5 µg/mL blasticidin, and cells from the well 
treated with the lowest amount of lentivirus that survived selection were 
expanded and cryo-preserved. To validate expression of HTP, treated and 
untreated EA.hy926 cells were plated onto precoated 96-well glass bottom plates 
and allowed to grow to confluency. Cells were then treated with 1:1000 cell 
impermeable AlexaFluor 488-conjugated HTL (G1001, Promega) and 1:1000 
Hoescht 33342 (H3750, ThermoFisher Scientific) in complete DMEM at 37 °C for 
15 min. Cells were rinsed thrice with complete DMEM and live imaged on an LSM 
710 confocal microscope (Zeiss) with a 10x objective. 
Glycan engineering and stimulation assay. EA.hy926-HTP cells were treated in 
suspension with 2 U/mL heparinase I/III in complete DMEM for 2 h at 37 °C with 
gentle mixing every 15 min. Cells were then plated on precoated six-well plates at 
100,000 cells per well and grown overnight at 37 °C with complete DMEM. The 
following day, medium was replaced with serum-starved DMEM (0.5% FBS) 
containing 5 µg/mL de-HS-CL or HS-CL for 2 h. Medium was removed, and cells 
were treated with serum-starved DMEM for an additional 4 h. Cells were then 
stimulated with serum-starved DMEM containing 500 ng/mL Ang1, Ang2, or 
Ang4 or no ligand for 30 min at 37 °C. Cells were rinsed with ice-cold PBS and 
then lysed in 200 µL SDS lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1% SDS, 
1x PIC-, 1x Phos-STOP (Sigma Aldrich)) at RT. Lysates were sonicated for 10 s at 
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40% intensity to sheer DNA and then centrifuged for 5 min at 21,000 x g to 
remove any insoluble debris. Lysates were subjected to Western blotting as 
described above. Blots were probed using 1:1000 Rb anti-phosphoAkt(T308) and 
1:1000 Ms anti-Akt (9275 and 9272, Cell Signaling Technology). Assay was 
performed in triplicate. Phospho-Akt values were normalized to total Akt levels 
and are reported as the average value as normalized to the untreated de-HS-CL 
control. Statistical analysis was performed by Prism 7 (GraphPad) using a two-
way ANOVA with Sidak’s multiple comparisons test. 
3.5.6 Transgenic Tie1 Mouse Model  
Generating and testing gRNA sequences. Murine Tie1 gDNA was amplified from a 
C57BL/6J mouse gDNA sample (Jackson Laboratories) purified by DNEasy Blood 
and Tissue Kit (Qiagen) using the Q5 2x hot-start PCR master mix (New England 
Biolabs) using the following primers: 
 Tie1-EGxxFP-F: 
 CGTGCTGCTGCCCGACAACCACTGAGGATCCGTGCTGTGGATGAGAGGTAAGTT	
 Tie1-EGxxFP-R: 
 GGGTCAGCTTGCCGATATCGAATTCGTCGACGAAGAGGCTTGCAGGTAAAGAGC	
The amplified region was gel purified and cloned into the pCAG-EGxxFP vector 
between BamHI and SalI sites. Correct incorporation of the sequence was 
validated using Sanger sequencing with the following primer: 
 EGxxFP-Seq: CTACAACAGCCACAACGTCTAT 
 
Guide RNA sequences were designed using the online CHOPCHOP tool 
(http://chopchop.cbu.uib.no/) against the Dec. 2011 (GRCm38/mm10) murine 
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genome assembly against regions surrounding the Tie1 Arg-38 and Arg-82 
codons. Sequences were selected based on predicted activity and minimal off-
target homology. Primers to clone these gRNA sequences into the pX459 vector 
are shown below: 
 Tie1 Arg-82: 
 Tie1-gRNA-1F: CACCGGTGAGAACCGTTGCGTGCC 
 Tie1-gRNA-1R: TTTGGGCACGCAACGGTTCTCACC 
 Tie1-gRNA-2F: CACCGTTCTCACCAGGTCACGCTG 
 Tie1-gRNA-2R: TTTGCAGCGTGACCTGGTGAGAAC 
 Tie1-gRNA-3F: CACCGGCACGCAACGGTTCTCACC 
 Tie1-gRNA-3R: TTTGGGTGAGAACCGTTGCGTGCC 
 Tie1-gRNA-4F: CACCGATCGTGCGCACCTTCCCGCC 
 Tie1-gRNA-4R: TTTGGGCGGGAAGGTGCGCACGATC 
 Tie1 Arg-38: 
 Tie1-gRNA-5F: CACCGCGCAGGTCAGGAAGAAACGC 
 Tie1-gRNA-5R: AAACGCGTTTCTTCCTGACCTGCGC 
 Tie1-gRNA-6F: CACCGTCCGAGCTCCTCCCTGCTC 
 Tie1-gRNA-6R: AAACGAGCAGGGAGGAGCTCGGAC 
 Tie1-gRNA-7F: CACCGTTCTTCCTGACCTGCGTGTC 
 Tie1-gRNA-7R: AAACGACACGCAGGTCAGGAAGAAC 
 Tie1-gRNA-8F: CACCGCCTGACCTGCGTGTCTGGTG 
 Tie1-gRNA-8R: AAACCACCAGACACGCAGGTCAGGC 
 Tie1-gRNA-9F: CACCGCCTCACCAGACACGCAGGTC 
 Tie1-gRNA-9R: AAACGACCTGCGTGTCTGGTGAGGC 
 
For gRNA sequences that did not begin with G, a single G:C bp was added (shown 
in bold) to the primers to allow for efficient transcription by RNA polymerase III. 
gRNA oligonucleotides were dissolved at 100 µM in ddH2O, and 
annealing/phosphorylation reactions were set up as follows: 1 µL forward primer, 
1 µL reverse primer, 1 µL 10x T4 ligation buffer, 6.5 µL ddH2O, 0.5 µL T4 PNK. 
Reactions were incubated using a thermocycler at 37 °C for 30 min, followed by 
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95 °C for 5 min and ramping down to 25 °C at 5 °C/min. The reaction mixture 
was diluted 1:250 in ddH2O and used in digestion/ligation reactions as follows: 
100 ng pX459 vector, up to 12.5 µL with ddH2O, 2 µL 1:250 diluted reaction, 1 µL 
10 mM DTT, 1 µL 10 mM ATP, 2 µL 10x FastDigest buffer (ThermoFisher 
Scientific), 1 µL FastDigest BpiI, 0.5 µL T7 DNA ligase. Reactions were incubated 
for six cycles of 5 min at 37 °C then 5 min at 23 °C and could then be used for 
transformation. Correct incorporation of the gRNA sequence was validated with 
Sanger sequencing using the following primer: 
 U6-F-Seq: GACTATCATATGCTTACCGT 
 
To test gRNAs, confluent six-well plates of HEK-293T cells were transfected with 
0.5 µg pCAG-EG(Tie1)FP with 0.5 µg of each of the gRNA-containing pX459 
vectors. After 48 h, cells were live imaged using an LSM 710 confocal microscope 
(Zeiss) with a 5x objective using GFP filter sets. gRNA efficiency was estimated 
by the percentage of GFP+ cells. gRNA1 and gRNA5 were the best performing 
gRNA sequences for Arg-82 and Arg-38 regions, respectively. 
Designing repair template. The repair template to be used for injection was 
designed either as a pair of single stranded oligonucleotides (ssODNs) or a larger 
double stranded DNA (dsDNA) fragment. In both cases, mutations for Arg-to-Ala 
and silent mutations disrupting the NGG PAM sequence were added. The R38A 
mutation produced a StuI restriction site, and a silent mutation was introduced at 
R82A to produce an EaeI restriction site to be used for rapid genotyping. ssODNs 
and dsDNA were purchased as DNA Ultramers and a gBlock gene fragment, 
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respectively (Integrated DNA Technologies). The sequences for the repair 
templates are shown below, with mutations bolded, the Arg-82 codon in green, 
and the Arg-38 codon in orange. 
 ssODN (Arg-38): 
 caggggcgggtccgagctcctccctgctccggcctcaccagacacgcaggtcaggaa
gaaGGCctgAgggtctgtgatgcgcaggttggccagcaatgttaagtcaacagacgc
acctaggaccaaa  
 
 ssODN (Arg-82): 
 gacgcctaccaaatccgagggcttggagaagcccctcagcgtgacctggtgagaacc
gttGGCGgccagAtacaggggctgcccaggcgggaaggtgcgcacgatgcgatcatc
cttctccagcagcagg  
 
 dsDNA:  
 cgcaggctcctggtccttttagtacagtaggagggtggctcagagctacagatgaga
gggaagcccctagaggttggtcacaaggatggcaggtgggtcagggtggactaagta
tatggtgggccatggatggaagacctaaggtgtcagcatcatgggtctccctgtccc
accaactgcccctcaccgttgttcttccagatcacgtcagtctgcttttccttgtgc
acatgggcagaaagcacagcagtgtcacctttgttcaccgtgtgtgtgaccttgtct
ggaaacaggtgtgctgtggatgagaggtaagttcagcgatctacaacacagccctcc
ctctggtggtcgatctcctggtaggccagactcaccccctgggctgttgtgcacata
gagaactcgagtgcgccgcgcgccagcaccacccacacaggagaagacgcctaccaa
atccgagggcttggagaagcccctcagcgtgacctggtgagaaccgttGGCGgccag
Atacaggggctgcccaggcgggaaggtgcgcacgatgcgatcatccttctccagcag
caggggcgggtccgagctcctccctgctccggcctcaccagacacgcaggtcaggaa
gaaGGCctgAgggtctgtgatgcgcaggttggccagcaatgttaagtcaacagacgc
acctaggaccaaacaacagtgactccatggtggatcctgccagctcagcagccccag
gagcccgggactccaacagtaacttgtgttaatatttcactgtgtccttagaagact
tcactttttcaaagatttccgcccattcccttcccttacacatgtgctcgctcttta
cctgcaagcctcttcgtcctaaaacataaacaaaagcacacatccttctctggtcca
gacagggaatgagctacgcttctgtctccttcccttactctgtccgtgtcaggtcat
tgccctgactcctgtgtgaaccattcccaccaaggctatccctgagccacctgtccc
tgccccatcatggaggtgcaggttagaagagtcgctgagactggagtgtcatgagga
cgcacaccctctttcttgcttaactaattgaggactatttgactggctgggattgaa
gatcggttagggccagagagacacagacacaggtgggtctgggccctaccttgggaa
gctggaggaccagacacaggcatccctcccagatggaggtgttggctcagagggagg
aacatctaaccagcaggggggcgggggaaggaaaggggacaggaaaagatgcagata
acaaacttcattagaaggtgcttgggtgaggaggaacgaaaggtcaggcgtagggag
aggccaccctacgctcaagtatgagaaatgttgtagtgtggggaggggagctgcccc
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gggctagtgcaactggagcgtaaaatctgtaccctgaagtgggcaagaccgaggaga
agaatgtgatcagcctgct 
 
Preparation of injection mixture. gRNAs were purchased as the crRNA/tracrRNA 
system from Integrated DNA Technologies. These constructs contain chemical 
modifications to increase RNA stability. RNA molecules were dissolved in sterile 
injection buffer (1 mM Tris pH 7.5, 0.1 mM EDTA) at 1 µg/µL. Mature 
crRNA:tracrRNA complexes were produced by combining 5 µL 1 µg/µL crRNA 
and 10 µL 1 µg/µL tracrRNA. Samples were incubated in a thermocycler at 95 °C 
for 5 min and then ramped down to 25 °C at 5 °C/min. Samples were diluted 
two-fold in injection buffer, and 4 µL of each complex was combined along with 
64 µL injection buffer. Cas9 protein (Integrated DNA Technologies) was diluted 
to 500 ng/µL in injection buffer, and 8 µL was added to the RNA mixture. Samples 
were incubated at RT for 15 min. The Cas9/gRNA mixture was aliquoted at 20 µL, 
and either 1 µL 500 ng/µL ssODN (Arg-82 and Arg-38) or 2.5 or 5 µL 100 ng/µL 
dsDNA repair template was added with injection buffer to achieve 25 µL total. 
Samples were centrifuged for 10 min at 21,000 x g, and 20 µL was transferred to a 
new tube. The final concentrations of the injection solution were 20 ng/µL each 
gRNA/Cas9 complex and 10 or 20 ng/µL repair template. Roughly 20 zygotes per 
condition from superovulated, mated B6SJL-F1/J (Jackson Laboratories) were 
harvested and cultured. The injection mixture was pronuclear injected into each 
zygote, and zygotes were allowed to develop for 3 d. 
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Blastocyst genotyping. Blastocysts were aliquoted into a V-bottom 96-well plate in 
10 µL culture medium and flash frozen. To each well, 10 µL 2x blastocyst lysis 
buffer (200 mM Tris pH 8.3, 200 mM KCl, 0.02% gelatin, 0.45% Tween-20, 60 
µg/mL yeast tRNA, 125 µg/mL proteinase K) was added and allowed to incubate 
for 5 min. Samples were mixed by pipetting, transferred to PCR tubes, and 
incubated for 10 min at 56 °C and 10 min at 95 °C. gDNA was amplified in two 
rounds of nested PCR with Q5 2x Hot-Start Master Mix (New England Biolabs). 
First, a 25 µL reaction was set up using 4 µL lysate and amplified for 35 cycles with 
annealing temperature of 65 °C. Next, 4 µL of the first reaction was using for a 
second PCR reaction using a second set of primers with the same annealing 
temperature. Primers used are shown below: 
 Tie1-gDNA-Geno-F1: AGAGCTACAGATGAGAGGGAAG  
 Tie1-gDNA-Geno-F2: CTAGAGGTTGGTCACAAGGATG  
 Tie1-gDNA-Geno-R1: CACATTCTTCTCCTCGGTCTTG  
 Tie1-gDNA-Geno-R2: TCACCCAAGCACCTTCTAATG  
 
Amplicons were gel purified and submitted for Sanger sequencing using the 
second forward primer. 
 For production of litters, roughly 80 zygotes were injected once per day for 
four days. Once zygotes had proceeded to the blastocyst stage, they were 
implanted into surrogate B6SJL-F1/J mice. Successful litters were tailed for 
genotyping. gDNA from tail samples was harvested using the DNEasy Kit and 
amplified in a single step using F1/R1 genotyping primers listed above. Amplicons 
were gel purified and submitted for Sanger sequencing using the F2 primer. 
  
128 
3.6 References 
 
1. J. Partanen et al. A novel endothelial cell surface receptor tyrosine kinase with 
extracellular epidermal growth factor homology domains. Mol Cell Biol. 
1992, 12: 1698-1707. 
2. D. J. Dumont, T. P. Yamaguchi, R. A. Conlon, J. Rossant, M. L. Breitman. Tek, 
a novel tyrosine kinase gene located on mouse chromosome 4, is expressed 
in endothelial cells and their presumptive precursors. Oncogene. 1992, 7: 
1471-1480. 
3. T. N. Sato, Y. Qin, C. A. Kozak, K. L. Audus. Tie-1 and Tie-2 define another 
class of putative receptor tyrosine kinase genes expressed in early 
embryonic vascular system. Proc Natl Acad Sci USA. 1993, 90: 9355-9358. 
4. A. Iwama et al. Molecular cloning and characterization of mouse TIE and TEK 
receptor tyrosine kinase genes and their expression in hematopoietic stem 
cells. Biochem Biophys Res Commun. 1993, 195: 301-309. 
5. S. Davis et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by 
secretion-trap expression cloning. Cell. 1996, 87: 1161-1169. 
6. P. C. Maisonpierre et al. Angiopoietin-2, a natural antagonist for Tie2 that 
disrupts in vivo angiogenesis. Science. 1997, 277: 55-60. 
7. D. M. Valenzuela et al. Angiopoietins 3 and 4: diverging gene counterparts in 
mice and humans. Proc Natl Acad Sci USA. 1999, 96: 1904-1909. 
8. N. Jones, K. Iljin, D. J. Dumont, K. Alitalo. Tie receptors: new modulators of 
angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol. 2001, 2: 
257-267. 
  
129 
9. H. G. Augustin, G. Y. Koh, G. Thurston, K. Alitalo. Control of vascular 
morphogenesis and homeostasis through the angiopoietin-Tie system. Nat 
Rev Mol Cell Biol. 2009, 10: 165-177. 
10. P. Saharinen, M. Jeltsch, M. M. Santoyo, V.-M. Leppänen, K. Alitalo. The TIE 
receptor family. In: D. L. Wheeler, Y. Yarden, Eds., Receptor Tyrosine 
Kinases: Family and Subfamilies.  Ed.: Humana Press; 2015. 
11. D. J. Dumont et al. Dominant-negative and targeted null mutations in the 
endothelial receptor tyrosine kinase, tek, reveal a critical role in 
vasculogenesis of the embryo. Genes Dev. 1994, 8: 1897-1909. 
12. T. N. Sato et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 
in blood vessel formation. Nature. 1995, 376: 70-74. 
13. M. C. Puri, J. Rossant, K. Alitalo, A. Bernstein, J. Partanen. The receptor 
tyrosine kinase TIE is required for integrity and survival of vascular 
endothelial cells. EMBO J. 1995, 14: 5884-5891. 
14. G. D'Amico et al. Loss of endothelial Tie1 receptor impairs lymphatic vessel 
development-brief report. Arterioscler Thromb Vasc Biol. 2010, 30: 207-209. 
15. X. Qu, K. Tompkins, L. E. Batts, M. Puri, H. S. Baldwin. Abnormal embryonic 
lymphatic vessel development in Tie1 hypomorphic mice. Development. 
2010, 137: 1285-1295. 
16. X. Qu, B. Zhou, H. S. Baldwin. Tie1 is required for lymphatic valve and 
collecting vessel development. Dev Biol. 2015, 399: 117-128. 
17. K. V. Woo et al. Tie1 attenuation reduces murine atherosclerosis in a dose-
dependent and shear stress-specific manner. J Clin Invest. 2011, 121: 1624-
1635. 
18. G. D'Amico et al. Tie1 deletion inhibits tumor growth and improves 
angiopoietin antagonist therapy. J Clin Invest. 2014, 124: 824-834. 
  
130 
19. H. Huang, A. Bhat, G. Woodnutt, R. Lappe. Targeting the ANGPT-TIE2 
pathway in malignancy. Nat Rev Cancer. 2010, 10: 575-585. 
20. S. Han et al. Amelioration of sepsis by TIE2 activation-induced vascular 
protection. Sci Transl Med. 2016, 8: 335ra355. 
21. H. J. Lee et al. Biological characterization of angiopoietin-3 and angiopoietin-
4. FASEB J. 2004, 18: 1200-1208. 
22. S. Savant et al. The Orphan Receptor Tie1 Controls Angiogenesis and 
Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk 
Cells. Cell Rep. 2015, 12: 1761-1773. 
23. S. B. Mueller, C. D. Kontos. Tie1: an orphan receptor provides context for 
angiopoietin-2/Tie2 signaling. J Clin Invest. 2016, 126: 3188-3191. 
24. H. Singh, T. A. Tahir, D. O. Alawo, E. Issa, N. P. Brindle. Molecular control of 
angiopoietin signalling. Biochem Soc Trans. 2011, 39: 1592-1596. 
25. T. C. Seegar et al. Tie1-Tie2 interactions mediate functional differences 
between angiopoietin ligands. Mol Cell. 2010, 37: 643-655. 
26. E. A. Korhonen et al. Tie1 controls angiopoietin function in vascular 
remodeling and inflammation. J Clin Invest. 2016, 126: 3495-3510. 
27. J. Schlessinger et al. Crystal structure of a ternary FGF-FGFR-heparin 
complex reveals a dual role for heparin in FGFR binding and dimerization. 
Mol Cell. 2000, 6: 743-750. 
28. C. Rolny, D. Spillmann, U. Lindahl, L. Claesson-Welsh. Heparin amplifies 
platelet-derived growth factor (PDGF)-BB-induced PDGF alpha -receptor 
but not PDGF beta -receptor tyrosine phosphorylation in heparan sulfate-
deficient cells. Effects on signal transduction and biological responses. J 
Biol Chem. 2002, 277: 19315-19321. 
  
131 
29. D. Xu, M. M. Fuster, R. Lawrence, J. D. Esko. Heparan sulfate regulates 
VEGF165- and VEGF121-mediated vascular hyperpermeability. J Biol Chem. 
2011, 286: 737-745. 
30. L. E. Kemp, B. Mulloy, E. Gherardi. Signalling by HGF/SF and Met: the role of 
heparan sulphate co-receptors. Biochem Soc Trans. 2006, 34: 414-417. 
31. V. Koprivica et al. EGFR activation mediates inhibition of axon regeneration 
by myelin and chondroitin sulfate proteoglycans. Science. 2005, 310: 106-
110. 
32. M. W. Barnett, C. E. Fisher, G. Perona-Wright, J. A. Davies. Signalling by glial 
cell line-derived neurotrophic factor (GDNF) requires heparan sulphate 
glycosaminoglycan. J Cell Sci. 2002, 115: 4495-4503. 
33. C. J. Rogers et al. Elucidating glycosaminoglycan-protein-protein interactions 
using carbohydrate microarray and computational approaches. Proc Natl 
Acad Sci USA. 2011, 108: 9747-9752. 
34. P. B. Murray. Heparin is an activating ligand of the orphan receptor tyrosine 
kinase ALK. Sci Signal. 2015, 8: ra6. 
35. G. Bezakova, M. A. Ruegg. New insights into the roles of agrin. Nat Rev Mol 
Cell Biol. 2003, 4: 295-308. 
36. T. Arai, A. Parker, W. Busby, Jr., D. R. Clemmons. Heparin, heparan sulfate, 
and dermatan sulfate regulate formation of the insulin-like growth factor-I 
and insulin-like growth factor-binding protein complexes. J Biol Chem. 
1994, 269: 20388-20393. 
37. M. Teran, M. A. Nugent. Synergistic binding of vascular endothelial growth 
factor-A and its receptors to heparin selectively modulates complex 
affinity. J Biol Chem. 2015, 290: 16451-16462. 
  
132 
38. J. M. Brown et al. A sulfated carbohydrate epitope inhibits axon regeneration 
after injury. Proc Natl Acad Sci USA. 2012, 109: 4768-4773, S4768/4761-
S4768/4710. 
39. C. J. Rogers et al. Chondroitin sulfate E influences retinotopic mapping via 
EphB3. in preparation. 2017. 
40. G. J. Miller et al. Chondroitin sulfate E mediates axonal inhibition via EphA4 
activation. in preparation. 2017. 
41. W. A. Barton et al. Crystal structures of the Tie2 receptor ectodomain and the 
angiopoietin-2-Tie2 complex. Nat Struct Mol Biol. 2006, 13: 524-532. 
42. L. Bordoli et al. Protein structure homology modeling using SWISS-MODEL 
workspace. Nat Protoc. 2009, 4: 1-13. 
43. K. Iljin et al. A fluorescent Tie1 reporter allows monitoring of vascular 
development and endothelial cell isolation from transgenic mouse 
embryos. FASEB J. 2002, 16: 1764-1774. 
44. G. Li et al. Glycosaminoglycanomics of cultured cells using a rapid and 
sensitive LC-MS/MS approach. ACS Chem Biol. 2015, 10: 1303-1310. 
45. S. R. Hubbard, W. T. Miller. Receptor tyrosine kinases: mechanisms of 
activation and signaling. Curr Opin Cell Biol. 2007, 19: 117-123. 
46. P. Saharinen et al. Multiple angiopoietin recombinant proteins activate the 
Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell 
Biol. 2005, 169: 239-243. 
47. H. T. Yuan et al. Activation of the orphan endothelial receptor Tie1 modifies 
Tie2-mediated intracellular signaling and cell survival. FASEB J. 2007, 21: 
3171-3183. 
  
133 
48. M. B. Marron, D. P. Hughes, M. D. Edge, C. L. Forder, N. P. Brindle. Evidence 
for heterotypic interaction between the receptor tyrosine kinases TIE-1 
and TIE-2. J Biol Chem. 2000, 275: 39741-39746. 
49. C. D. Kontos, E. H. Cha, J. D. York, K. G. Peters. The endothelial receptor 
tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to 
inhibit apoptosis. Mol Cell Biol. 2002, 22: 1704-1713. 
50. V. M. Leppanen, P. Saharinen, K. Alitalo. Structural basis of Tie2 activation 
and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci USA. 2017, 114: 
4376-4381. 
51. A. C. Dalton, T. Shlamkovitch, N. Papo, W. A. Barton. Constitutive 
Association of Tie1 and Tie2 with Endothelial Integrins is Functionally 
Modulated by Angiopoietin-1 and Fibronectin. PLoS One. 2016, 11: 
e0163732. 
52. O. Söderberg et al. Direct observation of individual endogenous protein 
complexes in situ by proximity ligation. Nat Methods. 2006, 3: 995-1000. 
53. N. Oh et al. A designed angiopoietin-1 variant, dimeric CMP-Ang1 activates 
Tie2 and stimulates angiogenesis and vascular stabilization in N-glycan 
dependent manner. Sci Rep. 2015, 5: 15291. 
54. E. Forsberg, L. Kjellen. Heparan sulfate: lessons from knockout mice. J Clin 
Invest. 2001, 108: 175-180. 
55. J. R. Bishop, M. Schuksz, J. D. Esko. Heparan sulphate proteoglycans fine-tune 
mammalian physiology. Nature. 2007, 446: 1030-1037. 
56. P. D. Hsu, E. S. Lander, F. Zhang. Development and applications of CRISPR-
Cas9 for genome engineering. Cell. 2014, 157: 1262-1278. 
57. H. Wang, M. La Russa, L. S. Qi. CRISPR/Cas9 in Genome Editing and Beyond. 
Annu Rev Biochem. 2016, 85: 227-264. 
  
134 
58. A. C. Komor, A. H. Badran, D. R. Liu. CRISPR-Based Technologies for the 
Manipulation of Eukaryotic Genomes. Cell. 2017, 168: 20-36. 
59. H. Yang et al. One-step generation of mice carrying reporter and conditional 
alleles by CRISPR/Cas-mediated genome engineering. Cell. 2013, 154: 
1370-1379. 
60. C. Tong, G. Huang, C. Ashton, P. Li, Q. L. Ying. Generating gene knockout rats 
by homologous recombination in embryonic stem cells. Nat Protoc. 2011, 
6: 827-844. 
61. D. Paquet et al. Efficient introduction of specific homozygous and 
heterozygous mutations using CRISPR/Cas9. Nature. 2016, 533: 125-129. 
62. D. Mashiko et al. Generation of mutant mice by pronuclear injection of 
circular plasmid expressing Cas9 and single guided RNA. Sci Rep. 2013, 3: 
3355. 
63. M. Srivastava et al., An inhibitor of nonhomologous end-joining abrogates 
double-strand break repair and impedes cancer progression. Cell 
(Cambridge, Massachusetts). 2012, 151: 1474-1487. 
64. Y. Xu, Q. Yu, Angiopoietin-1, Unlike Angiopoietin-2, Is Incorporated into the 
Extracellular Matrix via Its Linker Peptide Region. J Biol Chem. 2001, 276: 
34990-34998. 
65. Y. Xu, Y. J. Liu, Q. Yu, Angiopoietin-3 is tethered on the cell surface via 
heparan sulfate proteoglycans. J Biol Chem. 2004, 279: 41179-41188. 
66. A. Pulsipher, M. E. Griffin, S. E. Stone, L. C. Hsieh-Wilson, Long-lived 
engineering of glycans to direct stem cell fate. Angew Chem Int Ed Engl. 
2015, 54: 1466-1470. 
  
135 
67. M. A. Hunt, M. J. Currie, B. A. Robinson, G. U. Dachs, Optimizing transfection 
of primary human umbilical vein endothelial cells using commercially 
available chemical transfection reagents. J Biomol Tech. 2010, 21: 66-72. 
68. E. Campeau et al., A versatile viral system for expression and depletion of 
proteins in mammalian cells. PLoS One. 2009, 4: e6529. 
69. R. H. Kutner, X. Y. Zhang, J. Reiser, Production, concentration and titration of 
pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009, 4: 495-505. 
70. S. L. Mayo, B. D. Olafson, W. A. Goddard III, DREIDING: a generic force field 
for molecular simulations. J Phys Chem. 1990, 94: 8897-8909. 
71. V. W. Tak Kam, W. A. Goddard III, Flat-bottom strategy for improved 
accuracy in protein side-chain placements. J Chem Theory Comput. 2008, 4: 
2160-2169. 
 
  
136 
C h a p t e r  4  
Deciphering the Importance of O-GlcNAc Glycosylation Using 
Chemical Tools 
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4.1 O-GlcNAc Glycosylation of Proteins 
Although the human genome only contains between 19,000 and 20,000 genes,1  
cells have developed many mechanisms to increase the chemical diversity of 
protein structures. Methods of protein diversification can occur both before 
protein translation through the splicing of messenger RNA molecules and 
afterwards through chemical changes of amino acid residues, known as post-
translational modifications (PTMs). Collectively, these diversifying pathways 
exponentially increase the number of individual protein chemical structures or 
“proteoforms.”2 In turn, structural diversity provides a mechanism to increase 
functional diversity, allowing cells to adapt to a variety of internal and external 
stimuli. 
One type of PTM known as O-GlcNAc glycosylation or O-GlcNAcylation is 
remarkably suited as an environmental response element.3-7 This modification 
utilizes uridine 5’-diphospho-N-acetylglucosamine (UDP-GlcNAc) to attach a 
single β-linked GlcNAc (GlcNAc) to Ser or Thr residues of many different 
proteins (Figure 4-1). Because the biosynthesis of UDP-GlcNAc incorporates 
precursors from nucleotide, carbohydrate, amino acid, and lipid biosynthesis,5 it 
has been hypothesized that O-GlcNAcylation functions as an integrating signal for 
global metabolism,8-10 allowing it to directly connect environmental conditions 
like nutrient availability with protein function. 
 O-GlcNAcylation is uncommon in both its localization, as one of the few 
known intracellular glycosylation events, and its enzymatic cycling.11 PTMs  
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Figure 4-1. O-GlcNAc cycling on proteins. O-GlcNAc is added to Ser or Thr residues on 
intracellular proteins by OGT using UDP-GlcNAc and removed by OGA. 
generally rely on a highly regulated network of writing and erasing enzymes. For 
example, protein phosphorylation occurs via a network of hundreds of kinases 
and phosphatases, each with their own substrate specificities. However, O-
GlcNAcylation does not occur in such a partitioned fashion. Instead, only two 
enzymes have been discovered to cycle the O-GlcNAc PTM: O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA). These proteins work in an 
extremely widespread fashion, with a current tally of over 4,000 putatively O-
GlcNAcylated proteins.12 Unsurprisingly, no ubiquitous consensus sequence has 
been found for OGT recognition,13 highlighting the promiscuity of OGT and the 
difficulty in predicting O-GlcNAc sites.14 Interestingly, recent reports have 
further expanded the substrate scope of OGT to Cys residues as so-called S-
GlcNAcylation events.15, 16  
 Given the breadth of O-GlcNAcylation substrates, this PTM accordingly has 
far-reaching effects on a variety of biological processes, including transcription, 
translation, signal transduction, autophagy, protein homeostasis, circadian 
rhythm, and metabolism.8, 17-22 The molecular mechanisms by which O-
GlcNAcylation exerts these different activities are also diverse. For example, O-
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GlcNAcylation can compete with phosphorylation either directly by modification 
of the same residue or indirectly by modification of adjacent sites. The former 
mechanism can be observed on endothelial nitric oxide synthase (eNOS), in 
which the native Akt phosphorylation site Ser-1177 is blocked by O-
GlcNAcylation during hyperglycemia to impair its activity.23 The latter can be 
found on the tumor suppressor protein p53, on which O-GlcNAcylation at Ser-
149 prevents phosphorylation at Ser-155 to prevent proteolytic targeting and 
degradation.24 O-GlcNAcylation can also attenuate or countermand the activity of 
distal phosphorylation events. This phenomenon was detected on the 
transcription factor cAMP response element binding (CREB), where O-
GlcNAcylation at Ser-40 is induced specifically on activated, Ser-133 
phosphorylated CREB to lessen neuronal activity-dependent gene expression.17 
O-GlcNAcylation can also block protein-small molecule or protein-protein 
interactions. For example, phosphofructokinase 1 (PFK1) is O-GlcNAcylated at 
Ser-529 in the binding pocket of its allosteric activator fructose-2,6-bisphosphate 
(FBP), hindering the formation of the active tetrameric form of the enzyme.8 In 
stem cells, transcription factor sex determining region Y-box 2 (Sox2) is O-
GlcNAcylated at Ser-248, disrupting its interaction with poly-ADP ribose 
polymerase 1 (PARP1) to control self-renewal and differentiation.25 Conversely, 
O-GlcNAcylation can promote protein-protein interactions; in the case of signal 
transducer and activator of transcription 5 (Stat5), O-GlcNAcylation at Thr-92 
facilitates its interaction with CREB-binding protein (CBP) to enable gene 
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transcription.26 In all of these cases, the delineation of the exact site of O-
GlcNAcylation was instrumental in discovering the functional importance of the 
PTM. Therefore, it is crucial that robust methods be developed to enable O-
GlcNAc site identification to better understand the roles of this modification 
throughout diverse biological processes. 
 
4.2 Methods to Identify Sites of O-GlcNAcylation 
4.2.1 Complications in the Analysis of O-GlcNAcylation 
Identifying sites of O-GlcNAcylation is complicated by a number of biological 
and technical factors. Like other PTMs, protein O-GlcNAcylation is 
substoichiometric, making site identification on proteins that may be already 
poorly abundant even more difficult.12 During MS analysis, signal intensity from 
O-GlcNAcylated peptides suffers from ion suppression in the presence of 
unmodified peptides.27 Furthermore, the O-GlcNAc moiety is readily labile for 
common MS/MS ionization techniques used for PTM analysis like collision-
induced dissociation (CID) and higher-energy collisional dissociation (HCD).28 
Efforts on two fronts have helped to overcome these obstacles. First, the newer 
ionization technique known as electon transfer dissociation (ETD) has been 
developed as a milder MS/MS method that allows for the sequencing of peptides 
without loss of the O-GlcNAc group.29 Second, a number of different enrichment 
techniques have been produced to both concentrate O-GlcNAcylated substrates 
and separate them from unmodified proteins and peptides.30-32 These techniques 
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can be broadly separated into three categories: affinity enrichment, group 
replacement, and chemical functionalization. 
4.2.2 Affinity Enrichment of O-GlcNAcylated Substrates 
 One chromatographic method to enrich O-GlcNAcylated substrates is known 
as lectin weak affinity chromatography (LWAC).30 This method capitalizes on the 
affinity of natural plant proteins known as lectins for specific carbohydrate 
structures. In this process, a mixture of modified and unmodified substrates are 
isocratically passed over a chromatographic column that has wheat germ 
agglutinin (WGA) covalently attached to the stationary phase. This protein can 
weakly bind to terminal GlcNAc and sialic acid residues, causing these peptides to 
be retarded on the column compared to unmodified peptides. The lagging edge of 
the eluent is kept as the enriched O-GlcNAc fraction. As an alternative, 
succinylated WGA (sWGA) has been developed to no longer bind to sialic acid 
residues, providing further specificity for O-GlcNAcylated proteins.33 However, 
this method also enriches for N-linked glycans that contain terminal GlcNAc 
moieties, complicating MS analysis. This can be ameliorated by pre-treatment of 
samples with PNGase F, which removes all N-linked glycans.34 The natural 
binding mechanism for WGA requires multiple glycan structures, causing the 
structure to have a much weaker affinity for single O-GlcNAc groups (KD = ~10 
mM for the free monosaccharide).12 Therefore, longer columns (upwards of 3 
m)31 and/or multiple chromatographic enrichments32 are often necessary to 
sufficiently enrich O-GlcNAcylated substrates. Nevertheless, this method has 
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been employed successfully since its development in 2006 in numerous cases to 
identify sites of O-GlcNAcylation.30-32 The most successful application of this 
method in combination with downstream high pH reverse phase peptide 
fractionation identified 1,750 sites from murine synaptosomes, proving its 
usefulness as a method to identify sites of the O-GlcNAc modification.32 However, 
the method has only been reported by a single laboratory, so it remains to be seen 
if LWAC will be more widely embraced by the community. 
 A second method of affinity enrichment using O-GlcNAc-specific antibodies 
has also been employed to identify O-GlcNAcylation sites.28 A number of 
antibodies that recognize O-GlcNAc have been generated in the past, with the RL-
235 and CTD110.636 antibodies being the most widely used. However, they 
generally suffer from either specificity for certain O-GlcNAcylated structures like 
RL-2 for nuclear pore complex proteins or recognition of other terminal GlcNAc 
moieties as is the case for CTD110.6, precluding their use for enriching all O-
GlcNAcylated substrates over other GlcNAc-modified structures. Recently, three 
new general O-GlcNAc antibodies have been developed and used originally to 
enrich O-GlcNAcylated proteins.37 Interestingly, the immunoprecipitated 
proteins differed for each antibody, highlighting the need to use a combination of 
these antibodies to enrich O-GlcNAcylated proteins in an unbiased fashion. In a 
subsequent report, enriched proteins from immunoprecipitates of HEK-293T cell 
lysate using all three antibodies were subjected to MS analysis, where 172 O-
GlcNAcylated peptides were observed.28  
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Figure 4-2. Beta-elimination and Michael addition (BEMA). BEMA occurs first by removal of O-
GlcNAc using basic conditions to produce an α,β-unsaturated carbonyl group, which can then react 
with nucleophiles like DTT by Michael addition.  
4.2.3 O-GlcNAc Enrichment by Replacement 
 The relative lability of the β-glycosidic linkage of O-GlcNAc has been 
exploited in an enrichment protocol termed β-elimination Michael addition 
(BEMA, Figure 4-2).38-40 Originally designed to map phosphorylation sites, this 
method uses mild basic conditions to cause the elimination of O-GlcNAc on Ser 
and Thr residues and form an α,β-unsaturated carbonyl group, which can then be 
modified using a sulfhydryl nucleophile like DTT or biotinylated cystamine.40, 41 
Also known as BEMAD when using DTT, this method allows for enrichment of 
previously O-GlcNAcylated proteins and peptides via thiol-capture resin. 
Moreover, DTT isotopically labeled with 2H can be used to differentiate samples 
for quantification.42 DTT is stable to CID MS/MS fragmentation, eliminating the 
need for specialized MS techniques during peptide sequencing. BEMAD can suffer 
from cross-reactivity, as natural phosphorylated residues as well as alkylated Cys 
residues produced by reaction with iodoacetamide prior to MS analysis can also 
undergo β-elimination under stringent conditions.40 However, treatment of 
samples with phosphatase prior to analysis and optimization of BEMAD 
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conditions have improved selectivity.12 BEMAD has been applied in a variety of 
biological circumstances to identify O-GlcNAcylation sites, including in skeletal 
muscle, isolated proteasomes, and purified mitochondria.41-43 
4.2.4 O-GlcNAc Enrichment by Chemical Functionalization 
 The third major method to enrich for O-GlcNAcylated substrates is through 
the chemical functionalization of the GlcNAc moiety. The structure of the 
GlcNAc residue is readily susceptible to direct modification; therefore, two main 
avenues have been developed to install reactive groups at the O-GlcNAc site: 
metabolic oligosaccharide engineering (MOE) and chemoenzymatic labeling. 
 MOE, also known as metabolic labeling, uses the endogenous biosynthetic 
machinery of the cell to incorporate non-natural sugar analogs that contain a 
chemical handle for further derivatization.44-46 A number of different functional 
handles have been used to modify O-GlcNAc sites, including azide, alkyne, 
cyclopropene, and isonitrile groups.47-50 This method does suffer from some 
drawbacks, including competition between natural and non-natural substrates 
leading to substoichiometric incorporation of the functional tag as well as 
crosstalk between biosynthetic salvage pathways causing the functional tag to be 
incorporated into a number of different glycan structures. This is epitomized by 
the discovery that UDP-galactose 4’-epimerase (GALE) interconverts UDP-
GlcNAc and UDP-N-acetylgalactosamine (GalNAc) as well as the corresponding 
non-natural sugars.51 In fact, treatment of cells with peracetylated N-
azidoacetylgalactosamine (Ac4GalNAz, Figure 4-3) facilitated labeling of O- 
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Figure 4-3. Common carbohydrates used in MOE.  
GlcNAcylated structures better than treatment with the GlcNAc analog. 
Moreover, the non-natural sugar can incorporate into any glycan that utilizes 
GlcNAc, including N-linked glycans. Recent advances have been made to provide 
chemical probes that demonstrate selectivity for O-GlcNAc over other structures. 
For example, installation of the azide group at the C6 position of GlcNAc to 
produce peracetylated 6-azido-6-deoxy-N-acetylglucosamine (Ac46AzGlcNAc)52 
or at the C2 position of glucose (Glc) to produce acetylated 2-azido-2-deoxy-
glucose (Ac32AzGlc)53 provided labeling of O-GlcNAcylated substrates with 
minimal surface labeling, suggesting that these probes do not incorporate into N-
linked glycans like previous probes. However, neither of these specific probes has 
been used to map sites of O-GlcNAcylation. In any case, the installed functional 
handle can then be elaborated using bioorthogonal chemistry to install an 
enrichment marker, which is discussed further below. 
 An alternative way to install a chemical handle for functionalization is through 
the use of a permissive enzyme via chemoenzymatic labeling (Figure 4-4).12, 54, 55 
In this technique, a mutated form of bovine galactosyltransferase (Y289L GalT)56  
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Figure 4-4. Chemoenzymatic labeling. O-GlcNAcylated substrates are modified by Y289L GalT 
with a non-natural UDP-galactose sugar. This approach has been used to append a ketone (UDP-
ketoGal) or an azide (UDP-GalNAz) functional handle. 
is used to modify terminal GlcNAc moieties with a non-natural UDP-galactose 
(Gal) or UDP-GalNAc sugar. This method was first used to install a ketone handle 
with UDP-2-acetonyl-2-deoxygalactose (UDP-ketoGal)55, 57, 58 and more recently 
has been employed with the azide-containing UDP-GalNAz.59 This method has 
benefits over MOE including the stoichiometric addition of the functional handle, 
the lack of perturbation of the system by addition of high concentrations of 
exogenous carbohydrates, and the specificity for GlcNAc structures. As with 
WGA, Y289L GalT will recognize any terminal GlcNAc moiety,56 but treatment of 
samples with PNGase F to remove N-linked glycans or subcellular fractionation 
eliminate this cross-reactivity. As with MOE, this method installs a functional 
handle that allows for further derivatization and enrichment. 
 Currently, the majority of enrichment tags for O-GlcNAc site identification are 
installed onto an azide- or alkyne-tagged version of GlcNAc using copper-
catalyzed azide-alkyne cycloaddition (CuAAC). However, a variety of enrichment 
tags have been used. For example, addition of 4-pentynyl phosphate has been 
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used in combination with chemoenzymatic labeling to install a phosphorylation 
mimicking tag that can be purified by titanium dioxide affinity chromatography, 
revealing 42 sites of O-GlcNAcylation from mouse brain lysate.60 In a second 
approach using chemoenzymatic labeling, ethynylbenzaldehyde was added via 
CuAAC and used with hydrazide resin for peptide enrichment; however, this 
method was validated only with α-crystallin.61 Finally, a third method utilizing 
metabolic labeling reacted modified proteins directly to alkyne-containing agarose 
resin.62 After on-bead digestion and release of the modified proteins by β-
elimination revealed 185 modification sites from HEK-293T lysate. 
 The most common enrichment method used with MOE and chemoenzymatic 
labeling is the installation of a biotin group combined with streptavidin affinity 
purification. One of the first instances of this method to identify O-GlcNAc sites 
was employed in our own lab in combination with chemoenzymatic labeling using 
UDP-ketoGal.58 Here, 20 O-GlcNAcylated peptides were discovered from rat 
brain lysate, and incorporation of a peptide isotopic labeling technique known as 
dimethyl labeling allowed for quantification of modification dynamics on a subset 
of these sites. Although successful here, the relatively large size of the biotin tag 
likely hinders peptide ionization and sequencing by MS. Therefore, newer 
techniques have explored the incorporation of cleavable biotin moieties to reduce 
the residual size of the appended tag. 
 The first cleavable biotin tag used to map O-GlcNAc sites incorporated a 2-
nitrobenzyl group, which can be selectively cleaved by UV irradiation with 365 
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nm light.27 This tag leaves only the aminomethyltriazolyl group appended to 
GalNAz, significantly decreasing the added size from biotinylated compared to 
non-cleavable variants. Moreover, the amine residue imbues the peptide with an 
additional positive charge, which can facilitate MS sequencing by ETD. However, 
cleavage by UV irradiation was shown to be incomplete.27 Nevertheless, this 
approach was successfully applied to both purified mitotic spindles and 
cerebrocortical brain tissue to identify 141 and 458 O-GlcNAc sites, 
respectively.63, 64  
 A second cleavable tag uses the diphenylsilyl diether group, which can be 
easily removed by mild acid.65, 66 After reaction with this tag also containing a 
dibrominated core to provide an isotopic signature in MS1, metabolically labeled 
proteins were immobilized on streptavidin resin and subjected to on-bead 
digestion. The remaining modified peptides were cleaved by mild acid treatment 
and sequenced, providing 357 unique glycopeptides modified by either GalNAz or 
N-azidoacetylmannosamine (ManNAz).66 This method was recently expanded to 
use a mixture of 1H- and 2H-labeled probes that also present an isotopic 
signature in MS.67 Here, 1765 mono- and di-O-GlcNAcylated mass signatures 
were identified over 15 samples corresponding to 379 uniquely O-
GlcNAcylation sites. However, 36% of the modified peptides were only 
identified by the isotopic signature and were unable to be sequenced, 
underscoring the difficulty in sequencing O-GlcNAcylated peptides. 
Nevertheless, these results collectively demonstrate that the use of a cleavable 
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biotin tag is a useful approach to enrich for O-GlcNAcylated substrates and map 
modification sites. Newer methods should take advantage of benefits from 
multiple approaches like minimizing the residual tag left after cleavage while 
simultaneously improving on shortcomings of current approaches like 
incomplete cleavage and poor ETD fragmentation. 
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C h a p t e r  5  
Chemically Cleavable Tagging Method for the Enrichment and 
Detection of O-GlcNAc Glycosylated Proteins and Peptides 
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5.1 Abstract 
Post-translational modification by O-linked N-acetylglucosamine (O-GlcNAc) 
plays many important roles in controlling protein function.  However, relatively 
few O-GlcNAc modification sites have been mapped due to the difficulty of 
enriching and detecting O-GlcNAcylated peptides from complex samples. Here 
we describe an improved approach to quantitatively label and enrich O-
GlcNAcylated proteins for site identification. Chemoenzymatic labeling followed 
by copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) installs a new mass 
spectrometry (MS)-compatible linker designed for facile purification of O-
GlcNAcylated proteins from cell lysates. The linker also allows subsequent 
quantitative release of O-GlcNAcylated proteins for downstream MS analysis. We 
validate the approach by unambiguously identifying several established O-GlcNAc 
sites on the proteins α-crystallin and O-GlcNAc transferase (OGT), as well as 
discovering new, previously unreported sites on OGT. Notably, these novel sites 
on OGT lie in key functional domains of the protein, underscoring how this site 
identification method may reveal important biological insights into protein 
activity and regulation. We then describe the further optimization of this method 
to identify sites of O-GlcNAc modification on native proteins from complex 
lysate. Together, these experiments lay the groundwork for a straightforward 
method to label and enrich O-GlcNAcylated proteins and peptides for MS 
identification. 
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5.2 General Approach 
Understanding the roles of O-GlcNAcylation in specific physiological 
contexts will require a more comprehensive characterization of the O-GlcNAc 
proteome and the modification sites on proteins. Notably, although thousands of 
proteins have been putatively shown to be O-GlcNAcylated,1-7 relatively few 
glycosylation sites have been mapped. Mass spectrometric (MS) identification of 
O-GlcNAcylated peptides from complex mixtures has been challenging due to 
the substoichiometric nature of O-GlcNAcylation and is further exacerbated by 
suppression of O-GlcNAc peptide ionization in the presence of the unmodified 
peptide.8 Thus, improved methods to enrich O-GlcNAcylated peptides or 
proteins are much needed, particularly approaches that can be directly used in 
conjunction with MS/MS sequencing to achieve a more comprehensive 
understanding of O-GlcNAc modification sites.  
Robust enrichment of O-GlcNAcylated proteins can be accomplished using a 
two-step chemoenzymatic approach (Figure 5-1).3, 9 First, the O-GlcNAc moiety 
is tagged with a non-natural azide group by treatment of cell lysates with UDP-
GalNAz and a mutant galactosyltransferase (Y289L GalT)10 that specifically 
recognizes terminal GlcNAc moieties. Next, a biotin group is attached via 
copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC),11 which allows for 
affinity purification. Although a limited set of alkyne-biotin linkers are 
commercially available, many existing linkers are not ideal for mapping O-
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GlcNAc modification sites. In particular, harsh conditions are usually required to  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1. Two-step chemoenzymatic approach. O-GlcNAcylated substrates are modified by 
Y289L GalT with UDP-GalNAz to install an azide handle, which can be functionalized with a 
cleavable biotin linker using CuAAC. After enrichment, labeled O-GlcNAcylated substrates can be 
released by facile chemical cleavage with hydrazine. 
disrupt the femtomolar biotin–streptavidin interaction,12 which may hydrolyze 
the labile O-GlcNAc moiety. Additionally, many linkers contain a large spacer 
between the biotin group and the alkyne functionality,12 which appends a 
relatively large mass to the glycopeptide and can preclude its identification. 
Therefore, a facile method to release the labeled peptides and proteins with 
minimal added mass would greatly facilitate downstream analysis.  
Several cleavable linkers have been previously developed for enrichment of 
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O-GlcNAcylated proteins.6-8, 13 However, each suffers from significant 
drawbacks for site identification. For example, a photocleavable linker (alkyne-
PC-biotin 5-1, Figure 5-2) was employed in conjunction with UDP-GalNAz and 
Y289L GalT to sequence modified peptides from mouse brain lysate.7, 8 
Importantly, the moiety retained after cleavage provided a positively-charged 
amine group, which increased the overall peptide charge and facilitated 
ionization by electron-transfer dissociation (ETD), the most successful MS/MS 
method for O-GlcNAc peptide sequencing.4, 14 Unfortunately, cleavage of the 
linker was found to be incomplete.8 In a recent report, a dibromine-containing, 
acid-cleavable linker (5-2, Figure 5-2) was employed to identify various glycan 
modifications including O-GlcNAc.13 However, cleavage of the linker revealed 
only a neutral hydroxyl group, and the halogenated glycopeptides demonstrated 
poor fragmentation efficiency using ETD. Recently, this linker was updated to 
use a mixture of 1H- and 2H to produce a similar isotopic signature (5-3, Figure 
5-2); however, 36% of the modified peptides were only identified by the isotopic 
pattern and were unassignable to a specific sequence.15 The analysis was further 
complicated by GALE-mediated epimerization of GalNAz into GlcNAz,16 which 
allows simultaneous labeling of O-GalNAcylated and O-GlcNAcylated peptides 
that cannot be distinguished by MS and require manual annotation based on 
subcellular localization. Therefore, we aimed to develop a tagging approach that 
would be quantitatively appended and released, specifically modify only O-
GlcNAcylation sites, and incorporate a positive charge upon cleavage to 
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facilitate ETD-MS detection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2. Cleavable biotin tags used for O-GlcNAc site identification.  
 
5.3 Method Development 
5.3.1 Validation of Chemically Cleavable Linker 
To achieve these goals, we chose to examine the 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethyl (Dde) functional group. The Dde moiety has 
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demonstrating its compatibility with biomolecules. The group is stable to both 
acid and base and can be quantitatively removed by hydrazine.18 However, it  
 
Figure 5-3. Validation of Dde linker 5-4. Reverse phase LC-MS analysis of O-GlcNAc peptide 
labelling reactions at (A) time 0, (B) 16 h after addition of 1 and Y289L GalT, (C) 1 h after CuAAC 
with 2, and (D) 1 h after cleavage with 2% aqueous hydrazine. (A) and (B) show base peak 
chromatograms. (C) and (D) show extracted ion chromatograms of the starting material and product 
within 1 m/z of calculated values. 
was reported that the Dde group is incompatible with sodium dodecyl sulphate 
(SDS) and amine-containing buffers, common additives to protein labeling 
protocols.19 
We first investigated the labeling of a model O-GlcNAcylated peptide with 
commercially available alkyne-Dde-biotin (5-4, Figure 5-2) followed by cleavage 
of the linker using liquid chromatography (LC)-MS (Figure 5-3). Commercially 
available peptide TAPT(gS)TIAPG (Figure 5-3a), where gS is the O-
GlcNAcylated residue, was incubated with 100 ng mL Y289L GalT and 1 mM 
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UDP-GalNAz in 10 mM HEPES pH 7.9, 5.5 mM MnCl2 overnight at 4 °C. LC-MS 
analysis revealed quantitative conversion to the desired GalNAz- labeled  
 
 
 
 
 
 
 
 
 
 
Figure 5-4. Stability of Dde linker 5-4. Reverse-phase LC-MS analysis of alkyne-Dde-biotin-
labelled peptide after 1 h incubation with (A) 6 M urea, (B) 1% RapiGest, or (C) 2% hydrazine. All 
graphs show extracted ion chromatograms of the starting material and possible product within ± 1 
m/z. 
product (Figure 5-3b). Next, the azide-containing peptide was reacted with 100 
mM of 5-4 in 10 mM sodium phosphate pH 7.6 containing 2 mM sodium 
ascorbate (NaAsc), 100 mM THPTA, and 1 mM CuSO4. After 1 h, stoichiometric 
biotinylation of the peptide was observed (Figure 5-3c). Treatment with 2% 
aqueous hydrazine for 1 h at RT resulted in quantitative cleavage of the linker to 
afford a minimal, positively charged aminomethyltriazolyl group (Figure 5-3d). 
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To test whether the linker would be stable under stringent wash conditions, we 
incubated the labeled peptide with 1% RapiGest, a MS-compatible analogue of 
SDS, or 6 M urea for 1 h at RT (Figure 5-4). In both cases, the linker 
remained intact, highlighting the compatibility of the linker with rigorous 
washing steps.  
5.3.2 Comparing Dde and PC Linkers 
We next tested the performance of our linker in comparison to the 
previously described, widely utilized photocleavable linker alkyne-PC-biotin 5-
1.8 Briefly, HEK-293T cell lysate was subjected to chemoenzymatic labeling with 
UDP-GalNAz using Y289L GalT as described above. The azide-labeled protein 
was then split into two equal fractions and reacted with either 5-1 or 5-4 by 
CuAAC. An aliquot of each sample was reserved for analysis, and the remainder 
of each sample was subjected to cleavage using 2% hydrazine monohydrate or 
by UV irradiation at 365 nm. The samples were resolved by SDS-PAGE and 
probed for biotin using streptavidin conjugated to AlexaFluor 680 dye (Figure 5-
5). Notably, a stronger biotin signal was observed for lysate labeled with 5-4 
compared to 5-1, suggesting higher labeling efficiency with the Dde linker. 
Furthermore, although both linkers cleaved well, the 5-1 showed slightly higher 
residual signal compared to 5-4, suggesting that the Dde moiety was also 
released more efficiently than the photocleavable group. These results 
demonstrate that our new approach provides an improvement in both labeling 
efficiency and recovery of O-GlcNAcylated proteins compared to the most 
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widely used method.  
5.3.3 Validation Using Known O-GlcNAcylated Proteins 
We then evaluated the potential of the approach to pull down known O- 
 
 
 
 
 
 
 
 
 
 
Figure 5-5. Comparison of Dde linker 5-4 and PC linker 5-1. Protein lysate was labeled using 
the chemoenzymatic approach using 5-4 or 5-1 and then resolved by SDS-PAGE. Protein lysates 
labelled with 5-4 show higher biotin signal after labelling (lane 2 vs. lane 4) and lower residual signal 
after cleavage (lane 3 vs. lane 5) compared to the PC linker. 
GlcNAcylated proteins and identify sites of modification. The well-characterized 
O-GlcNAcylated protein α-crystallin was selected to assess the sensitivity of the 
method because it has a relatively low glycosylation stoichiometry (<10%).20 
Short-form OGT (sOGT)21, 22 from Sf9 cells has multiple sites of O-
GlcNAcylation4 and was thus used to determine whether comprehensive site 
mapping could be achieved. To test the robustness of our method in a complex 
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mixture, each protein was added to 200 mg of adult mouse cortical lysate and 10 
subjected to chemoenzymatic labeling and CuAAC using 5-2. The labeled 
proteins were applied to high-capacity Neutravidin resin and washed with 0.5 
mL of 1% SDS, 6 M urea, and phosphate buffered saline (PBS). The resin was 
then incubated for 1 h with 2% aqueous hydrazine to cleave the O-GlcNAcylated 
proteins from the resin. Eluted samples were precipitated, re-dissolved in 
denaturing buffer and subjected to reduction, alkylation, and proteolytic 
digestion. Digested peptides were separated by nanoLC-MS and analyzed on an 
LTQ-Velos by a combination of collision-induced dissociation (CID) and ETD-
MS.  
Impressively, a large number of O-GlcNAcylation sites were identified on α-
crystallin and sOGT (Table 5-1). The known O-GlcNAc site on α-crystallin A 
(Ser-162)23 was readily recognized despite the low abundance of the O-GlcNAc 
modification at this site. Importantly, we observed both known and novel sites 
on sOGT.4, 24 For example, we identified the previously reported Thr-662 site, 
which is found in the catalytic domain of sOGT. The new linker design also 
revealed a number of new O-GlcNAcylation sites within the N-terminal 
tetratricopeptide repeat-containing (TPR) domains (Ser-10/Thr-12, Ser-20, Ser-
52, and Ser-56) of sOGT, and we observed a doubly modified peptide at both 
Ser-10/Thr-12 and Ser-20, highlighting the sensitivity of the approach to 
identify novel glycosylation sites and multiply occupied states. As the TPR 
domains of OGT are thought to mediate protein-protein interactions,25-27 such 
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modifications could play an integral role in OGT regulation and may provide a 
mechanism to selectively modulate its activity toward specific substrates.  
 
 
Protein Peptide sequence Site(s) 
Mascot 
ion 
score 
Mascot 
delta ion 
score 
MS 
αCryA AIPVSREEKPSSAPSS S162 24.9 23.5 ETD 
sOGT ISPTFADAYSNMGNTLK S10*/T12* 46.5 – ETD 
sOGT ISPTFADAYSNMGNTLK S20* 21.6 13.6 ETD 
sOGT ISPTFADAYSNMGNTLK S10*/T12*,S20* 38.4 – ETD 
sOGT EMQDVQGALQCYTR T38 41.8 35.0 CID 
sOGT AIQINPAFADAHSNLASIHKDSGNIPEALASYR S52* 53.5 7.9 ETD 
sOGT AIQINPAFADAHSNLASIHKDSGNIPEALASYR S56* 56.8 15.7 ETD 
sOGT LYLQMWEHYAAGNKPDHMIKPVEVTESA T662 33.1 8.0 ETD 
 
Table 5-1. Validation of 5-4 to identify O-GlcNAc sites. O-GlcNAc sites identified following 
labeling with 5-4, Neutravidin affinity purification, and hydrazine-mediated elution. Sites and regions 
of modification are denoted in red or maroon italics, respectively. Novel site identifications are 
marked by an asterisk. 
 
5.4 Extension to Native O-GlcNAcylation Sites 
5.4.1 Choosing a Workflow 
We next aimed to expand this enrichment and identification method to 
detect O-GlcNAcylation events on native proteins. Our original method called 
for the enrichment of intact proteins and tryptic digestion after elution.28 
Although this method was successful for exogenously added proteins and would 
be amenable to proteins purified by immunoprecipitation, the preponderance of 
unmodified peptides that would still be produced by the digestion of enriched 
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O-GlcNAcylated proteins may impede the detection of modified peptides by ion 
suppression. Therefore, two separate approaches were considered. First, we 
considered an approach for on-bead digestion. Here, labeled proteins would be 
immobilized onto Neutravidin resin, and the mixture would be subjected to 
tryptic digestion. Unmodified peptides would no longer be attached to the resin 
support and could be removed prior to chemical elution of the remaining, 
labeled peptides. This approach has been successfully used in a number of cases 
including the identification of O-GlcNAcylated sites in conjunction with isotopic 
labeling using the dibrominated or deuterated linker described earlier.15, 29 
Alternatively, we envisioned a digestion-first protocol, which would digest 
complex lysate directly and then proceed with labeling and enrichment steps 
using the tryptic peptides. This tactic had also been used successfully to enrich 
O-GlcNAcylated peptides using the photocleavable linker.7, 8 
 Selection of the proper workflow depended heavily on the extended 
stability of the linker to the conditions of on-bead tryptic digestion. Although 
the linker had shown stability to stringent wash conditions for 1 h, it was 
unclear if the linker could withstand elevated temperatures for 16 h. To test this, 
we took a practical approach by conjugating Cy3-azide dye to alkyne-Dde-biotin 
5-4 using CuAAC conditions. The resulting compound, Cy3-Dde-biotin 5-5 
(Figure 5-6), was used crude by incubating with Neutravidin beads, producing 
pink beads visible to the naked eye. Samples were then incubated for 24 h in a 
variety of buffer conditions (1x PBS, pH 7.4; 2 M urea, PBS; 1% SDS, PBS; 20 mM 
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HEPES pH 7.9, 1% SDS) at room temperature or at 37 °C with gentle rotation. 
The beads were then pelleted and visually inspected to see if the dye color was 
lost from the beads. Interestingly, all conditions incubated at 37 °C showed a  
 
 
 
 
 
 
Figure 5-6. Synthesis of Cy3-Dde-biotin 5-5. (a) 5-4 (1.2 eq), NaAsc (24 eq), THPTA (1.2 eq), 
CuSO4 (12 eq), PBS, RT, 2 h. 
decrease in dye color localized on the beads with a pink hue in the buffer  
(Figure 5-7), suggesting that incubation at 37 °C caused hydrolysis of the linker. 
To confirm that the hydrolysis was not catalyzed by some unknown additive 
found in the beads, solutions of 5-5 were incubated in 1x PBS, pH 7.4 overnight 
at room temperature or 37 °C with or without the addition of the Neutravidin 
beads. Again, both samples incubated at 37 °C showed less dye color on the 
beads regardless of whether the beads were present (Figure 5-8), suggesting that 
the elevated temperature alone is enough to facilitate hydrolysis.  
Previous reports using Dde as a protecting group during peptide synthesis 
have described some instances of migration between Lys residues under 
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extended incubation times.18, 30 These events only occurred when excess base 
was present. A previous report indicated that the Dde group would also degrade 
under similar basic conditions of 0.05% SDS, 200 mM Tris pH 8.5.19 
Interestingly, the thermal instability we have observed has not been previously  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7. Long-term stability of Dde linker. Cy3-Dde-biotin 5-5 was (A) immobilized on 
Neutravidin beads and (B) incubated overnight in different buffers at RT and 37 °C.  Beads 
incubated at 37 °C showed loss of dye to the solution, suggesting that the linker is sensitive to 
higher temperatures. 
reported. To rectify the lability of the Dde group in peptide synthesis, a 
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sterically hindered alternative known as Ddiv or ivDde was developed by 
replacing the ethyl group of Dde with a more bulky isovaleryl group.18 The 
biotin group provides a steric environment similar to the ivDde group; yet, the 
linker may be made more resistant to hydrolysis by increasing the steric bulk  
 
 
 
 
 
 
 
Figure 5-7. Long-term stability of Dde linker in solution. Cy3-Dde-biotin 5-5 was diluted in 
PBS and incubated overnight with or without beads at RT or 37 °C. Regardless of whether beads 
were present, less dye was immobilized onto beads when incubated at 37 °C. 
adjacent to the cyclohexylidene group. Nevertheless, we decided to move 
forward with the alternative digestion-first approach. 
5.4.2 Digestion-First Method 
In this method, complex lysate would first be subjected to trypsin digestion. 
After numerous attempts using in solution digestion failed, we decided to turn 
our attention to filter-assisted sample preparation (FASP).31 Here, filters are 
used to buffer exchange solubilized proteins after reduction and alkylation into a 
solution amenable to trypsin activity. There have also been recent reports of 
37 °C
RT
beads no beads
  
173 
improved FASP methods,32, 33 and these approaches were attempted as well. 
Procedure details are given in the experimental methods section. Briefly, cell 
lysates from two 15-cm plates of HEK-293T cells at 75% confluency were lysed 
using SDS lysis buffer, quantified by the BCA assay, and adjusted to 2 mg/mL 
protein with lysis buffer. Samples (20 mg) were reduced by incubation for 5 min 
at 95 °C with 20 mM dithiothreitol (DTT) and then concentrated on Amicon 
centrifugal filter units (10 mg per filter unit). Samples were diluted with 8 M 
urea, 50 mM Tris pH 7.9 containing 20 mM IAA and allowed to react in the dark 
for 30 min at RT. The reduced and alkylated lysate was then concentrated and 
washed twice with urea buffer and twice with Tris buffer. Sequencing-grade 
trypsin was added to each sample at 1:50 w/w and incubated overnight at 37 °C. 
Peptides were separated from undigested material by centrifugation, and the 
filter was washed twice with Tris buffer. The filtrate was combined, acidified to 
pH 3 using TFA, and desalted with HLB columns. For the enhanced methods, 
the buffer in the final wash step was replaced with 0.2% w/v sodium 
deoxycholate, 50 mM Tris pH 7.9. Alternatively, the sample was first washed 
with 4% w/v sodium deoxycholate, 8 M urea, 50 mM Tris pH 7.9 before 
continuing with the urea and Tris washes. Acidification after filtration 
precipitated all remaining sodium deoxycholate, allowing for it to be easily 
separated prior to desalting. Trypsin is active in the presence of sodium 
deoxycholate, and the detergent is thought to remove excess, protein-bound 
SDS, which could inhibit trypsin activity. However, in all cases, we observed 
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yields of roughly 5-7 mg peptides from a starting amount of 20 mg protein. 
Therefore, we proceeded with the unmodified FASP method for all future 
sample preparation. 
 The remaining steps of the peptide labeling protocol were left largely 
unchanged from the original protein labeling protocol with a few exceptions. 
Generally, HLB desalting columns were used in place of protein precipitation as 
described in the original protocol. The clean-up step for the CuAAC step in 
other protocols used strong cation exchange (SCX) to separate the peptides 
from excess alkyne reagent.7, 8, 34 However, repeated experiments using SCX 
columns failed to retain the peptides. Instead, we opted to remove excess Dde-
alkyne-biotin by adding in azide agarose resin after the peptide reaction was 
complete. Remaining, unreacted reagent conjugated to the agarose, which could 
easily be filtered off. Finally, we decided to switch from 2% w/v hydrazine to a 
buffered solution containing 2% w/v hydroxylamine. The β-O-GlcNAc linkage is 
cleaved under basic conditions,1 so we aimed to produce an elution buffer with a 
neutral pH. The pKa of the hydrazinium ion is about 8, so a buffered solution of 
pH 7 will only contain about 10% of the reactive, deprotonated nucleophile. 
Conversely, hydroxylammonium has a pKa of about 6, which would yield a 
solution containing roughly 90% of the deprotonated compound at pH 7.  
5.4.3 Comparing Dde and PC Linkers with Endogenous O-GlcNAc Sites 
With these adjustments, we conducted the protocol using both 5-1 and 5-4 as 
a direct comparison. Samples were eluted twice and analyzed separately to 
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ensure that complete elution was achieved and avoid incomplete cleavage that 
was observed previously with the 5-1.8 In total, 445 unique O-GlcNAcylated 
peptides on 256 different proteins were identified across all four samples using 
higher-energy collisional dissociation (HCD) MS/MS (Table 5-2). Here, 
peptides are counted as the number of unique peptide sequences; however, 
possible multiple modifications or different modification sites on the same 
peptide were not counted as additional unique peptides. Therefore, this count is 
likely an underestimation of the number of possible sites.  Importantly, peptides 
containing either tag could easily be identified with their MS/MS spectra by the 
presence of up to three signature ions caused by the fragmentation of glycosidic 
bonds within the linker: 300.1 (GalNAz-GlcNAc), 318.1 (H2O adduct), and 
503.2 (GlcNAc-Ser/Thr) m/z, which are observed from both linkers due to the 
identical aminomethyltetrazolyl group left after cleavage.8 5-4 strongly 
outperformed 5-1 in peptide coverage. Of the 442 unique peptides identified in 
all samples, 414 were observed in the Dde samples, whereas only 257 were 
observed in the PC sample. In both cases, a single elution step was sufficient to 
release nearly all of the identified peptides, with only 7 unique peptides 
identified solely in the second Dde elution step and 16 in the second PC elution. 
The modified peptides revealed by this analysis covered a variety of known 
O-GlcNAcylated proteins.5, 7, 8, 13 As expected, sites on many multiply O-
GlcNAcylated proteins such as host cell factor 1 (Hcfc1), Msx2-interacting 
protein (Mint), myosin phosphatase target subunit 1 (Mypt1), nucleoporins 
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(Nup98, Nup153, Nup214), glutamine and serine rich protein 1 (Qser1), and 
lysine deficient protein kinase 1 (Wnk1) were observed in the dataset. 
Interestingly, Qser1 and the related protein proline and serine rich protein 1 
(Prsr1), which was also observed to be O-GlcNAcylated in this dataset, are 
ubiquitously expressed but have no known function. Thus, these results may 
help provide evidence for the role of these proteins in the cell and its regulation 
by O-GlcNAcylation. 
5.5 Conclusions and Outlook 
 The results presented herein provide the framework for a new approach to 
identify sites of O-GlcNAcylation on proteins using a novel cleavable tag 5-4 
based on the Dde functional group. This linker provides numerous benefits over 
existing linkers due to its complete cleavage by hydrazine and hydroxylamine as 
well as its ability to leave only the small aminomethyltetrazolyl group after 
cleavage. Moreover, the remaining linker provides an additional positive charge 
to the labeled peptide, aiding in ETD fragmentation. There still remain areas of 
improvement for the linker, including synthetic variants closer to the ivDde 
structure to avoid cleavage at elevated temperatures. Nevertheless, we envision 
that this linker can be combined with isotopic labeling methods such as SILAC 
or dimethyl labeling to allow for the quantitative measure of O-GlcNAcylation 
dynamics based on individual sites. These experiments will provide critical 
information regarding the regulation of protein O-GlcNAcylation to help 
delineate its physiological functions in diverse biological systems. 
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Table 5-2. O-GlcNAc sites identified from HEK-293T lysate. Samples were processed using a 
digestion-first protocol and labeled using the two-step chemoenzymatic approach with 5-4 or 5-1. 
Peptides were identified by HCD-MS/MS and are presented as unique sequences. 
Uniprot Peptide sequence Peptide counts  
  Dde-1 Dde-2 PC-1 PC-2 
4ET_HUMAN SVLHPPGSGSHAAAVSVQTTPQNVPSR 1    
AAK1_HUMAN LTDPIPTTETSIAPR   1  
ABLM1_HUMAN STSQGSINSPVYSR 1    
ADRM1_HUMAN SQSAAVTPSSTTSSTR 1 1 1 2 
AF10_HUMAN NPGTTVSAASPFPQGSFSGTPGSVK 2    
AGFG1_HUMAN APVGSVVSVPSQSSASSDK 6 3 5 3 
 SSSADFGTFNTSQSHQTASAVSK 6 3 7 4 
 VVASVHASISGSSASSTSSTPEVKPLK 1    
AGFG2_HUMAN TLLGDPAPSLSVAASTSSQPVSQSHAR 4 1 2  
AHNK_HUMAN GPQVSSALNLDTSK 4 2 3 2 
AHNK2_HUMAN ESEIPTSEIQTPSYGFSLLK 1    
AINX_HUMAN SNVASSAACSSASSLGLGLAYR 1    
ALMS1_HUMAN ISVASEPVDQTTGTPAVTSTSYSQYR 1  1  
 TETPSVSSSLYSYR 1    
 VSVAPGPVGQTTGAPTITSPSYSQHR 1  2  
AMRA1_HUMAN TSASSVSLLSVLR 1    
ANKH1_HUMAN NAFPLGAPTLVTSQATTLSTFQPANK 4 3 2 3 
 SIHANFSSGVGTTAASSK 2    
 VSTSPVGLPSIDPSGSSPSSSSAPLASFSGIPGTR 2    
ANR17_HUMAN IGSSAPTTTAANTSLMGIK 4  2 1 
 LKVEDEPEVLTEPPSATTTTTIGISATWTTLAGSHGK 2    
 MTTVALSSTSQTATALTVPAISSASTHK 3  1  
 MTVPPLATSSAPVAVPSTAPVTYPMPQTPMGCPQPTPK 1    
 QHFSPLSLLTPCSSASNDSSAQSVSSGVR 2  1  
 TSNATTTTVTTTASNNNTAPTNATYPMPTAK 1    
APMAP_HUMAN AGPNGTLFVADAYK   1  
ARI1A_HUMAN GGTPGSGAAAAAGSKPPPSSSASASSSSSSFAQQR 2  1 1 
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 NPQMPQYSSPQPGSALSPR 1    
ARI1B_HUMAN VMPTVPTSQVTGPPPQPPPIR 9 2 6 2 
ARI3A_HUMAN LPVSLAGHPVVAAQAAAVQAAAAQAAVAAQAAALEQLR 1    
ARIP4_HUMAN VVTTTDIVIPGLNSSTDVQAR 5  4 1 
ARNT_HUMAN HSNPTQGATPTWTPTTR 2   3 
ASPP2_HUMAN ENLPVSSDGNLPQQAASAPSR   1  
ATF1_HUMAN TTPSATSLPQTVVMTSPVTLTSQTTK 3 2 5  
ATF7_HUMAN SAAEAVATSVLTQMASQR 1    
ATX1L_HUMAN APSATSPSGQLPHHSSTQPLDLAPGR 2  2  
ATX2L_HUMAN SAAPAPISASCPEPPIGSAVPTSSASIPVTSSVSDPGVGSISPASPK 3 1 2 1 
BAG3_HUMAN SQSPAASDCSSSSSSASLPSSGR   2  
BAZ2B_HUMAN GGLSTGVASLSSTINPCGHLFR 2    
 LPSSAASSTTPTSSSTPSVASVVSK 2    
BCORL_HUMAN TPPMPVLTPVHTSSK 1    
BPTF_HUMAN FLFTPLATTATTASTTTTTVSTTAAGTGEQR 5  2 1 
 GQPVSTAVSAPNTVSSTPGQK 4 2 2 2 
 LEQQKPTVIATSTTSPTSSTTSTISPAQK   1  
 STVTTTTTTVTK 1    
 TVITEVTTMTSTVATESK 4 2 6 3 
 VMVAPISGSVTTGTK 3 1 2 1 
BRD8_HUMAN LLEAGPTQFTTPLASFTTVASEPPVK   1  
CACL1_HUMAN AAPAPTASSTININTSTSK   1  
CARF_HUMAN SSSSTNTSLLTSK 1   1 
CATL1_HUMAN YSVANDTGFVDIPK 2  1  
CBL_HUMAN VPVSAPSSSDPWTGR 3 1 2 2 
CDK12_HUMAN TSAVSSQANSQPPVQVSVK 5 2 4 2 
CDK13_HUMAN TENQHVPTTSSSLTDPHAGVK 2    
CDK8_HUMAN VVPPTTTSGGLIMTSDYQR 3    
CE170_HUMAN EINDVAGEIDSVTSSGTAPSTTVSTAATTPGSAIDTR 1    
CIC_HUMAN GYGSAPSSSASSPASSSASAATSFSLGSGTFK 1  1  
CKAP5_HUMAN ISTSTGISPQMEVTCVPTPTSTVSSIGNTNGEEVGPSVYLER 2  2 1 
CLIP1_HUMAN VQAEDEANGLQTTPASR 1    
CNOT1_HUMAN APLAGQVSTMVTTSTTTTVAK 16 3 18 5 
CNOT2_HUMAN SLSQGTQLPSHVTPTTGVPTMSLHTPPSPSR 1    
CNOT4_HUMAN SNPVIPISSSNHSAR 1    
CRTC2_HUMAN SLQQPGLPSQSCSVQSSGGQPPGR 2 1 1  
CUL4B_HUMAN MAEESSSSSSSSSPTAATSQQQQLK 1  2  
CUX1_HUMAN QAPLSQSDITILTPK 1    
DAPLE_HUMAN TCSTSATTTAPSNSTPIAR 1  1  
DIDO1_HUMAN TYFPGPPGDGHPEPSPLEDLSPCPASCGSGVVTTVTVSGR  1 1  
 VLSSLKPAAPSPATAATTAAAASTAASSTASSASK 4  1  
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DLG5_HUMAN SLTPSTTVSSILR 1    
DSRAD_HUMAN NAEFLTCNIPTSNASNNMVTTEK 1  4 1 
E41L1_HUMAN DVLTSTYGATAETLSTSTTTHVTK 2    
E41L2_HUMAN TITYESPQIDGGAGGDSGTLLTAQTITSESVSTTTTTHITK 2  1  
ELF1_HUMAN FILQAIPSSQPMTVLK 2    
ELF2_HUMAN ALTPVSIAHGTPVMR 1    
 VAMQVPVVMTSLGQK 1    
EMD_HUMAN LSPPSSSAASSYSFSDLNSTR 3    
EMSA1_HUMAN VKEEQYLGHEGPGGAVSTSQPVELPPPSSLALLNSVVYGPER   1  
EMSY_HUMAN IISSNIVSGTTTK 2    
 ITFTKPSTQTTNTTTQK 1    
 MSNIMQSIANSLPPHMSPVK 2    
 QTASQVEQPIITQGSSVTK 1    
 TTSGSIITVVPK 1  2  
 VIIVTTSPSSTFVPNILSK 3 1 3 2 
EP300_HUMAN SGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSMVK 1    
EP400_HUMAN AAAAPFQTSQASASAPR 1   1 
 AQPAITTGGSAAVLAGTIK 1    
 AVGSPATATPDLVSMATTQGVR 3 2 4 2 
 AVTSVTASAVVTTNLTPVQTPAR 5 1 1 1 
 SLVPQVSQATGVQLPGK 1 1 1  
 TAAPTTASAAPQGPLR 1    
 TQFLTTPISQAQK 3 1  1 
 TSVTGTSMPTGAVSGNVIVNTIAGVPAATFQSINK 3    
EPC1_HUMAN LTVPSSVATVNSIAPINAR 1    
EYA4_HUMAN TEPLNSSETTATTGDGALDTFTGSVITSSGYSPR 1    
F193A_HUMAN SPPSVSSASSGSGSSSPITIQQHPR 2    
 TATTTPGFVDTR   1  
 VVMATSSATSSVSCTATTVQSSNSQFR 2 1 1  
F208B_HUMAN ETPLPVSLPSDK 2    
 SLSDTLVSTTAPSGIVNVSVK 1    
 VASYSGTVTQATFTR 1    
FLIP1_HUMAN VTSTITITPVTTSSAR 2 1 1 2 
FNBP4_HUMAN ATEISTAVVQR  1 1  
FOXC1_HUMAN GSPQSAAAELSSGLLASAAASSR 2    
FOXK1_HUMAN EPAAAVAATATTTPATATTASASASSTGEPEVK 13 4 11 3 
 HAVPTNSLAGNAYALTSPLQLLATQASSSAPVVVTR 1  2  
 VVTTSANSANGYILTSQGAAGGSHDAAGAAVLDLGSEAR 5 1 4  
FOXK2_HUMAN FAQSAPGSPLSSQPVLITVQR 1    
GABPA_HUMAN YVLASQEQQMNEIVTIDQPVQIIPASVQSATPTTIK 2    
GANP_HUMAN SPTSVGAFPSTSAFGQEAGEIVNSGFGK 3 2 1  
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GCR_HUMAN VSASSPSLAVASQSDSK  1   
GEMI5_HUMAN TVIESSPESPVTITEPYR 1    
GMEB2_HUMAN VVSTLPSTVLGK 2    
GPKOW_HUMAN EGVLPLTAASTAPISFGFTR 1    
GSCR1_HUMAN QVPVSGYLASAAGPSEPVTLASAGVSPQGAGLVIQK 1    
GSE1_HUMAN RVPMGPIIVPPGGHSVPSTPPVVTIAPTK 1    
HCFC1_HUMAN APVTVTSLPAGVR 3 2 3 1 
 AVTTVTQSTPVPGPSVPPPEELQVSPGPR 2    
 HSHAVSTAAMTR 1    
 IPPSSAPTVLSVPAGTTIVK 12 5 7 5 
 ISVATGALEAAQGSK 7 3 5 2 
 LVTPVTVSAVKPAVTTLVVK 6 3 3 1 
 QEAAASLVTSTVGQQNGSVVR 7 2 5 1 
 QTSATSTTMTVMATGAPCSAGPLLGPSMAR 7 3 8 1 
 SGTVTVAQQAQVVTTVVGGVTK 16 4 13 3 
 SPISVPGGSALISNLGK 2 1 1 1 
 SPITIITTK 6 3 5 2 
 SSVGAGEPR 1    
 TAAAQVGTSVSSATNTSTRPIITVHK 20  7 2 
 TIPMSAIITQAGATGVTSSPGIK 25 13 18 9 
 TMAVTPGTTTLPATVK 11 4 12 4 
 VASSPVMVSNPATR 3  1 1 
 VMSVVQTKPVQTSAVTGQASTGPVTQIIQTK 7 2 6 4 
 VMTSGTGAPAK 1  1 2 
 VTGPQATTGTPLVTMRPASQAGK 2  2  
 YDIPATAATATSPTPNPVPSVPANPPK 2  1  
HGS_HUMAN AEPMPSASSAPPASSLYSSPVNSSAPLAEDIDPELAR 11 3 10 3 
HSPB1_HUMAN LATQSNEITIPVTFESR 3 1 1 1 
HTF4_HUMAN GSTSSSPYVAASHTPPINGSDSILGTR 1    
 LSYPPHSVSPTDINTSLPPMSSFHR 1    
I2BP2_HUMAN AAASLAAVSGTAAASLGSAQPTDLGAHK 3  4  
 INGEAQPWLSTSTEGLK 2  2  
I2BPL_HUMAN FEYPPPPVSLGSSSHTAR 8 3 5 2 
 GPPTPAPPGAPGGPACLGGTPGVSATSSSASSSTSSSVAEVGVGAGGK 1  1 1 
 SRFEYPPPPVSLGSSSHTAR 5  4  
IF4G3_HUMAN EQEGQTSETTAIVSIAELPLPPSPTTVSSVAR 11  3 1 
 KEQEGQTSETTAIVSIAELPLPPSPTTVSSVAR 2  1  
 STIAAPTSSALSSQPIFTTAIDDR 8 2 2 3 
ITB1_HUMAN VCECNPNYTGSACDCSLDTSTCEASNGQICNGR 2  5 2 
ITSN2_HUMAN AQSLIDLGSSSSTSSTASLSGNSPK 1  1  
JHD2C_HUMAN HSVPQSLPQSNYFTTLSNSVVNEPPR 4  2  
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 SPTHLTVSSTNTLR 1    
JUNB_HUMAN LIVPNSNGVITTTPTPPGQYFYPR 1    
K2026_HUMAN CLTSALQIPVTVALPTPATTSPK 1    
K2C8_HUMAN TTSGYAGGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSR 3  1  
KANL3_HUMAN LPTPMQSLGAITTGTSTIVR 3    
 SSSSEGGVSASPVPSVVSSSTAPSALHTLQSR 2  1  
 VPTTITLTLR 1    
KCMF1_HUMAN SNMHFTSSSTGGLSSSQSSYSPSNR   1  
KDM3B_HUMAN NSILASSGFGAPLPSSSQPLTFGSGR 1 1 2  
 TLEQVGQGIVASAAVVTTASSTPNTVR 10 1 8 5 
 TLVVQDEPVGGDTPASFTPYSTATGQTPLAPEVGGAENK 1    
 VEHSPFSSFASQASGSSSSATTVTSK 7 1 5 2 
KMT2D_HUMAN SLPSDPFSR 1    
KRT81_HUMAN LCEGIGAVNVCVSSSR  1   
LAP2A_HUMAN SSSSSSQPEHSAMLVSTAASPSLIK 1    
LAR4B_HUMAN EPSVPASCAVSATYER 1    
 TLSADASVNTLPVVVSR 1    
LIMD1_HUMAN TPSVSAPLALSCPR 1    
LIN54_HUMAN LGAQTPVTISANQIILNK 1    
 TITISESGVIGSTLNSTTQTPNK 1  1  
LMNA_HUMAN ASASGSGAQVGGPISSGSSASSVTVTR 9 5 8 3 
 SVGGSGGGSFGDNLVTR 1 1  1 
LMO7_HUMAN TSTTGVATTQSPTPR   1  
LPP_HUMAN STGEPLGHVPAR 2 1 1 2 
LRIF1_HUMAN ILATATTSTSGMVEASQMPTVIYVSPVNTVK 1    
MAFK_HUMAN STELSSTSVPFSAAS 2 2 2 1 
 VATTSVITIVK 2 1 2 1 
MAP4_HUMAN ASPSKPASAPASR 1   1 
MATR3_HUMAN DLSAAGIGLLAAATQSLSMPASLGR 3 1 2 1 
MAVS_HUMAN VPTTLMPVNTVALK 1    
MBD5_HUMAN DIPNPLIAGISNVLNTPSSAAFPTASAGSSSVK 1    
MCAF1_HUMAN NPTASAAPLGTTLAVQAVPTAHSIVQATR 1    
 NPVSLPSLPNPTKPNNVPSVPSPSIQR 1    
 TSLPTVGPSGLYSPSTNR 2    
MED15_HUMAN FPPTTAVSAIPSSSIPLGR 9  7  
MGAP_HUMAN IPGVSTPQTLAGTQK 1    
 TTGITTPVASVAFPK 2    
MINT_HUMAN ADRPSLEKPEPIHLSVSTPVTQGGTVK 3  2  
 AQSTPSPALPPDTK 1  1  
 ASDVDTSSSTLR 1  1 1 
 QPLFVPTTSGPSTPPGLVLPHTEFQPAPK 3  2  
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 SLVSTPAGPVNVLK 1    
 VNTSEGVVLLSYSGQK 2 2 2  
MKL2_HUMAN VSESPSPVTTNTPAQFASVSPTVPEFLK 1    
MLXIP_HUMAN EGMLASTVSQSNVVIAPAAIAR 2    
MUC5A_HUMAN GCPVTSTPVTAPSTPSGR   1  
MYPT1_HUMAN DSVPTAVTIPVAPTVVNAAASTTTLTTTTAGTVSSTTEVR 3  1 3 
 QDDLISSSVPSTTSTPTVTSAAGLQK 12 2 5 1 
 RQDDLISSSVPSTTSTPTVTSAAGLQK 6  2 3 
 TKPLASVTNANTSSTQAAPVAVTTPTVSSGQATPTSPIK 3  1 1 
NASP_HUMAN ATLVESSTSGFTPGGGGSSVSMIASR 2    
NCOA3_HUMAN AVSLDSPVSVGSSPPVK 1    
NCOA6_HUMAN SIVTTLVPSELISAVPTTK 3  1 1 
NCOR1_HUMAN HTSVVSSGPSVLR 1    
 IMPLPAGGPSISQGLPASR 2    
 NQVSSQTPQQPPTSTFQNSPSALVSTPVR 3 1 5 2 
 SSHLEVSQASQLLQQQQQQQLR 1    
 YPPHSVQYTFPNTR 3    
NCOR2_HUMAN AISSASIEGLMGR    1 
 VVTLAQHISEVITQDYTR 1  1  
 YPPHSLSYPVQIAR 3    
NFIA_HUMAN ASPHATPSTLHFPTSPIIQQPGPYFSHPAIR 3    
NFIC_HUMAN LALPPATKPATTSEGGATSPTSPSYSPPDTSPANR 1    
NFRKB_HUMAN IQTVPASHLQQGTASGSSK 1  2  
 LMPALGVSVADQK 1    
 QVPVSTTVVSTSQAGK 2  2 1 
 TVAVASGAASTPISISTGAPTVR 6 1 2 2 
NOTC1_HUMAN CNCLLPYTGATCEVVLAPCAPSPCR   1  
NOTC2_HUMAN YSCVCSPGFTGQR  1  1 
NOTC3_HUMAN CQCPAGYTGPLCENPAVPCAPSPCR 1    
NPM_HUMAN MSVQPTVSLGGFEITPPVVLR 1    
NU153_HUMAN ALTLTVVSESAETMTASSSSCTVTTGTLGFGDK 4  2  
 CQPVFSFGNSEQTK   1  
 CVSCMSEKPGSSVPASSSSTVPVSLPSGGSLGLEK 2  1  
 FGVSSSSSGPSQTLTSTGNFK 11 1 5 3 
 GFDTSSSSSNSAASSSFK  2 1 2 
 IGVSSDSGSINPMSEGFK 2 1 4 2 
 ISLPITSSSLPTFNFSSPEITTSSPSPINSSQALTNK 8 4 6 2 
 QQEPVTSTSLVFGK 6 2 4 2 
 SSSAGFSFGTGVINSTPAPANTIVTSENK 6 4 3 3 
 STEANVLPPSSIGFTFSVPVAK 31 6 12 10 
 VQMTSPSSTGSPMFK 2 2  2 
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NU214_HUMAN ASSTSLTSTQPTK 2 2  1 
 EPVLAQPAVSNSGTAASSTSLVALSAEATPATTGVPDAR 6 2 2  
 GGGFFSGLGGKPSQDAANKNPFSSASGGFGSTATSNTSNLFGNSGAK 1    
 KEPVLAQPAVSNSGTAASSTSLVALSAEATPATTGVPDAR 8 1 4  
 LGELLFPSSLAGETLGSFSGLR 4 2 2 3 
 NNPATPSTAMGSSVPYSTAK 4  4 1 
 NPFSSASGGFGSTATSNTSNLFGNSGAK 10 4 5 3 
 SSATVTGEPPSYSSGSDSSK 1    
 TFGGFASSSFGEQKPTGTFSSGGGSVASQGFGFSSPNK 5  2  
 TGGFGAAPVFGSPPTFGGSPGFGGVPAFGSAPAFTSPLGSTGGK 1  1  
NUFP2_HUMAN TIQNSSVSPTSSSSSSSSTGETQTQSSSR 1  1  
NUP53_HUMAN ASTSDYQVISDR 1    
NUP98_HUMAN AASLMNIPSTSSWSVPPPLTSVFTMPSPAPEVPLK 1  3  
 FTSGAFLSPSVSVQECR 2  1 2 
 GPQNQVGAGTTTGLFGSSPATSSATGLFSSSTTNSGFAYGQNK 1  1 1 
 KGPQNQVGAGTTTGLFGSSPATSSATGLFSSSTTNSGFAYGQNK 3   1 
P121A_HUMAN APPTLQAETATKPQATSAPSPAPK 2    
P121B_HUMAN QSFLFGTQNTSPSSPAAPAASSASPMFKPIFTAPPK 2    
P66A_HUMAN GTTATSAQANSTPTSVASVVTSAESPASR 2  4 3 
 TPLSTGGTLAFVSPSLAVHK 2    
P66B_HUMAN LQQQAALSPTTAPAVSSVSK 2 1   
PACS1_HUMAN LAQATSSSSSTSAAAASSSSSSTSTSMAVAVASGSAPPGGPGPGR 1    
PAPOA_HUMAN EQLDTETSTTQSETIQTAASLLASQK   1  
PCF11_HUMAN SPEEPSTPGTVVSSPSISTPPIVPDIQK   1  
PDLI5_HUMAN ANNSQEPSPQLASSVASTR 2  2 1 
 EVVKPVPITSPAVSK 4    
PF21A_HUMAN FTPTTLPTSQNSIHPVR 3 1 3 1 
PHAR4_HUMAN FIISTSITTAPAATTAATSLAK 17 4 7 2 
PHC1_HUMAN QPGTAQAQALGLAQLAAAVPTSR 4  2 1 
PHC3_HUMAN STSQTQSLTICHNK 1  1  
PHF3_HUMAN GSAVATSHFEVGNTCPSEFPSK 1    
PICAL_HUMAN KPHTSLTTAASPVSTSAGGIMTAPAIDIFSTPSSSNSTSK 5  3 1 
 SSGDVHLSISSDVSTFTTR   1  
PKCB1_HUMAN SSAQTSAAGATATTSTSSTVTVTAPAPAATGSPVK 1    
 SSAQTSAAGATATTSTSSTVTVTAPAPAATGSPVKK 1    
 TPPSTTVGSHSPPETPVLTR 1  1  
PKHA5_HUMAN IVNVSLADLR 4 1 2 1 
PLEC_HUMAN AGVAAPATQVAQVTLQSVQR 1    
PLIN3_HUMAN TLTAAAVSGAQPILSK 3  2 1 
 VASMPLISSTCDMVSAAYASTK 4 1 2  
PLRG1_HUMAN MPSESAAQSLAVALPLQTK 1    
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POGZ_HUMAN LAPSFPSPPAVSIASFVTVK 6 3 2 1 
 STPSTSTTPTATQPTSLGQLAVQSPGQSNQTTNPK 4  1  
PRC2B_HUMAN DSDFSLPPGSASGPTGSPVVK 6    
 GGLPVSQSQEIFSSLQPFR 4 3 2 2 
PRC2C_HUMAN AVSEMSTEIGTMISVSSAEYGTNAK 3  3  
 ESVTDYTTPSSSLPNTVATNNTK 2 2 2 1 
 ETIQQSSSLTSVPPTTFSLTFK 6 1 7 2 
 RETIQQSSSLTSVPPTTFSLTFK 5  3  
PRSR1_HUMAN GFLTSNDTNLINSSALSSAVTSGLASLSSLTLQNSDSSASAPNK 1    
 GPHPGTSDLHISSTPAATTLPVMIK 2    
PTN12_HUMAN TNISTASATVSAATSTESISTR 2 1 2  
PUM1_HUMAN SASSASSLFSPSSTLFSSSR 2 1 2 2 
QSER1_HUMAN KTEALQVATTSPTANTTGTATTSSTTVGAVK 2    
 QSSLSCSPIGDSTQVSNGGLQQK 1    
 SCSTEQPLTSTK   1 1 
 TAQAAASGTTLLPQFR 2  1  
 TEALQVATTSPTANTTGTATTSSTTVGAVK 1 1 1  
 TSQGTVPTALAFER 3  1 2 
RBM12_HUMAN VNLPTTVSNFNNPSPSVVTATTSVHESNK 16  8 2 
RBM14_HUMAN AQPSVSLGAAYR 1   2 
RBM27_HUMAN AANIVIQTEPPVPVSINSNITR 5 4 7 1 
 MMSKPQTSGAYVLNK 1    
 TQTQRPNLIGLTSGDMDVNPR 1    
RBM4_HUMAN HLLPTSGAAATAAAAAAAAAAVTAASTSYYGR 5  1  
RBM7_HUMAN TMDNMTSSAQIIQR 1  1 1 
RBMS2_HUMAN MLAQSALSPYLSSPVSSYQR 2 1   
RC3H2_HUMAN VGVNNTVTTTAGNVISVIGSTETTGK 1    
RFX5_HUMAN TAEVPVSEASGQAPPAK 1   1 
RGPD3_HUMAN,RG
PD4_HUMAN EGFSIPVSADGFK 2    
 TDVIQGDDVADAASEVEVSSTSETTTK 1    
RIPK1_HUMAN MQSLQLDCVAVPSSR  1   
RLA2_HUMAN LASVPAGGAVAVSAAPGSAAPAAGSAPAAAEEK   1  
RPRD2_HUMAN SAVSTSVPTKPTENISK 3  1  
 SFNYSPNSSTSEVSSTSASK 1  1  
 SLFSPQNTLAAPTGHPPTSGVEK 1 1 1  
 TPAPATTTSHNPLANILSK 2  1  
RPTOR_HUMAN NYALPSPATTEGGSLTPVR 1  1  
RRP1B_HUMAN TPTSSPASSPLVAK 1    
RSBNL_HUMAN QLQPPAAPSPQSYGSPASWSFAPLSAAPSPSSSR 1    
S30BP_HUMAN GTTTNATSTTTTTASTAVADAQK 7 2 8 2 
 KGTTTNATSTTTTTASTAVADAQK 3  3  
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 SKWDSAIPVTTIAQPTILTTTATLPAVVTVTTSASGSK 3    
 WDSAIPVTTIAQPTILTTTATLPAVVTVTTSASGSK 5 1 3  
SAP_HUMAN DNATEEEILVYLEK 1    
 TNSTFVQALVEHVK 5  2  
SARNP_HUMAN FGIVTSSAGTGTTEDTEAK   1  
SBNO1_HUMAN FIQTTASTRPSVSAPTVR 1    
 TPPVTTNR   1  
SC16A_HUMAN TLENPVNVYNPSHSDSLASQQSVASHPR 2    
SC24A_HUMAN ASSQPTVSGNTSLTTNHQYVSSGYPSLQNSFIK 1 1   
SC24B_HUMAN SSPVVSTVLSGSSGSSSTR 7 2 5 2 
 TPPTANHPVEPVTSVTQPSELLQQK 9 2 4 2 
SC24C_HUMAN APPSSGAPPASTAQAPCGQAAYGQFGQGDVQNGPSSTVQMQR 5 1 2  
SCAF8_HUMAN ETVQTTQSPTPVEK 1   1 
 SSEPVKETVQTTQSPTPVEK 1    
SCML2_HUMAN NPMYIHTSVSQDFSR 1 1   
SCYL2_HUMAN SSASSTFTSVPSMGIGMMFSTPTDNTK 1    
SET1A_HUMAN GSTPYSQDSAYSSSTTSTSFKPR 1    
 QDTPSSFGQFTPQSSQGTPYTSR 2    
SET1B_HUMAN DFSFTPTFSEPSGPLLLPVCPLPTGR   1  
SFPQ_HUMAN FPPLGGGGGIGYEANPGVPPATMSGSMMGSDMR 1    
SH3R1_HUMAN IGVFPGNYVAPVTR 1    
 LQGNGVAGSPSVVPAAVVSAAHIQTSPQAK 1    
SI1L3_HUMAN RPVSFPETPYTVSPAGADR 1    
SIX4_HUMAN VLQSSANSATTTSYSPSVPVSFPGLIPSTEVK 2    
SKIL_HUMAN TCTSVPETLHLNPSLK 1    
SLAI1_HUMAN MPSTTAISSNISSPVTVR 2  1  
SMAP2_HUMAN STAPVMDLLGLDAPVACSIANSK   1  
SMG7_HUMAN KTPVSEAR 1    
 YPNNSMFNEVYGK 1    
SNRPA_HUMAN AVQGGGATPVVGAVQGPVPGMPPMTQAPR 1    
SON_HUMAN ILDSFAAAPVPTTTLVLK 4 2 2 2 
 SMMSSYSAADR    1 
SP2_HUMAN TPSGEVQTVLVQDSPPATAAATSNTTCSSPASR 2  1  
SPAT2_HUMAN CDSLLTCPPASKPSAFPSK 1    
SPTB2_HUMAN DDEEMNTWIQAISSAISSDKHEVSASTQSTPASSR 2    
 HEVSASTQSTPASSR 3  2 2 
SRC8_HUMAN NASTFEDVTQVSSAYQK 5  2 1 
SRCAP_HUMAN AETQGANHTPVISAHQTR 1  2  
SRGP1_HUMAN NSPTPATSTESLSPLHNVALR 2  1  
SRP14_HUMAN AAAAAAAAAPAAAATAPTTAATTAATAAQ 2 2 4  
SRRM2_HUMAN IPAASAAAMNLASAR 4 1 3 1 
  
186 
 MAPALSGANLTSPR 1    
 TPAALAALSLTGSGTPPTAANYPSSSR 4    
STAT3_HUMAN FICVTPTTCSNTIDLPMSPR 2 1 3  
SUGP1_HUMAN AQTSTDAPTSAPSAPPSTPTPSAGK 3  2  
SYNJ1_HUMAN IDPFEDLSFNLLAVSK 1    
SYNPO_HUMAN VSTPATTTSTFSR 1 1 1 1 
TAB1_HUMAN VYPVSVPYSSAQSTSK 2 1 2 2 
TAB2_HUMAN VVVTQPNTK 1  1  
TAF4_HUMAN QVSQAQTTVQPSATLQR 3  4 1 
TAF9_HUMAN ASIPATSAVQNVLINPSLIGSK 2  2  
TAF9B_HUMAN LSVGAVSSKPTTPTIATPQTVSVPNK 4    
TANC1_HUMAN MSSSTSSLTSSSSFSDGFK 1    
TCF20_HUMAN VGQFGQHYQSSASSSSSSSFPSPQR 3    
TIF1A_HUMAN QWQISSGQGTPSTTNSTSSTPSSPTITSAAGYDGK 2    
TNR6A_HUMAN ASNYNVPLSSTAQSTSAR 3  1  
 LTWSPGSVTNTSLAHELWK   1  
TNR6B_HUMAN DNTTGSNSSLNTSLPSPGAWPYSASDNSFTNVHSTSAK 1    
TOB1_HUMAN STQPLTFTTATFAATK 1    
TOX4_HUMAN GLQLGQTSTATIQPSQQAQIVTR 5 2 3 2 
 QMLPSSITMSQGGMVTVIPATVVTSR 6 1 3  
TPD54_HUMAN SWHDVQVSSAYVK 1    
TPR_HUMAN GIASTSDPPTANIKPTPVVSTPSK 2    
TRI33_HUMAN QHSNPGHAGPFPVVSVHNTTINPTSPTTATMANANR 2    
TRIP6_HUMAN TGSLKPNPASPLPASPYGGPTPASYTTASTPAGPAFPVQVK   1  
TROAP_HUMAN TSVSQASGLLLETPVQPAFSLPK 1    
UBAP2_HUMAN GVSVSSSTTGLPDMTGSVYNK 4 3 1 2 
 IPYQSPVSSSESAPGTIMNGHGGGR 1    
 LLQLPSTTIENISVSVHQPQPK 6  3  
UBN1_HUMAN TPASSSSALSHPAKPHSVSSAGSSYK 1    
UBP2L_HUMAN QAFTPSSTMMEVFLQEK 1    
 SPAVATSTAAPPPPSSPLPSK 7 3 5 3 
 TAQALAQLAAQHSQSGSTTTSSWDMGSTTQSPSLVQYDLK 1    
UBQL2_HUMAN SQNRPQGQSTQPSNAAGTNTTSASTPR 1  2 4 
UTRO_HUMAN VVLVSSASDIPVQSHR 3  1  
VCIP1_HUMAN TEPSVFTASSSNSELIR 3 3 2 3 
VEZF1_HUMAN KTPTTVVPLISTIAGDSSR 11  3  
 TPTTVVPLISTIAGDSSR 13 4 4 3 
 TSLVSTIAGILSTVTTSSSGTNPSSSASTTAMPVTQSVK 5  2  
WAC_HUMAN INEVLTAAVTQASLQSIIHK 1    
WNK1_HUMAN EGPVLATSSGAGVFK 3 2 3 1 
 FSAPGQLCISMTSNLGGSAPISAASATSLGHFTK 3  1 2 
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 QPIPASSMPQQIGIPTSSLTQVVHSAGR 7 1 5 1 
 TLSPEMITVTSAVGPVSMAAPTAITEAGTQPQK 11  3  
 VFPSEITDTVAASTAQSPGMNLSHSASSLSLQQAFSELR 3    
WNK3_HUMAN QIMAPVTNSSSYSTTSVR 1 1 2  
XRN1_HUMAN EAQSSQATPVQTSQPDSSNIVK   2  
YETS2_HUMAN QLTTGSVVQGTLGVSTSSAQGQQTLK 2    
YTHD3_HUMAN IGGDLTAAVTK 2  2  
 TVGTALSSSGMTSIATNSVPPVSSAAPKPTSWAAIAR 3    
ZBT20_HUMAN SVLQQPSVNTSIGQPLPSTQLYLR 1  1  
ZC3HE_HUMAN TSQEELLAEVVQGQSR 1    
ZCH14_HUMAN TAQQPALVVETSTAATGTPSTVLHAARPPIK 2  2  
ZEP1_HUMAN LEQVYNIAVTSSVGLTSPSSR 2  1  
 QVFLLSVPSLDCLPITR 2  1  
 SNGPSAALVTTSTPSALPTGEK 1 1 1  
 SNSMPTTGYSAVPANIIPPPHPLR 1    
 VNIQEQSQQPVTSLSLFNIK 2    
ZEP2_HUMAN ALYHNPPLSMGQYLQAEPIVLGPPNLR 1 2   
 APQTLPLGLESSIPLCLPSTSDSVATLGGSK 1    
 DGLQSGSSSFSSLSPSSSQDYPSVSPSSR 2    
 EQTYPCYSGASGLHPK 2  3 1 
 SESAEQQISPPNTNAK 1    
 SFDYGNLSHAPVSGAAASTVSPSR 2  1 1 
 SNSVPTSSATNLTIPPSLR 2    
 STETPSEQVLQEDFASANAGSLQSLPGTVVPVR 2  3 1 
 TLVTNAAMQGIGFNIAQVLGQHAGLEK 2   1 
ZFHX3_HUMAN NFQHPLVSTANLIGPGHSFYGK 1  1  
ZFR_HUMAN AGYSQGATQYTQAQQTR 5 2 3 5 
 QAAAAAAAAAATAAWTGTTFTK 4  2  
 QQEAPPPPPPATTQNYQDSYSYVR 8 3 7 2 
 QYYQQPTATAAAVAAAAQPQPSVAETYYQTAPK 3 1 3  
 STPVTSAVQIPEVK 2  1  
ZHX1_HUMAN EEIVENPSSSASESNTSTSIVNR 2  1  
 ENEIKPDREEIVENPSSSASESNTSTSIVNR 1    
 IHPSTASTVVTPAAVLPGLAQVITAVSAQQNSNLIPK 1    
ZHX3_HUMAN EGDHSFINGAVPVSQASASSAK 2  1  
 VPEVTCIPTTATLATHPSAK 2  1  
ZN281_HUMAN TNESQISNNINMQSYSVEMPTVSSSGGIIGTGIDELQK 1    
ZN318_HUMAN TVVAHTSPWMPVVTTSTQTK 1    
ZN384_HUMAN GCGLAPPHYPTLLTVPASVSLPSGISMDTESK 3    
 SDQLTPHSQASVTQNITVVPVPSTGLMTAGVSCSQR 4 1 2  
ZN507_HUMAN NETIPDIPVSVDNLQTHTVQTASVAEMGR 2    
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ZN532_HUMAN QVTIKPVATAFLPVSAVK 1    
ZNT6_HUMAN GTDDLNPVTSTPAKPSSPPPEFSFNTPGK 1    
ZO1_HUMAN TPSTEAAHIMLR 1    
ZYX_HUMAN GPPASSPAPAPK 1    
 VSSGYVPPPVATPFSSK 11 4 4 2 
 Total Peptides Dde-1 Dde-2 PC-1 PC-2 
 442 407 118 241 133 
 
 
 
 
 
 
5.6 Experimental Methods 
Reagents and materials. All proteins, chemicals, and reagents were of analytical 
grade, obtained from Sigma Aldrich (St. Louis, MO), and used without further 
purification unless specified. The O-GlcNAcylated peptide TAPT(gS)TIAPG, 
high-capacity Neutravidin agarose resin, spin columns, and C18 desalting tips 
were purchased from ThermoFisher Scientific (Waltham, MA). Thiamet G was 
received from Tocris Biosciences (Avonmouth, Bristol, UK). cOmplete protease 
inhibitor cocktail without EDTA (PIC-EDTA) was purchased from Roche 
Diagnostics Corp. (Indianapolis, IN). Baculovirus preparation and protein 
expression of short-form OGT (sOGT) in Spodoptera frugiperda (Sf9) cells was 
performed as previously described.24 Cerebral cortices were obtained from adult 
C57BL/6 mice bred in house. All protein concentrations were measured using a 
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BCA assay kit (ThermoFisher Scientific). RapiGest and UDP-GalNAz were 
synthesized as referenced.35, 36 Y289L GalT was expressed and purified as 
described previously. Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), 
alkyne-Dde-biotin 5-4, the alkyne photocleavable biotin linker (alkyne-PC-biotin, 
5-1), Cy3-azide, and azide agarose beads were purchased from Click Chemistry 
Tools (Scottsdale, AZ). 
Peptide labeling. The labeling protocol was adapted from a previously reported 
method. The peptide TAPT(gS)TIAPG (20 µM final) was dissolved in a 200 µL 
solution of 10 mM HEPES pH 7.9, 5.5 mM MnCl2, 1 mM UDP-GalNAz, and 100 
ng/µL Y289L GalT and rotated end-over-end overnight at 4 °C. Prior to enzyme 
addition, an aliquot was removed as an initial time point for LC-MS analysis. The 
reaction was acidified to 0.1% TFA, desalted using a C18 tip, and an aliquot was 
saved for analysis. The labeled peptide (10 µM final) was diluted into a 400 µL 
solution of 10 mM sodium phosphate pH 7.6, 100 µM alkyne-Dde-biotin 5-4, 2 
mM sodium ascorbate, and 100 µM THPTA. CuSO4 was added (1 mM final), and 
the reaction was incubated while rotating end-over-end at RT for 1 h. After 
removing a sample, the reaction was acidified and desalted again. The peptide (10 
µM) was then split into fractions of 50 µL containing 25 mM sodium phosphate 
pH 7.6 and either 1% RapiGest, 6 M urea, or 2% hydrazine monohydrate and 
incubated for 1 h at RT. Samples were acidified, desalted, and subjected to LC-MS 
analysis. 
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LC-MS analysis of O-GlcNAc peptide labeling. Liquid chromatography and mass 
spectrometry (LC-MS) were performed using an LTQ linear ion trap mass 
spectrometer combined with an Accela LC and PAL autosampler (Thermo 
Scientific, Waltham, MA). Approximately 10 pmol peptide from each sample was 
injected onto a CORTECS UPLC C18+ column (2.1 x 50 mm, Waters Corp., 
Milford, MA). Flow rate was set at 0.4 mL/min. Solvent A (ddH2O, 1% formic 
acid) and Solvent B (acetonitrile, 1% formic acid) were used to create a gradient. 
The gradient consisted of 0-0.2 min, 5% B; 0.2-3.5 min 5-65% B, 3.5-4.0 min 65% B 
with injection into the MS starting at 0.2 min to avoid salt contamination. All 
peptide products were found to elute during the linear gradient between 0.2 and 
2.0 min. For the biotinylated and cleaved peptide, alkyne reagent 2 was not 
sufficiently removed by the C18 tips. Therefore, the reaction was monitored using 
an extracted ion chromatogram by extracting all ions within ± 1 m/z of the 
calculated masses. 
Linker comparison by protein labeling. Labeling with Y289L GalT and UDP-GalNAz 
was conducted as previously described.3 Briefly, 500 µg of HEK-293T cell lysate in 
1% SDS, 1x PBS pH 7.4 (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 
mM KCl), 10 µM Thiamet G, and 1x PIC-EDTA was diluted to a protein 
concentration of 1 mg/mL using 1% SDS, 1x PBS pH 7.4 and precipitated by 
adding three volumes of methanol, one volume of chloroform, and two volumes 
of ddH2O with vortex mixing after each addition. Protein was pelleted at the 
aqueous-organic interface by centrifuging at 21,000 x g for 5 min. The top, 
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aqueous layer was removed, and one volume of methanol was added with mixing. 
The protein was pelleted again, and all liquid was removed. After the pellets were 
air-dried, samples were redissolved at 5 mg/mL (100 µL) in 1% SDS, 20 mM 
HEPES pH 7.9 by sonication. To each sample, the following were added in the 
given order: 10 µL of 50x PIC-EDTA, 112.5 µL of ddH2O, 200 µL of 2.5x labeling 
buffer (50 mM HEPES pH 7.9, 125 mM NaCl, 5% NP-40), and 27.5 µL of 100 mM 
MnCl2. Samples were briefly mixed by pipetting and placed on ice. Next, 25 µL of 
0.5 mM UDP-GalNAz was added followed by pipetting to mix. Finally, 25 µL of 2 
mg/mL Y289L GalT was added, and samples were rotated end-over-end for 16 h 
at 4 °C. Proteins were then precipitated again, and pellets were air dried. Pellets 
were next dissolved at 4 mg/mL (125 µL) in 1% SDS, 20 mM HEPES pH 7.9. An 
aliquot of the GalT-labeled sample was removed (25 µL), and the remaining 
sample was split into two equal portions (50 µL each) to be labeled with either 
alkyne-Dde-biotin 5-4 or alkyne-PC-biotin 5-1. All manipulations with the 
photocleavable linker were performed in the dark. To each sample, the following 
were added in the given order with mixing: 4 µL of 50x PIC-EDTA, 78 µL of 
ddH2O, and 10 µL of 20x PBS pH 7.4. Next, the CuAAC reagents were added with 
vortex mixing after each addition: 4 µL of 5 mM alkyne-Dde-biotin 5-4 or alkyne-
PC-biotin 5-1 (stock in DMSO), 4 µL of 100 mM sodium ascorbate (freshly 
prepared), 10 µL of 2 mM THPTA (stock in 4:1 tBuOH/DMSO), and 4 µL of 50 
mM CuSO4 (freshly prepared). Samples were rotated endover-end for 1 h at RT, 
and the reaction was halted by the addition of 25 µL EDTA pH 8.0. Samples were 
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acetone precipitated, and the pellet was washed once with 1 mL MeOH to remove 
residual, unreacted linker. The pellet was then air-dried and redissolved at 4 
mg/mL (50 µL) in 1% SDS, 20 mM HEPES pH 7.9. An aliquot of each sample was 
reserved (25 µL), and the remaining sample was cleaved. For the Dde sample, the 
mixture was diluted to 1 mg/mL with 2% hydrazine monohydrate, and the sample 
was rotated end-over-end for 1 h at RT. For the PC sample, the protein was 
diluted to 1 mg/mL with ddH2O, and the liquid was irradiated from the open top 
of the tube (2 cm distance) with 365 nm UV light (UVGL-25 handheld UV lamp, 
1.5 mW/cm2) for 1 h at RT with mixing every 10 min. Both samples were then 
precipitated by addition of four volumes of -20 °C acetone and storage at -20 °C 
for 1 h. Samples were air-dried and then redissolved at 4 mg/mL (25 µL) in 1% 
SDS, 20 mM HEPES pH 7.9. 
Coomassie staining and streptavidin blotting. Aliquots corresponding to 20 µg of 
protein (5 µL) for each sample were resolved by SDS-PAGE as follows. Samples 
were added to 10 µL ddH2O and 5 µL 4x SDS-PAGE loading buffer (200 mM Tris 
pH 6.8, 400 mM DTT, 8% SDS, 0.4% bromophenol blue, 40% glycerol) and were 
then used directly without boiling to avoid cleaving the linkers. The mixtures 
were loaded in duplicate on NuPAGE Novex 4-12% Bis-Tris protein gels 
(ThermoFisher Scientific, 1.0 mm, 10-well). One duplicate was then stained with 
Imperial protein stain (ThermoFisher Scientific) according to the manufacturer’s 
specifications and imaged by an Odyssey scanner (LI-COR Biosciences). The 
other set of samples was transferred onto an Immobilon-FL PVDF membrane 
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(EMD Millipore, 0.45 µM) and blocked for 1 h at RT with 5% bovine serum 
albumin (BSA) in 1x TBST (19 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 0.1% 
Tween 20). The blot was then incubated with 1:20,000 AlexaFluor-680- 
conjugated streptavidin (ThermoFisher Scientific) in 5% BSA/TBST for 1 h at RT, 
washed thrice with TBST for 5 min, and imaged with an Odyssey scanner. 
α-Crystallin and sOGT labeling. Labeling was conducted as described above using 
200 µg of cortical lysate, 20 µg of α-crystallin, and 5 µg of sOGT. 
Enrichment and elution of labeled proteins. Labeled samples were diluted to 1 mL 
using 1x PBS pH 7.4, 1x PIC-EDTA. For each sample, 25 µL (settled volume) of 
high-capacity Neutravidin agarose was washed twice with 500 µL of 1x PBS in 
spin columns, and samples were added to the washed beads. Mixtures were 
rotated end-over-end for 1 h at RT. Lysate was removed by centrifugation at 
2,000 x g for 30 s. The beads were washed with 1% SDS (5 x 0.5 mL), 6 M urea (5 
x 0.5 mL), and 1x PBS pH 7.4 (5 x 0.5 mL). Beads were then resuspended in 50 µL 
of 2% hydrazine monohydrate in ddH2O and rotated end-over-end for 1 h at RT. 
The elution volume was removed, and beads were washed with 50 µL of 1x PBS 
pH 7.4. The wash volume was combined with the elution volume, and samples 
were flash-frozen and stored at -80 °C prior to analysis. 
Processing proteins for MS analysis. Samples were thawed and precipitated by 
addition of four volumes of - 20 °C acetone. Samples were stored at -20 °C for 1 h 
and centrifuged at 21,000 x g for 5 min. Pellets were redissolved in 20 µL of 8 M 
urea, 100 mM Tris pH 8.0, 10 mM DTT and incubated at 60 °C with shaking for 20 
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min. Cysteine residues were blocked by addition of 25 mM IAA for 45 min. 
Samples were diluted four-fold with 100 mM Tris pH 8.0. Samples were split in 
two and digested with 0.01 mg/mL trypsin or chymotrypsin for 4-16 h at 37 °C. A 
portion of the trypsin digests was further digested with 7 µg/mL AspN for 6 h at 
37 °C. Digests were acidified to a final concentration of 0.5% formic acid, 0.05% 
TFA. 
LC separation and MS analysis. The digests were analyzed by nanoLC/MS on the 
LTQ-Velos with a 0 to 30% B in 120 min gradient with top 5 MS/MS (A: ddH2O, 
0.1% formic acid; B: acetonitrile, 0.1% formic acid). Samples were desalted on a 
360 x 100 µm Kasil fritted pre-column (2 cm Monitor C18) prior to separation on 
a 360 x 75 µm (10 cm BEH130 C18, 1.7 µm) analytical column/tip. Full scan MS 
was acquired at 60,000 resolution followed by top 5 tandem MS in the linear ion 
trap alternating between ETD and CID modes of the same precursor. The ETD 
reaction time was 100 ms with supplemental activation. RAW files were 
converted to MGF files for Mascot searching using Proteome Discoverer with CID 
and ETD spectra extracted to separate MFG files. Data was searched against a 
custom database with fixed modifications of carbamidomethyl (C) and variable 
mods of oxidation (M) and a custom modification for the tagged O-GlcNAc. The 
custom modification was defined as addition of C19H30N6O10 to Ser or Thr (net 
addition of 502.202341 Da). For CID, a scoring neutral loss of C19H30N6O10 was 
included, but this was omitted for ETD. Enzyme specificity was trypsin (KR), 
chymotrypsin (FLYW), or trypsin-AspN_ND (cleave C-term KR and N-term 
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ND). Mass tolerances were 25 ppm and 0.8 Da for precursor and fragments ions, 
respectively. The instrument type was chosen as either ESI-TRAP or ETD-TRAP. 
Search results were combined in Scaffold 4.4, filtered for 80% peptide confidence 
and modifications manually evaluated. 
Testing linker in on-bead digestion conditions. Cy3-Dde-biotin 5-5 was synthesized 
using conditions similar to protein labeling. To 15 µL 20x PBS and 259 µL ddH2O, 
the following reagents were added in order: 6 µL 5 mM alkyne-Dde-biotin 5-4, 5 
µL 5 mM Cy3-azide (0.83 eq), 6 µL 100 mM NaAsc, 3 µL 10 mM THPTA, and 6 µL 
50 mM CuSO4. The reaction was incubated for 1 h at RT, and the crude product 
was used directly without purification. Eight 40 µL aliquots of the reaction were 
diluted to 500 µL in PBS and were added to 20 µL settled volume high-capacity 
Neutravidin resin. The mixture was incubated for 1 h at RT, and then the beads 
were washed five times with PBS to remove excess dye. An image of the samples 
was taken. Samples were then incubated in 500 µL buffer (PBS; 2 M urea, PBS; 
0.1% SDS, PBS; 0.1% SDS, 20 mM HEPES pH 7.9) overnight at RT or 37 °C with 
end-over-end rotation. Beads were pelleted the following day, and a second image 
of the samples was taken. Because of the obvious difference between samples by 
eye, Cy3 released into solution was not quantified. To test if the beads were 
playing a role in linker cleavage, four 40 µL aliquots were diluted to 500 µL in PBS, 
and only two were immobilized on Neutravidin beads as described above. The 
beads were then rotated end-over-end overnight at RT or 37 °C. Samples that had 
not been incubated with beads overnight were then immobilized on Neutravidin 
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beads as described above to capture all linker-bound Cy3. All beads were washed 
twice with PBS to remove all released Cy3, and an image of the samples was 
taken. 
Cell culture. All reagents used for cell culture were obtained from ThermoFisher 
Scientific unless otherwise noted. The HEK-293T cell line and HUVECs were 
obtained from the American Type Culture Collection. HEK-293T cells were 
cultured in DMEM with 10% fetal bovine serum (FBS) and 1x 
penicillin/streptomycin (P/S) (referred to now on as complete DMEM). 
Protein digestion. All work prior to trypsinization was performed in a laminar flow 
hood to minimize keratin contamination. Protein lysate from HEK-293T cells in 
1% SDS, 50 mM Tris pH 7.6, 150 mM NaCl, 1x PIC- was quantified using the BCA 
assay (ThermoFisher Scientific), and 20 mg was diluted to 2 mg/mL in lysis 
buffer. Samples were reduced by incubation for 5 min at 95 °C with 20 mM DTT. 
Two 15-mL Amicon centrifugal filter units (10 kDa NMWL, UFC901024, EMD 
Millipore) were centrifuged at 4,000 x g with 5 mL ddH2O to wet the filters, and 
both the retentate and filtrate were discarded. The reduced sample was split in 
two (10 mg per filter unit) and then concentrated to ~1 mL by centrifugation at 
4,000 x g at RT. All remaining centrifugation steps occur at 4,000 x g at RT. No 
time is specified since the rate at which buffer exchange occurs is not always 
equivalent. All samples should be concentrated to ~1 mL before proceeding to 
the next step. Solutions of 8 M urea, 50 mM Tris pH 7.9 and 50 mM Tris pH 7.9 
were sterile filtered to remove all particulate matter. Samples were diluted to 15 
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mL in the filter units with 8 M urea, 50 mM Tris pH 7.9 containing 20 mM IAA 
and allowed to alkylate for 30 min at RT in the dark. The samples were then 
concentrated and buffer exchanged twice with 15 mL 8 M urea, 50 mM Tris pH 
7.9 and twice with 15 mL 50 mM Tris pH 7.9. Alternative 1: The final Tris 
exchange step was replaced with 15 mL 50 mM Tris pH 7.9, 0.2% w/v sodium 
deoxycholate that had been sterile filtered. Alternative 2: Prior to the first urea 
exchange step, an additional exchange step was added using 15 mL 8 M urea, 50 
mM Tris pH 7.9, 4% w/v sodium deoxycholate that had been sterile filtered. 
Samples were then diluted up to 5 mL with 50 mM Tris pH 7.9, 1 mM CaCl2 in 
the filter units and treated with 1:50 w/w sequencing-grade trypsin (90305, 
ThermoFisher Scientific). Samples were rotated end-over-end overnight at 37 
°C. Peptides were separated from undigested protein by centrifugation for 5 min 
at 4,000 x g, and the filter was washed twice with 2 mL 50 mM Tris pH 7.9 and 
centrifuged. All filtrates were combined and acidified to pH 3 with TFA. 
Samples were centrifuged for 5 min at 15,000 x g without the filter cup to pellet 
any residual sodium deoxycholate. Solutions were combined and desalted using 
a 20 cc HLB cartridge. Peptide concentrations were measured using a NanoDrop 
2000C (ThermoScientific) with absorbance at 205 nm (ε2051 mg/mL = 31). 
HLB desalting. Oasis HLB cartridges (3 cc, WAT094226; Plus short, 186000132; 
20 cc, 186000117; Waters Corp.) were first conditioned with methanol (1 mL, 5 
mL, 10 mL) and then equilibrated with 0.1% TFA (2 mL, 10 mL, 20 mL) on a 
vacuum manifold (WAT200677, Waters Corp.). Acidified samples were then 
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applied to the cartridge and allowed to flow through at a rate of ~1 drop per 
second. Columns were then washed with 0.1% TFA (2 mL, 10 mL, 20 mL), and 
samples were eluted in 70% acetonitrile, 0.1% TFA (1 mL, 5 mL, 10 mL). 0.1% 
FA was used for the wash and elution steps for the clean up step immediately 
prior to MS analysis. Peptides were aliquoted as 5-mg samples and were dried by 
either vacuum centrifugation or freeze-drying. 
GalT labeling of peptides. The peptide sample (5 mg) was resuspended in 1 mL 
ddH2O. Peptides may not dissolve readily and may require sonication and 
vortexing. To the solution was added 1 mL 100 mM HEPES pH 7.9, 275 µL 100 
mM MnCl2, 50 µL 5 M NaCl, and 2.15 mL ddH2O. The pH was checked at this 
point to ensure that any residual TFA from HLB elution did not acidify the 
solution lower than pH 7.5. Then, to the solution was added 250 µL 0.5 mM UDP-
GalNAz, 250 µL 2 mg/mL Y289L GalT, and 20 µL PNGase F (P0705L, New 
England Biolabs). The reaction was rotated at overnight at RT. Some Y289L GalT 
may precipitate out, but this does not affect labeling. The following day, the 
reaction was acidified to pH 3 with TFA. Any precipitated protein was pelleted by 
centrifugation, and the solution was desalted using an HLB Plus short cartridge. 
CuAAC reaction of peptides. Dried peptides were resuspended in 1 mL ddH2O 
with sonication and vortexing, if necessary. A 2x CuAAC reagent mixture was 
produced in the following order: 860 µL ddH2O, 40 µL 5 mM alkyne-Dde-biotin 5-
4 or 5 mM alkyne-PC-biotin 5-1, 40 µL 100 mM NaAsc, 20 µL 10 mM THPTA, and 
40 µL 50 mM CuSO4. 1 mL of the 2x mixture was immediately added to the 
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peptide solution, and the reaction was rotated end-over-end for 2 h at RT. 100 µL 
settled volume azide agarose resin (1038-2, Click Chemistry Tools) was washed 
thrice with ddH2O, resuspended in 1 mL ddH2O, and then added to the reaction. 
The bead-reaction mixture was rotated end-over-end for 1 h at RT. The reaction 
was filtered, and beads were rinsed twice with 1 mL ddH2O. Samples were 
acidified to pH 3 with TFA and desalted using an HLB Plus short cartridge. 
Peptide enrichment and elution. Dried peptides were resuspended in 1 mL ddH2O 
with sonication and vortexing, if necessary. The sample was diluted to 10 mL with 
PBS. 0.5 mL settled volume of high-capacity Neutravidin beads were washed 
thrice with PBS and then added to the sample. The suspension was rotated end-
over-end for 2 h at RT. The suspension was transferred to a column, and beads 
were rinsed with 5 mL PBS, 5 mL PBS + 2 M NaCl, and 5 mL PBS. Beads were 
transferred to a clean tube for elution. For 5-4, samples were rotated for 2 h at RT 
with 2 mL 100 mM sodium phosphate pH 6.6, 2% w/v hydroxylamine (final pH 
7.2). For 5-1, samples were irradiated (2 cm distance) with 365 nm UV light 
(UVGL-25 handheld UV lamp, 1.5 mW/cm2) for 1 h at RT with mixing every 10 
min. Elution buffer was removed, and beads were washed twice with 1 mL 100 
mM sodium phosphate pH 7.2. Washes were combined with elution buffer as the 
first elution fraction. The elution procedure was repeated as described above and 
combined as the second elution fraction. Samples were acidified to pH 3 with TFA 
and desalted using and HLB 6 cc cartridge. Dried samples were stored at -20 °C 
prior to MS analysis as described above. 
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A p p e n d i x  A  
Expedient Synthesis of Chondroitin Sulfate Glycomimetic 
Polymers  
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A.1 Rationale 
 The activity of sulfated glycosaminoglycans (GAGs) depends on protein 
binding, which occurs through multiple protein-carbohydrate interactions along 
the length of an oligosaccharide. However, the chemical synthesis of defined 
oligosaccharides is extremely difficult, necessitating alternative approaches to 
obtain higher order, chemically pure carbohydrates. One method used by our lab 
is the production of glycomimetic polymers based on ring-opening metathesis 
polymerization (ROMP). In this procedure, disaccharide units of known sulfation 
pattern are appended to a ROMP monomer.1-4 After polymerization with a 
ruthenium-based catalyst, the formed structure displays a number of disaccharide 
units on a single backbone as controlled by the catalyst loading, providing a 
macromolecular scaffold that mimics the natural multivalent presentation of GAG 
sulfation patterns. Unfortunately, production of the disaccharide starting material 
was still an arduous task, requiring nine and eight steps for the glucuronic acid 
(GlcA) and galactosamine (GalNAc) monomers, respectively, followed by a 
coupling step to reach the fully protected dissacharide building block for further 
sulfation steps.1, 2, 5 Here, we describe the adaptation of an efficient hydrolysis of 
natural chondroitin sulfate (CS) polysaccharides6 to produce an equivalent 
disaccharide building block in only four steps on a multi-gram scale and its 
elaboration into CS sulfation epitope monomers and the respective polymers. 
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A.2 General Chemical Methods 
 Unless otherwise noted, reactions were performed under Ar in sealed, flame-
dried glassware using dry, deoxygenated solvents by passing through a column of 
activated alumina with Ar. Commercially obtained reagents were used as 
received. Thin-layer chromatography (TLC) was performed using E. Merck silica 
gel 60 F254 precoated plates (0.25 mm) and visualized by UV fluorescence 
quenching or staining with potassium permanganate, ceric ammonium molybdate, 
p-anisaldehyde, or ninhydrin. Flash column chromatography was performed using 
ICN silica gel (particle size 0.032 – 0.063 mm). Ion exchange chromatography was 
performed using Amberlite IR-120 H+ form (Sigma Aldrich, washed with 1 M 
HCl, ddH2O, MeOH, then Et2O) or Na+ form (Sigma Aldrich). For sulfated 
compounds, gel filtration chromatography was used with Sephadex LH-20 gel 
resin (GE Healthcare Life Sciences) preswollen in 1:1 CH2Cl2/MeOH. Polymers 
were purified using gel filtration chromatography with Sephadex G-25 Fine gel 
resin (GE Healthcare Life Sciences) preswollen in ddH2O. 
 1H NMR spectra were recorded on either a Varian Inova 500 (500 MHz) or a 
Varian Mercury 300 (300 MHz) and are reported relative to the solvent residual 
peak (CDCl3 at δ 7.26, CD3OD at 3.31, and D2O at 4.79). Data for NMR spectra are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, b = broad), coupling constant in Hz, and 
integration. HRMS were acquired using an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray or mixed mode ionization. 
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A.3 Norbornenyl Linker Synthesis 
 
 
 
 
Figure A-1. Synthesis of norbornene linker.2 (a) KI (3 eq), I2 (1 eq), 0.75 M NaHCO3, 1 h, RT, 
90% recovery of exo isomer; (b) LiAlH4 (3 eq), Et2O, 0° to 50°C, 97% yield; (c) NaH (1.33 eq), 2-(2-
((tert-butyldimethylsilyl)oxy)ethoxy) ethyl methanesulfonate (0.83 eq), 18-crown-6 (0.17 eq), 4 Å 
mol. sieves, THF, 0° to RT, 3 h, then 0.5 M TBAF, THF, 0° to RT, 3 h, 43% over two steps. 
 
(1R, 2S, 4R)-Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid (A-1). A 4:1 mixture of 
endo- and exo-5-norbornene-2-carboxylic acid (25.0 g, 181 mmol) was dissolved 
in 820 mL 0.75 M NaHCO3. KI (90.12 g, 543 mmol, 3 eq) and I2 (45.94 g, 181 
mmol, 1 eq) were dissolved separately in 115 mL H2O. This brown solution was 
added dropwise to the stirring solution of the carboxylic acid using an addition 
funnel. Once completely added, the solution was extracted with Et2O (5 x 150 
mL), and the organic layers were discarded. After decolorizing with 10% 
Na2SO3, the pH of the aqueous layer was lowered to 2 using 1 N H2SO4, and the 
solution was extracted again with Et2O (5 x 150 mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated to give the pure exo 
enantiomer (4.52 g, 90%) as a clear oil. If desired, the product could be further 
purified by precipitating in pentane at -78 °C; however, the product was 
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generally used directly in the next step. 1H NMR (300 MHz, CDCl3) δ 6.14 (tt, J 
= 7.1, 4.1 Hz, 2H), 3.12 (d, J = 2.3 Hz, 1H), 2.95 (s, 1H), 2.28 (ddt, J = 8.4, 4.2, 
1.7 Hz, 1H), 2.03 – 1.89 (m, 1H), 1.54 (dd, J = 8.3, 1.7 Hz, 1H), 1.41 (td, J = 9.4, 
1.9 Hz, 2H). 
(1R, 2S, 4R)-Bicyclo[2.2.1]hept-5-ene-2-ylmethanol (A-2). Exo-5-norbornene-2-
carboxylic acid A-1 (4.52 g, 32.7 mmol) was dissolved in dry Et2O (80 mL) and 
cooled to 0 °C. Lithium aluminum hydride (3.75 g, 98.8 mmol, 3 eq) was then 
added portionwise with vigorous stirring between additions. The resulting 
suspension was refluxed at 50 °C. After 5 h, the suspension was cooled down to 
0 °C and excess lithium aluminum hydride was quenched (4 mL H2O, 8 mL 10% 
NaOH, then 12 mL H2O). The white aluminum salts were filtered washed, and 
the solution was concentrated. Column chromatography (5:1 to 3:1 
hexanes/EtOAc) gave the product (3.93 g, 97%) as a volatile, clear oil. Rf 0.24 
(5:1 hexanes/EtOAc); 1H NMR (300 MHz, CDCl3) δ 6.09 (qd, J = 5.6, 2.8 Hz, 
2H), 3.70 (dd, J = 10.6, 6.4 Hz, 1H), 3.54 (dd, J = 10.6, 8.8 Hz, 1H), 2.82 (s, 1H), 
2.75 (s, 1H), 1.68 – 1.55 (m, 1H), 1.38 – 1.19 (m, 3H), 1.11 (ddd, J = 11.7, 4.5, 
3.5 Hz, 1H). 
2-(2-((1R,2S,4R)-Bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethanol (A-3). Exo-
5-norbornenyl-2-methanol A-2 (11.10 g, 89 mmol, 1.2 eq) was added to dry 
THF (80 mL) with 4 Å molecular sieves under Ar. The mixture was stirred at RT 
for 30 minutes then cooled to 0 °C. NaH (2.83 g, 118 mmol, 1.6 eq) was added 
portionwise, and the resulting mixture was stirred for 30 minutes at 0 °C. 2-(2-
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((tert-butyldimethylsilyl)oxy)ethoxy) ethyl methanesulfonate (22.23 g, 74 
mmol) and 18-crown-6 (3.94 g, 15 mmol, 0.2 eq) were then added. The reaction 
was allowed to warm to RT while stirring for 3 h. After quenching with a 
minimum of H2O, the mixture was diluted with CH2Cl2 and filtered through 
Celite. The organic layer was washed with saturated NaHCO3, dried by MgSO4, 
filtered, and concentrated. The crude was then redissolved in dry THF (120 mL) 
and cooled to 0 °C. 1 M TBAF in THF (150 mL) was added dropwise, and the 
reaction was stirred for 3 hours while warming to RT. The mixture was diluted 
with EtOAc and washed with H2O. The organic layer was dried (MgSO4), 
filtered, and concentrated. Column chromatography (1:1 hexanes/EtOAc) 
yielded the pure product (6.78 g, 43% over two steps) as a yellow oil. Rf 0.26 
(1:1 hexanes/EtOAc); 1H NMR (500 MHz, CDCl3) δ 6.10 (dd, J = 5.7, 3.1 Hz, 
1H), 6.05 (dd, J = 5.7, 2.9 Hz, 1H), 3.76 – 3.72 (m, 2H), 3.70 (t, J = 4.7 Hz, 2H), 
3.66 – 3.57 (m, 4H), 3.53 (dd, J = 9.4, 6.3 Hz, 1H), 3.39 (t, J = 9.2 Hz, 1H), 2.80 
(s, 1H), 2.74 (s, 1H), 2.17 (bs, 1H) 1.75 – 1.67 (m, 1H), 1.36 – 1.21 (m, 3H), 
1.10 (ddd, J = 11.7, 4.3, 3.4 Hz, 1H); HRMS: calculated [M+H]+ 213.1491, 
determined: 213.1473. 
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 A.4 Production of the CS Disaccharide Building Block 
 
 
 
 
 
 
 
 
 
 
Figure A-2. Synthesis of core CS monomer building block. (a) 0.5 M H2SO4, H2O, reflux, 6 h; 
(b) 0.02 M HCl, MeOH, 0 °C, 4 d; (c) TCACl (11.3 eq), pyridine, 0 °C, 1 h, then MeOH, DCM, 
pyridine, RT, 4 h; (d) benzaldehyde (36.5 eq), TFA (2.64 eq), neat, RT, 1 h, then Ac2O (27.3 eq), 
NaOAc (3.9 eq), pyridine, RT, 16 h, 11.5% yield over four steps; (e) hydrazine acetate (1.5 eq), 
DMF, RT, 1 h; (f) trichloroacetonitrile (8 eq), DBU (0.6 eq), DCM, RT, 1 h, 56% yield over two steps; 
(g) A-3 (1.6 eq), 0.5 M TMSOTf (0.1 eq), 4 Å mol. sieves, DCM, -65 to -40 °C, 30 min, 95% yield; 
(h) Bu3SnH (6 eq), AIBN (0.17 eq), benzene, reflux, 3 h, 76% yield; (i) 80% AcOH, 80 °C, 99% yield. 
 
O-(Methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-1-O-acetyl-4,6-O-
benzylidene-2-deoxy-2-trichloroacetamido-α-D-galactopyranose (A-4).6 100.0 g of 
CS-A polymer (Federal Laboratories, Corp., Alden, NY, USA) was dissolved in 1 
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L deionized H2O, and the pH of the solution was lowered to 1.6 by addition of 
Amberlite IR-120 H+ resin. The solution was filtered, and the resin was washed 
with deionized H2O (4x100 mL). The final volume was adjusted to 1.94 L and 
55.6 mL conc. H2SO4 was added. The solution was boiled at 100 °C for 6 h. 
Ba(OH)2·8H2O was added while vigorously stirring until the pH reached 3.5. 
The solids were allowed to settle overnight, then the solution was filtered with 
Celite. The solid was washed with deionized H2O until the filtrate was clear. The 
solution was concentrated to 1 L then applied to a column of Amberlite IR-120 
H+ resin (1 L settled volume). The column was flushed with H2O (2 L), 3:1 
AcOH/H2O (2 L), and 1 M HCl (6 L). The positively staining fractions via 
ninhydrin were concentrated and then coconcentrated with H2O (2x500 mL). 
The crude solid was dried overnight in vacuo, then dissolved in 1 L 0.02 M 
methanolic HCl, and stirred at 0 °C for 4 d. This solution was then concentrated 
and co-concentrated with EtOH (2x100 mL) to give the crude disaccharide 
(55.93 g) as the hydrochloride salt. A portion of this crude disaccharide (20.0 g, 
49.3 mmol) was then dissolved in 220 mL pyridine and cooled to -30 °C. 
Trichloroacetyl chloride (62 mL, 0.555 mol, 11.3 eq) was added dropwise. Once 
the addition was complete, the reaction was stirred at 0 °C for 1 hour then 
cooled to -30 °C again. Deionized H2O (4.2 mL) was added very slowly while 
maintaining temperature. This was then diluted with CH2Cl2, washed with 
deionized water, brine then deionized water, dried over MgSO4, and 
concentrated. The residue was redissolved in 150 mL 1:1:1 
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CH2Cl2/MeOH/pyridine and stirred for 4 hours at RT. The solution was 
concentrated and dried in vacuo. A silica plug (4:1 CH2Cl2/MeOH) was used to 
yield the crude trichloroacetamide (10.54 g), which was again used directly as 
well. The crude trichloroacetamide (10.0 g, 19.4 mmol) was dissolved in 
benzaldehyde (72 mL, 709 mmol, 36.5 eq) along with TFA (3.8 mL, 51.2 mmol, 
2.64 eq). This mixture was for 24 hours at RT. Directly to the mixture, NaOAc 
(6.20 g, 75.6 mmol, 3.90 eq), pyridine (80 mL, 989 mmol, 51.0 eq), and acetic 
anhydride (50 mL, 529 mmol, 27.3 eq) were added sequentially. This was then 
stirred for 16 hours at RT. The solution was then added to ice-cold deionized 
H2O and stirred for an additional 2 h. This was then extracted with CH2Cl2 
(2x150 mL). The organic layers were combined, washed with deionized H2O, 
saturated NaHCO3 (aq.), then deionized H2O, dried over MgSO4, and 
concentrated. Column chromatography (100% CH2Cl2 →15:1 CH2Cl2/acetone) 
afforded the pure alpha anomer (6.10 g, 11.5% yield from polymer) as a white 
powder. Rf 0.44 (15:1 CH2Cl2/acetone); 1H NMR (500 MHz, CDCl3) δ 7.55 – 
7.49 (m, 2H, PhH), 7.42 – 7.31 (m, 3H, PhH), 6.77 (d, J = 7.7 Hz, 1H, GalN NH), 
6.49 (d, J = 3.4 Hz, 1H, GalN H-1), 5.55 (s, 1H, PhCH), 5.30 – 5.19 (m, 2H, GlcA 
H-3, H-4), 5.10 (dd, J = 8.7, 7.8 Hz, 1H, GlcA H-2), 4.95 (d, J = 7.8 Hz, 1H, GlcA 
H-1), 4.65 (ddd, J = 11.1, 7.7, 3.4 Hz, 1H, GalN H-2), 4.51 (dd, J = 3.3, 1.2 Hz, 
1H, GalN H-4), 4.47 (dd, J = 11.1, 3.3 Hz, 1H, GalN H-3), 4.30 (dd, J = 12.6, 1.6 
Hz, 1H, GalN H-6a), 4.12 (d, J = 9.7 Hz, 1H, GlcA H-5), 4.08 (dd, J = 12.6, 1.8 
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Hz, 1H, GalN H-6b), 3.85 (m, 1H, GalN H-5), 3.74 (s, 3H, CO2CH3), 2.19 (s, 3H, 
OCH3), 2.04 (m, 9H, OCH3). 
O-(Methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4,6-O-
benzylidene-2-deoxy-2-trichloroacetamido-1-O-trichloroacetimidoyl-α-D-
galactopyranose (A-5). Disaccharide A-4 (8.10 g, 10.51 mmol) was dissolved in 
65 mL dry DMF. To this solution, hydrazine acetate (1.48 g, 16.07 mmol, 1.5 eq) 
was added. The reaction was stirred at RT for 2 hours then diluted with EtOAc 
and washed with deionized H2O, brine, then deionized H2O. The organic layer 
was dried over MgSO4 and concentrated. The residue was redissolved in 65 mL 
dry CH2Cl2, and DBU (0.25 mL, 1.67 mmol, 0.16 eq) and trichloroacetonitrile 
(8.51 mL, 84.87 mmol, 8 eq) were added. Upon addition of DBU, the reaction 
turned bright yellow and slowly darkened to brown. After stirring for 1 hour at 
RT, the reaction was concentrated to afford an orange solid. This solid was 
passed through a silica plug (15:1 CH2Cl2/acetone). The crude product was then 
recrystallized with Et2O to afford the pure imidate (5.32 g, 56%) as white 
crystals. Rf 0.78 (15:1 CH2Cl2/acetone); 1H NMR (500 MHz, CDCl3) δ 8.76 (s, 
1H, =NH), 7.57 – 7.50 (m, 2H, PhH), 7.42 – 7.32 (m, 3H, PhH), 6.79 (d, J = 8.1 
Hz, 1H, -NH), 6.65 (d, J = 3.4 Hz, 1H, GalN H-1), 5.57 (s, 1H, CHPh), 5.25 (t, J = 
9.4 Hz, 1H, GlcA H-3), 5.20 (t, J = 8.8 Hz, 1H, GlcA H-4), 5.09 (dd, J = 8.6, 7.6 
Hz, 1H, GlcA H-2), 4.95 (d, J = 7.6 Hz, 1H, GlcA H-1), 4.77 (ddd, J = 11.4, 8.1, 
3.4 Hz, 1H, GalN H-2), 4.56 (d, J = 4.1 Hz, 1H, GalN H-4), 4.40 (dd, J = 11.0, 3.4 
Hz, 1H, GalN H-3), 4.34 (dd, J = 12.6, 1.6 Hz, 1H, GalN H-6a), 4.17 – 4.05 (m, 
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2H, GalN H-6b, GlcA H-5), 3.93 (s, 1H, GalN H-5), 3.72 (s, 3H, -CO2CH3), 2.05 
– 1.98 (m, 9H, -OCH3); HRMS: calculated [M+Na]+ 894.9802, determined: 
894.9742. 
2-(2-((1R,2S,4R)-Bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl O-(methyl 
2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4,6-O-benzylidene-2-deoxy-
2-trichloroacetamido-β-D-galactopyranose (A-6). Disaccharide A-5 (1.84 g, 2.11 
mmol, 1 eq) was dissolved in 30 mL dry CH2Cl2 with 4 Å molecular sieves under 
Ar, and the solution was cooled to –60 °C. To this was added the norbornenyl 
linker 3 (0.70 g, 3.30 mmol, 1.6 eq) dissolved in 7 mL dry CH2Cl2. The mixture 
was stirred at –60 °C for 1 h, then 440 µL 0.5 M TMSOTf in CH2Cl2 (0.1 eq) was 
injected by syringe. This was then stirred at –60 °C for 30 minutes then allowed 
to warm to –40 °C over 45 m. The reaction was subsequently quenched with 
NEt3, filtered using Celite, and concentrated. Column chromatography (2:1 to 
1:2 hexanes/EtOAc) yielded the final product as a white solid (1.82 g, 95%). Rf 
0.95 (1:2 hexanes/EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.56 – 7.50 (m, 2H, 
PhH), 7.40 – 7.30 (m, 3H, PhH), 7.08 (dd, J = 6.7, 1.4 Hz, 1H, NH), 6.07 (ddd, J 
= 22.4, 5.7, 2.9 Hz, 2H, CH=CH), 5.59 (s, 1H, CHPh), 5.23 (dd, J = 9.8, 9.3 Hz, 
1H, GlcA H-3), 5.16 (t, J = 9.0 Hz, 1H, GlcA H-4), 5.09 (d, J = 8.3 Hz, 1H, GalN 
H-1), 5.04 (dd, J = 8.8, 7.6 Hz, 1H, GlcA H-2), 4.91 (d, J = 7.5 Hz, 1H, GlcA H-1), 
4.67 (ddd, J = 11.0, 3.5, 1.8 Hz, 1H, GalN H-3), 4.43 (d, J = 3.6 Hz, 1H, GalN H-
4), 4.32 (dd, J = 12.3, 1.6 Hz, 1H, GalN H-6a), 4.09 (d, J = 10.9 Hz, 1H, GalN H-
6b), 4.02 (d, J = 9.9 Hz, 1H, GlcA H-5), 4.02 – 3.96 (m, 1H, -OCH), 3.85 – 3.78 
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(m, 1H, GalN H-2), 3.79 – 3.70 (m, 1H, OCH), 3.72 (s, 3H, CO2CH3), 3.65 (dd, J 
= 5.5, 4.3 Hz, 2H, 2 OCH), 3.63 – 3.60 (m, 2H, 2 OCH), 3.59 – 3.54 (m, 2H, 2 
OCH), 3.52 – 3.50 (m, 1H, GalN H-5), 3.50 – 3.48 (m, 1H, OCH), 3.34 (td, J = 
9.3, 1.1 Hz, 1H, OCH), 2.79 (bs, 1H, NB-H), 2.73 (bs, 1H, NB-H), 2.06 – 1.96 (m, 
9H, 3 C(O)CH3), 1.68 (tt, J = 8.8, 4.7 Hz, 1H, NB-H), 1.33 – 1.18 (m, 3H, NB-H), 
1.12 – 1.04 (m, 1H, NB-H); HRMS: calculated [M-H]- 920.2072, determined: 
920.2090. 
2-(2-((1R,2S,4R)-Bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl O-(methyl 
2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-4,6-O-benzylidene-2-deoxy-
2-acetamido-β-D-galactopyranose (A-7). To a solution of disaccharide glycoside 
A-6 (0.405 g, 0.439 mmol, 1 eq) in 13 mL dry benzene, Bu3SnH (0.72 mL, 2.86 
mmol, 6 eq) and AIBN (12 mg, 0.073 mmol, 0.17 eq) were added. The mixture 
was stirred at RT for 1 hour with Ar bubbling through the solution. The reaction 
was then refluxed at 80 °C under Ar for 3 hours then quenched with NEt3. 
Column chromatography (100% EtOAc to 100:1 to 20:1 EtOAc/MeOH) afforded 
the product as a white solid (0.310 g, 86%). Rf 0.45 (9:1 EtOAc/MeOH); 1H NMR 
(500 MHz, CDCl3) δ 7.57 – 7.52 (m, 2H, PhH), 7.41 – 7.29 (m, 3H, PhH), 6.14 – 
6.03 (m, 2H, CH=CH), 5.98 (s, 1H, NH), 5.55 (s, 1H, CHPh), 5.32 – 5.17 (m, 2H, 
GlcA H-3, GlcA H-4), 5.09 (dd, J = 8.2, 1.6 Hz, 1H, GalN H-1), 5.00 (t, J = 8.1 Hz, 
1H, GlcA H-2), 4.92 (d, J = 7.6 Hz, 1H, GlcA H-1), 4.71 (dt, J = 11.2, 3.0 Hz, 1H, 
GalN H-3), 4.34 (d, J = 3.4 Hz, 1H, GalN H-4), 4.30 (dd, J = 12.4, 1.6 Hz, 1H, 
GalN H-6a), 4.06 (dd, J = 12.5, 1.8 Hz, 1H, GalN H-6b), 4.02 (d, J = 8.3 Hz, 1H, 
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GlcA H-5), 4.00 – 3.96 (m, 1H, OCH), 3.76 – 3.70 (m, 1H, OCH), 3.69 (s, 3H, 
CO2CH3), 3.67 – 3.61 (m, 4H, 4 OCH), 3.61 – 3.55 (m, 2H, 2 OCH), 3.54 – 3.46 
(m, 3H, OCH, GalN H-2, GalN H-5), 3.36 (td, J = 9.2, 3.7 Hz, 1H, OCH), 2.79 
(bs, 1H, NB-H), 2.73 (bs, 1H, NB-H), 2.05 – 1.93 (m, 12H, 4 C(O)CH3), 1.72 – 
1.65 (m, 1H, NB-H), 1.33 – 1.19 (m, 3H, NB-H), 1.09 (dtd, J = 11.7, 3.8, 2.3 Hz, 
1H, NB-H); HRMS: calculated [M-H]- 820.3386, determined: 820.3384. 
2-(2-((1R,2S,4R)-Bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl O-(methyl 
2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-2-deoxy-2-acetamido-β-D-
galactopyranose (A-8). Acetamide A-7 (0.310 g, 0.378 mmol) was suspended in 9 
mL 80% AcOH. The suspension was stirred at 80 °C for 30 minutes, during 
which the compound dissolved. The reaction was concentrated, and column 
chromatography (9:1 EtOAc/MeOH) afforded the product as a white solid 
(0.273 g, 99%). Rf 0.18 (9:1 EtOAc/MeOH); 1H NMR (500 MHz, CDCl3) δ 6.69 
(t, J = 7.0 Hz, 1H, NH), 6.15 – 6.04 (m, 2H, CH=CH), 5.26 (td, J = 9.4, 1.9 Hz, 
1H, GlcA H-3), 5.16 (t, J = 9.6 Hz, 1H, GlcA H-4), 5.01 (ddd, J = 9.3, 7.9, 1.2 Hz, 
1H, GlcA H-2), 4.78 (dd, J = 8.5, 2.9 Hz, 1H, GalN H-1), 4.74 (d, J = 8.0 Hz, 1H, 
GlcA H-1), 4.25 – 4.02 (m, 3H, GlcA H-5, GalN H-3, H-4), 3.98 – 3.84 (m, 2H, 
OCH, GalN H-2), 3.86 – 3.67 (m, 4H, OCH, CO2CH3), 3.70 – 3.44 (m, 8H, OCH, 
GalN H-5), 3.42 (bs, 1H, GalN OH), 3.43 – 3.29 (m, 1H, OCH), 3.28 (bs, 1H, 
GalN OH), 2.81 (bs, 1H, NB-H), 2.72 (bd, J = 6.8 Hz, 1H, NB-H), 2.09 – 1.93 (m, 
12H, C(O)CH3), 1.72 – 1.61 (m, 1H, NB-H), 1.37 – 1.15 (m, 3H, NB-H), 1.17 – 
1.04 (m, 1H, NB-H); HRMS: calculated [M-H]- 730.2928, determined: 730.2945. 
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A.5 Elaboration to CS Sulfation Epitope Monomers 
 
 
 
 
 
 
 
 
Figure A-3. Synthesis of CS sulfation epitope monomers.5 (a) SO3·TMA (2.7 eq), DMF, 50 
°C, 40 min, 90% yield; (b) SO3·TMA (25 eq), DMF, 50 °C, 1 d, 43% yield; (c) BzCN (2 eq), 
pyridine, RT, 16 h, 80% yield; (d) SO3·TMA (6 eq), DMF, 50 °C, 1.5 d, 36% yield. 
 
CS-C monomer (A-9). Diol A-8 (100 mg, 0.137 mmol) was dissolved in 3.8 mL 
dry DMF under Ar. To this, sulfur trioxide trimethylamine complex (56 mg, 
0.369 mmol, 2.7 eq) was added. The reaction was stirred at 50 °C for 40 m then 
cooled and added directly to an LH-20 column. After eluting the product from 
the LH-20 column, the crude mixture was subjected to cation exchange 
chromatography (Amberlite IR-120 Na+ form) followed by silica column 
chromatography (10:2:1 EtOAc/MeOH/H2O), which gave the product as a 
white solid (103 mg, 90%). Rf 0.37 (10:2:1 EtOAc/MeOH/H2O); 1H NMR (500 
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MHz, MeOD-d4) δ 6.10 (ddd, J = 18.7, 6.3, 3.5 Hz, 2H, CH=CH), 5.32 (td, J = 9.5, 
1.6 Hz, 1H, GlcA H-3), 5.11 (td, J = 9.8, 1.6 Hz, 1H, GlcA H-4), 4.99 (ddd, J = 
9.6, 7.8, 1.6 Hz, 1H, GlcA H-2), 4.91 (dd, J = 7.9, 1.5 Hz, 1H, GlcA H-1), 4.48 
(dd, J = 8.5, 1.6 Hz, 1H, GalN H-1), 4.30 (dt, J = 10.0, 1.7 Hz, 1H, GlcA H-5), 
4.19 (d, J = 5.8 Hz, 2H, GalN H-6a, H-6b), 4.12 – 4.05 (m, 2H, GalN H-3, H-5), 
4.01 – 3.91 (m, 1H, OCH), 3.87 – 3.76 (m, 2H, GalN H-2, H-4), 3.78 – 3.67 (m, 
4H, OCH, CO2CH3), 3.70 – 3.51 (m, 7H, OCH), 3.43 (td, J = 9.3, 1.6 Hz, 1H, 
OCH), 2.81 (bs, 1H, NB-H), 2.74 (bs, 1H, NB-H), 2.14 – 1.93 (m, 12H, 
C(O)CH3), 1.74 – 1.65 (m, 1H, NB-H), 1.39 – 1.21 (m, 3H, NB-H), 1.21 – 1.13 
(m, 1H, NB-H); HRMS: calculated [M-H]- 810.2496, determined: 810.2511.  
CS-E monomer (A-10). Diol A-8 (250 mg, 0.343 mmol) was dissolved in 12 mL 
dry DMF under Ar. To this, sulfur trioxide trimethylamine complex (1.19 g, 8.55 
mmol, 25 eq) was added. The reaction was stirred at 50 °C for 24 hours then 
cooled and added directly to an LH-20 column. After eluting the product from 
the column, the crude mixture was subjected to cation exchange 
chromatography (Amberlite IR-120 Na+ form) followed by silica column 
chromatography (5:2:1 EtOAc/MeOH/H2O), which yielded the product as a 
white solid (139 mg, 43%). Rf 0.18 (10:2:1 EtOAc/MeOH/H2O); 1H NMR (500 
MHz, MeOD-d4) δ 6.09 (ddd, J = 19.9, 6.0, 3.2 Hz, 2H, CH=CH), 5.31 (t, J = 9.4 
Hz, 1H, GlcA H-3), 5.20 (t, J = 9.9 Hz, 1H, GlcA H-4), 5.07 (t, J = 8.7 Hz, 1H, 
GlcA H-2), 4.95 (d, J = 8.1 Hz, 1H, GlcA H-1), 4.86 (hidden under HDO peak, 
1H, GalN H-4),  4.51 (d, J = 8.3 Hz, 1H, GalN H-1), 4.38 (dd, J = 11.8, 3.4 Hz, 1H, 
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GalN H-6a), 4.31 – 4.24 (m, 2H, GalN H-6b, GlcA H-5), 4.06 (t, J = 9.6 Hz, 1H, 
GalN H-2), 4.03 – 3.88 (m, 3H, OCH, GalN H-3, H-5), 3.75 (s, 3H, CO2CH3), 
3.72 – 3.51 (m, 8H, OCH), 3.42 (t, J = 9.2 Hz, 1H, OCH), 2.79 (bs, 1H, NB-H), 
2.73 (bs, 1H, NB-H), 2.11 – 1.95 (m, 12H, C(O)CH3), 1.74 – 1.63 (m, 1H, NB-
H), 1.38 – 1.20 (m, 3H, NB-H), 1.15 (dt, J = 11.7, 3.9 Hz, 1H, NB-H); HRMS: 
calculated [M-Na]- 912.1883; determined: 912.1905. 
2-(2-((1R,2S,4R)-Bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl O-(methyl 
2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-(1→3)-6-O-benzoyl-2-deoxy-2-
acetamido-β-D-galactopyranose (A-11). Diol A-8 (200 mg, 0.273 mmol) was 
dissolved in 5.0 mL dry pyridine along with benzoyl cyanide (72 mg, 0.547 
mmol, 2 eq) under Ar. The reaction was stirred at RT for 16 h. MeOH (2 mL) 
was added to quench the reaction, after which the solution was concentrated. 
Column chromatography (100% EtOAc) afforded the product as a white solid 
(0.251 g, 80%). Rf 0.16 (100% EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.07 – 8.01 
(m, 2H, PhH), 7.60 – 7.53 (m, 1H, PhH), 7.48 – 7.41 (m, 2H, PhH), 6.14 – 6.06 
(m, 2H, CH=CH), 6.00 – 5.91 (m, 1H, NH), 5.28 – 5.15 (m, 2H, GlcA H-3, H-4), 
5.02 (dd, J = 9.0, 7.7 Hz, 1H, GlcA H-2), 4.93 (dd, J = 8.4, 4.1 Hz, 1H, GalN H-1), 
4.74 (d, J = 7.7 Hz, 1H, GlcA H-1), 4.60 (dd, J = 11.4, 5.6 Hz, 1H, GalN H-6a), 
4.56 (dd, J = 11.4, 6.9 Hz, 1H, GalN H-6b), 4.49 (td, J = 11.5, 3.2 Hz, 1H, GalN H-
3), 4.15 – 4.11 (m, 1H, GalN H-4), 4.03 (dd, J = 9.4, 7.0 Hz, 1H, GlcA H-5), 3.94 
(dt, J = 11.6, 4.1 Hz, 1H, OCH), 3.88 (t, J = 6.3 Hz, 1H, GalN H-5), 3.74 (dt, J = 
11.2, 5.4 Hz, 1H, OCH), 3.66 (s, 3H, CO2CH3), 3.66 – 3.46 (m, 8H, GalN H-2, 
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OCH), 3.37 (dt, J = 16.0, 9.2 Hz, 1H, OCH), 2.81 (bs, 1H, NB-H), 2.73 (bd, J = 
7.4 Hz, 1H, GalN 4-OH), 2.67 (bs, 1H, NB-H), 2.09 – 1.95 (m, 12H, C(O)CH3), 
1.74 – 1.64 (m, 1H, NB-H), 1.42 – 1.20 (m, 3H, NB-H), 1.11 (ddt, J = 11.3, 7.4, 
3.9 Hz, 1H, NB-H); HRMS: calculated [M+Cl]- 870.2951, determined: 870.2966. 
CS-A monomer (A-12). Disaccharide A-11 (250 mg, 0.299 mmol) was dissolved in 
15 mL dry DMF under Ar. To this, sulfur trioxide trimethylamine complex (250 
mg, 1.79 mmol, 6 eq) was added. The reaction was stirred at 50 °C for 36 hours 
then cooled and added directly to an LH-20 column. After eluting the product 
from the LH-20 column, the crude mixture was subjected to cation exchange 
chromatography (Amberlite IR-120 Na+ form) followed by silica column 
chromatography (10:2:1 EtOAc/MeOH/H2O), which gave the product as a white 
solid (101 mg, 36%). Rf 0.55 (10:2:1 EtOAc/MeOH/H2O); 1H NMR (500 MHz, 
MeOD-d4) δ 8.06 (dt, J = 9.0, 1.7 Hz, 2H, PhH), 7.63 – 7.55 (m, 1H, PhH), 7.47 
(td, J = 7.6, 1.5 Hz, 2H, PhH), 6.12 – 6.02 (m, 2H, CH=CH), 5.31 (td, J = 9.4, 2.4 
Hz, 1H, GlcA H-3), 5.23 (td, J = 9.6, 2.3 Hz, 1H, GlcA H-4), 5.07 (ddd, J = 10.5, 
8.4, 2.4 Hz, 1H, GlcA H-2), 5.02 – 4.90 (m, 2H, GlcA H-1, GalN H-3), 4.65 (dd, J = 
6.5, 2.4 Hz, 2H, GalN H-6a, H-6b), 4.61 (d, J = 8.1 Hz, 1H, GalN H-1), 4.23 (dq, J = 
9.9, 1.9 Hz, 1H, GlcA H-5), 4.10 (d, J = 11.0 Hz, 1H, GalN H-4), 4.04 – 3.96 (m, 
2H, GalN H-2, H-5), 3.87 (dt, J = 11.4, 4.3 Hz, 1H, OCH), 3.77 – 3.66 (m, 4H, 
OCH, CO2CH3), 3.66 – 3.46 (m, 7H, OCH), 3.37 (ddt, J = 11.6, 9.4, 1.7 Hz, 1H, 
OCH), 2.78 (bs, 1H, NB-H), 2.71 (bs, 1H, NB-H), 2.06 – 1.93 (m, 12H, C(O)CH3), 
1.70 – 1.61 (m, 1H, NB-H), 1.36 – 1.26 (m, 2H, NB-H), 1.22 (ddd, J = 11.1, 8.4, 2.4 
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Hz, 1H, NB-H), 1.13 (dt, J = 11.7, 3.9 Hz, 1H, NB-H); HRMS: calculated [M-Na]- 
914.2758, determined: 914.2770. 
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A.6 CS Polymerization 
General polymerization procedure.1, 2 A vial with a rubber septum was charged 
with disaccharide monomers (60.0 mg) under Ar. To this dry, degassed MeOH 
(0.25 mL) and DCE (1.25 mL) were added. The solution was heated to 55 °C, 
and then an appropriate amount (mol % to determine polymer size) of the fast-
activating Grubbs 3rd generation catalyst (2.0 mg/mL in DCE) was rapidly added 
by syringe injection. This was stirred for 1 hours at 55 °C. The reaction was 
quenched with ethyl vinyl ether (0.30 mL) with stirring for 30 minutes at 55 °C 
and concentrated. The polymer residue was dissolved in a minimum of 1:1 
DCM/MeOH and precipitated by adding dropwise to a vortexing solution of 1:1 
hexanes/diethyl ether (50 mL). The precipitate was centrifuged down and the 
solvent decanted. This was repeated three times to give a white pellet. 
Deprotection steps. The precipitated pellet was redissolved in 2:1 THF/H2O (3 
mL). The solution was cooled to 0 °C, and LiOH (1 M, 0.50 mL) and H2O2 (30%, 
0.25 mL) were added. The reaction was stirred at 0 °C for 1 hour then allowed 
to warm to RT while stirring for another 12 h. To this, NaOH (4 M, 0.8 mL) and 
MeOH (2.0 mL) were added directly. The reaction was stirred at RT for 24 
hours then neutralized with Amberlite IR-120 H+. The solution was filtered 
through a 0.2 µm syringe filter, and organic solvents were removed. The 
remaining H2O was removed by lyophilization. Gel filtration chromatography 
(G-25 Fine, ddH2O) and subsequent lyophilization affording the deprotected 
polymers as a white solid. For long-term storage, polymers were subjected to 
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cation exchange with tributylammonium containing Amberlite IR-120. 
Amberlite IR-120 H+ resin was loaded into a column and then washed with ten 
column volumes of 1 M TBACl, and excess reagent as removed by washing with 
ten column volumes of ddH2O. Next, the CS polymers were dissolved at 1 
mg/mL in ddH2O and flowed over the column by gravity. The flowthrough was 
then combined, lyophilized, and subjected to gel filtration chromatography as 
previously described. Polymers were stored as the lyophilized powder at -80 °C. 
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